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"I found it so truly difficult that I almost believed that it was 
to be understood by God Alone". 
William Harvey, De Motu Cordis (1628) 
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INTRODUCTION 
AND AIM 
OF THE STUDIES 
The literature on hypertension has grown at such an explosive rate that few, if any, are 
able to keep abreast of it. "The problem is not that we know too little, but that we don't 
know how much we know", these words of an anonymous session chairman cited by 
Folkow in 1984 seem even more appropriate to date. Hypertension has become accepted as 
a multifactorial disease of regulation; it results from an inbalance in various mechanisms 
such as hormones, enzymes, peptides, endothelial and vascular factors which all serve to 
control arterial pressure at a normal level. The contribution of the studies described in this 
thesis to this complex problem is small and sometimes allready outdated. Fortunately, the 
frustrated reader easily can turn to the wealth of other studies available in the field. In 
collecting the papers for this thesis I found solace in the words of Auguste Comte: To 
understand a science one must know its history. 
PART 1 ACE INHIBITION 
In the course of a longlasting and often passionate research of the renin-angiotensin-
aldosterone system the group around professor Schalekamp has followed many tracks, but 
in 1979 we fell almost instantaneously in love with captopril and with the idea for which 
the drug stands: blocking the activity of the renin angiotensin system by angiotensin 
converting enzyme (ACE) inhibition. However we were not alone in our adoration and 
captopril appeared to be no virgin. In a rush for publication many groups opted for 
simplicity: captopril acted primarily by blocking the formation of circulating angiotensin 
II. However diversity and confusion regarding the mechanism of action of captopril soon 
became apparent. 
CHAPTER 1 
Chapter 1 of this thesis brings together studies which deal with the question of the 
specificity of captopril's mode of action. In studies bound to be controversial we have tried 
to clarify whether or not pretreatment plasma renin is an important predictor of the blood 
pressure response to ACE inhibition. For this purpose the effects of captopril and later 
ramipril on blood pressure were investigated in patients with an extremely wide range of 
plasma levels of renin i.e. normotensive fluid-depleted anephric patients in whom active 
renin in plasma was almost zero, patients with essential hypertension with low to normal 
renin, patients with renovascular hypertension with normal to high renin, and finally 
normotensive patients with heart failure with renin levels that were often extremely high. 
Theoretically, the change in vascular resistance after converting enzyme inhibition might 
correlate more closely with pretreatment renin than does the change in blood pressure. 
Therefore, the goal of the last study presented in chapter 1 was to provide some insight into 
the relation between pretreatment plasma renin, degree of inhibition of converting enzyme 
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with captopril and the haemodynamic profile of action of the drug. Both short- and long-
term responses of total peripheral resistance to ACE inhibition were investigated. 
CHAPTER2 
We were much impressed by the beneficial effects of a single gift of captopril in 
hypertensive patients who appeared to be in some state of heart failure. At that time heart 
failure was not considered to be an indication for ACE inhibition (sic !) and the results of 
studies started in the United States and Switzerland were unknown to us. So we followed 
our own research instinct. Professor Hugenholtz and the staff of the Thoraxcentrum were 
very cooperative and helpful but not much impressed by the idea. However on short notice 
they did help us to collect a series of patients. The results of that venture are presented in 
the single paper of this chapter. 
CHAPTER3 
In chapter 3 we go back to that black box that is of utmost importance for the regulation 
of blood pressure and the activity of the renin angiotensin system, the kidney. The renin 
story however is a very complicated one and a little history is may be helpful. 
During the final decade of the last century, interest was shown in extracting various 
organs and measuring their effect on blood pressure, chiefly it seems because of Brown-
Sequard's claim (1854) that testicular extracts had rejuvenating power. Tigerstedt and 
Bergman in 1898 followed the trend by making water extracts of kidneys and showing that 
they had pressor activity (for overview, see Page, Hypertension Mechanisms). What they 
showed was that the activity of extracts of rabbit kidney was destroyed by boiling, it was 
nondialyzable, and the active material was largely contained in the cortex. There was an 
initial fall in blood pressure, followed by a rise. Nephrectomy greatly prolonged its action. 
They theoretized that their "renin" acted on peripheral nerve centers, and not on vascular 
muscle. Further, they recognized a possible relationship with renal disease, but specifically 
disavowed proposing a new hypothesis to explain cardiorenal disease. 
Not unlike many of our research associates Bergman disappeared into medical practice 
and was never heard from, and Tigerstedt did nothing more with his renin. This discovery 
of renin laid dormant for more than 30 years before its significance was recognized by 
Goldblatt and coworkers, who produced hypertension in the dog by clamping the renal 
artery. These experiments indicated that a "pressor" substance, renin, was released from the 
kidney with the constricted artery. 
Renin ceased being a pressor substance after the discovery that it was an enzyme. This 
proteolytic activity of renin is responsible for the catalytic hydrolysis of the leu-10/val-11 
bond of renin substrate, angiotensinogen. Because this reaction is the rate-limiting step in a 
series of reactions leading to the formation of the potent vasoconstrictor angiotensin-II, 
renin is considered to play a key role in blood pressure regulation and in sodium and water 
homeostasis. 
In respect of its enzymatic activity, renin is comparable to other proteolytic enzymes in 
plasma. In contrast to precursors of polypeptide hormones, proteolytic enzymes in plasma 
are largely present as inactive precursor molecules that are activated outside their site of 
production. In case of the coagulation system, for instance, 99 percent or more of the total 
quantity of the individual enzymes circulates in plasma as inactive precursor. It was 
therefore of great interest that Lumbers and Morris and Skinner and later our group 
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reported on the presence of an inactive form of plasma renin that can be converted into 
active renin by limited proteolysis. It now appears that more than 90 percent of the renin in 
plasma is present in this inactive form. This inactive form of renin in plasma is identical 
with the biosynthetic precursor of renin in the kidney and is therefore called prorenin. 
In the first part of chapter 3 we describe the development of an assay of prorenin, in 
which the conversion of prorenin into active renin occurred under apparently optimal 
condition, without any loss of prorenin, activated prorenin or naturally occurring active 
renin. The assay was used for measurements of prorenin and active renin in peripheral and 
renal vein plasma of patients with and without renal artery stenosis. ACE inhibition with 
captopril was used to stimulate renin release by the kidney. 
The last two complimentary papers of chapter 3 focus on the renal haemodynamic 
influences of ACE inhibition. We studied patients with and without renal artery stenosis. 
This proved to be not an easy subject. Intensive investigative efforts probing the many 
characteristics and potential functions of the renin-angiotensin system have resulted in an 
exponentially expanding literature. We now know that renal artery stenosis sets into motion 
complex compensatory mechanisms. Because of its unique localisation and structure the 
juxtaglomerular apparatus, the major site of renin and angiotensin formation, plays a 
keyrole. Despite a lower perfusion pressure behind the stenosis renal blood flow is, at least 
initially, well maintained by an autoregulatory fall in pre glomerular resistance. At the other 
side of the glomerulus locally formed angiotensin II is thought to maintain glomerular 
hydrostatic pressure and glomerular filtration rate by effects on postglomerular arteriolar 
tone. Increased renin secretion and hypertension in the systemic circulation contribute to 
restoration of the low perfusion pressure behind the stenosis. The non- stenotic kidney 
suffers from and contributes to hypertension by a reduction in cortical blood flow, 
glomerular filtration and excretory function in response to increased levels of circulating 
angiotensin II. 
Thus ACE inhibitors could have a major impact on renal function, in particular of the 
stenotic kidney. However in unilateral renal disease such an effect may easily go unnoticed 
because of the functional reserve of the opposite kidney. We therefore performed split renal 
function studies in these patients. 
CHAPTER4 
Screening for renovascular hypertension is the subject of chapter 4. It should be realized 
that renovascular hypertension is the most common form of secondary hypertension and 
that this form of hypertension is potentially curable with surgical intervention or 
angioplasty. It is estimated that up to 5% of the hypertensive Dutch population, or 
approximately 50.000, may have this form of hypertension. Current diagnostic techniques 
for identifying patients with renovascular hypertension are not ideal. Clinical findings, 
urography, and radio-isotope renography are of questionable or unproven value. 
Arteriography, which has been suggested as gold standard technique, is invasive, 
expensive, and not accurate in the sense that demonstration of renal artery stenosis in a 
hypertensive patient does not determine whether the stenosis is the cause of the 
hypertension. 
Renin activity in peripheral plasma is higher on average in patients with renal artery 
stenosis than in patients with essential hypertension but there is a large overlap between the 
two groups. We hypothesized that the overlap would be reduced by administering an ACE 
inhibitor. There were good reasons for this assumption. First, in the kidney affected by 
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artery stenosis the intraglomerular pressure is critically dependent on angiotensin 
II. Reduction of angiotensin II by ACE inhibition will therefore activate the 
juxtaglomerular baroreceptor mechanism with stimulation of renin secretion as a result. 
Second, the juxtaglomerular apparatus is hypertrophied in kidneys with artery stenosis and 
may therefore expected to be hyperresponsive to stimuli for renin secretion. Finally, since 
the systemic blood pressure in patients with renal artery stenosis is also more dependent on 
angiotensin II than in patients without renal artery stenosis, the systemic and glomerular 
pressures were expected to fall more strongly after ACE inhibition. Evidence concerming 
the clinical utility of single dose captopril in the diagnosis of renovascular hypertension 
was evaluated in the first paper of this chapter. 
The second paper of this chapter deals with the diagnostic value of renal vein renin 
sampling, a more sensitive method for diagnosis than measurement of peripheral plasma 
renin. In this study we employed a new immunoradiometric assay to measure renin. 
This direct assay makes use of a highly specific monoclonal antibody that recognizes 
active renin but not prorenin. This assay has some advantages over the indirect assay. For 
instance the procedure does not involve the incubation step for generating angiotensin I, 
thereby circumventing problems with recovery of angiotensin I and the varying levels of 
renin substrate. A disadvantage of the direct assay is its lower sensitivity. In the case of 
renal vein renin measurements we tried to solve this problem by stimulating the secretion 
of renin prior to sampling by giving an ACE inhibitor. 
CHAPTERS 
The ACE inhibitors, captopril and enalapril, have undoubtedly proved to be effective 
agents for the treatment of essential hypertension. However, the two agents differ in several 
ways: the nature of the molecule's adherence to the active site on the converting enzyme, 
the form in which the agent is administered (active compound or prodrug), and the kinetics 
of elimination. In contrast to enalapril captopril's elimination half-life is short, 2 hours 
versus 11 hours. However captopril's blood pressure lowering effect has been noted to 
outlast its inhibition of serum ACE. Inhibition of tissue ACE or some other effect such as 
drug accumulation could be involved, but hard data about these possibilities are not 
available. Current trends favour twice-daily administration of captopril and once- daily 
dosing of enalapril. The results of a European multicentre trial even suggested that once-
daily captopril was as effective as once-daily enalapril. A point of criticism of these studies 
could be the fact that blood pressure was measured, at one moment in time, 21-27 hours 
after dosing and that increasing doses were used. We therefore used an automatic semi-
continuous ambulatory blood pressure recording device to compare, in the same patient, a 
twice-daily dosing regimen of captopril with an once-daily of enlapril. 
PART 2 SEROTONIN ANTAGONISM 
It has been known for more than a century that blood gains vasoconstrictor properties 
after clotting. The responsible serum factor was isolated and its structure identified in the 
late forties. The substance was called serotonin, and was subsequently found to be 5-
hydroxytryptamine (5-HT). Its synthesis followed shortly thereafter. However the serotonin 
story has taken about 35 years to develop. We now know that platelets of all mammals 
contain serotonin and that serotonin contained in these platelets originates in the 
enterochromaffin cells of the gastrointestinal tract Serotonin is taken up by platelets during 
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their lifetime in the circulating blood. The only blood containing measurable amounts of 
serotonin in plasma is that in the portal vein, problably because of release of the amine 
from the enterochromaffin cells of the intestinal mucosa. Under normal conditions the 
concentration of free serotonin is too low to produce measurable cardiovascular effects. 
As the epithelial lining of the cardiovascular system, the endothelium acts as a barrier 
that excludes circulating cellular elements and harmful substances. However we now know 
that the endothelium also plays an important role in the modulation of the function of blood 
cells, the blood vessel wall and the tissues that the blood vessel supplies. Platelets interact 
both physically and biochemically with the blood vessel wall. The endothelium plays an 
important role in these interactions. Where the endothelium is damaged, platelets aggregate 
on the subendothelial collagen and smooth muscle. As an inevitable consequence of their 
aggregation, platelets release serotonin, nucleotides, prostaglandines, catecholamines, and 
various proteins, all of which may have profound effects on other platelets, the surrounding 
endothelium, the smooth muscle or the tissues beyond. The serotonin content of platelets is 
more than sufficient to exert vascular effects upon its release. 
In most patients with chronic hypertension, the etiology of the increase in blood pressure 
remains obscure. As the cardiac output of these patients is basically normal, the chronic 
increase in arterial blood pressure is due primarily to an augmented peripheral vascular 
resistance, owing to an abnormal narrowing of the systemic arterioles. Except perhaps in 
patients with renovascular hypertension, primary aldosteronism or pheochromocytoma, no 
single derangement can be held responsible for the sustained increase in peripheral 
resistance. Factors such as genetic predisposition, increased activity of the sympathetic 
nervous system, altered function of the adrenergic neuroeffector junction, augmented 
activity of the renin- angiotensin-aldosterone axis, abnormal secretion of natriuretic 
hormone or of vasopressin, and adaptive changes in the blood vessel wall all may 
contribute. 
The second part of this thesis entertains the idea that the peripheral vasocontrictor effects 
of serotonin may contribute to the sustained increase in peripheral resistance, at least in 
part and in some patients with hypertension. 
Serotonin however has complex and multiple actions on cardiovascular function. In the 
intact animal, it can cause either an increase or a decrease in blood pressure depending on 
the species studied and the dose used. The local effect of the monoamine on blood flow is 
similarly confusing: depending on the species, the vascular bed, the experimental 
conditions, the degree of sympathetic tone, and the route of administration, serotonin 
augments or reduces blood flow. 
It is now realized that these bewildering cardiovascular and other effects of serotonin can 
be explained by activation of different receptors. According to the current classification, 
three main classes of serotonin receptors, designated 5-HTI, 5-HT2 and 5-HT3, are 
distinguished. 5-HT receptors mediating contraction of vascular smooth muscle are of the 
5-HT2type. 
Our clinical interest in the cardiovascular effects of serotonin has been stimulated by the 
introduction of the selective 5-HT2 serotonergic receptor antagonist ketanserin.Other 
serotonergic antagonists such as methylsergide, cyproheptadine, and pizotifen have incon-
sistent effects on arterial blood pressure. This might be related to lack of selectivity and to 
partial agonistic activity. Some serotonergic antagonists have marked central actions. 
Ketanserin is devoid of agonistic activity and animal studies have indicated that the com-
pound is more potent as a serotonergic antagonist in the periphery than in the central 
nervous system. Chapters 6, 7 and 8 offer a survey of studies on the hemodynamic effects 
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of keta.nserin in hypertensive patients and in patients with local vasoconstriction 
(Raynaud's phenomenon). 
CHAPTER6 
The two papers of chapter 6 present data about the acute and chronic blood pressure 
lowering effects of keta.nserin in patients with essential hypertension. In the first pilot study 
10 mg ketanserin was administered intravenously to 12 patients with untreated essential 
hypertension and its acute effects on intra-arterial blood pressure, heart rate, right atrial 
pressure, pulmonary artery pressure, cardiac output, renal blood flow and glomerular 
filtration rate were followed for several hours. In the second study ketanserin was given 
orally, in a dose of 40 mg b.i.d., for six weeks to 24 subjects with mild to moderate 
essential hypertension. Its effects were evaluated in a placebo-controlled double-blind 
crossover study. In 18 subjects 24- hour ambulatory intra-arterial measurements were 
made,besides the usual sphygmomanometer measurements. 
CHAPTER 7 
During our studies it became apparent that ketanserin also interacts with other cell 
membrane receptors, alphru -adrenoceptors in particular. Thus, the question of alphru-
adrenoceptor blockade by ketanserin has to be answered before it can be concluded that the 
antihypertensive and vasodilatory effect of ketanserin supports the involvement of the 
peripheral actions of serotonin in hypertension and other vascular disorders. In this context, 
one should keep in mind that conclusive evidence in this matter may only come from 
studies in humans, since animal models such as the spontaneously hypertensive rat may not 
allow better prediction of the efficacy of serotonergic blockers to lower blood pressure than 
they did years ago for beta-adrenergic blockers. 
The first paper of chapter 7 describes the hemodynamic profiler of ketanserin's 
antihypertensive action in patients with essential hypertension. The possibility that the 
antihypertensive effect of ketanserin depends on interference with alphru-adrenoceptor-
mediated vasoconstriction was tested by comparing of the pressor effects of the alphal-
adrenoceptor agonist, phenylephrine, before and after keta.nserin and by an assessment of 
the antihypertensive effect ofketanserin after administration of the alphru-adrenoceptor 
antagonist, prazosin.The cardiovascular effects ofketanserin were also studied in a small 
group of patients with autonomic insufficiency, who were unresponsive to the hypotensive 
action of the nonselective alpha-adrenoceptor antagonist, phentolamine. The last paper of 
this chapter explores these issues further. 
CHAPTERS 
During its initial clinical evaluation as an antihypertensive agent, we found that 
keta.nserin improved digital blood flow in patients with hypertension and concomitant 
Raynaud's phenomenon. Primary Raynaud's phenomenon is characterized by episodic 
reversible vasospasms of blood supply to fingers and toes, triggered by cold exposure or 
emotional stress. The often severe vasoconstriction has been suggested to be a consequence 
of overactivity of the sympathetic nervous system but therapy with alpha-adrenoceptor 
blocking agents has been disappointing. 
In vitro, serotonin caused contraction of isolated arteries and veins from the hand of 
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healthy humans with an intrinsic activity approximately equal to that of noradrenaline and 
adrenaline. Direct infusion of serotonin into the brachial artery of humans caused a drop in 
the digital temperature and induced the characteristic sequential skin discoloration of 
Raynaud'sphenomenon. 
Chapter 8 explores the mode of action of ketanserin in patients with primary Raynaud's 
phenomenon. Changes in digital blood flow after ketanserin were studied by venous 
occlusion plethysmography and laser-Doppler flowmetry. The effects on transcutaneously 
measured oxygen pressure were also evaluated. 
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CHAPTER 1 
ACE INHIBITION AND PLASMA 
RENIN 
Does captoprillower blood pressure in anephric patients? 
Man in 't Veld AJ, Wenting GJ, Schalekamp MADH. 
British Medical Journal1979; 2: 1110-1111. 
Blood pressure response of nephrectomized subjects and patients with 
essential hypertension to ramipril (HOE 498): indirect evidence that 
inhibition of tissue angiotensin converting enzyme is important. 
Wenting GJ, Blankestijn PJ, Poldermans D, Van Geelen JA,Derkx FHM, 
Man in 't Veld AJ, Schalekamp MADH. 
American Journal of Cardiology 1987; 59 (suppl D): 92-97. 
Hemodynamic effects of captopril in essential hypertension, 
renovascular hypertension and cardiac failure: correlations with 
plasma renin. 
Wenting GJ, De Bruyn JHB, Man in 't Veld AJ, Woittiez AJJ, Derkx 
FHM, Schalekamp MADH. 
American Journal of Cardiology 1982; 49: 1453-1459. 
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Reprinted from the BRITISH MEDICAL JOURNAL, 
3 November 1979, 2, 1110 
Does captoprillower blood 
pressure in anepluic patients? 
Captopril inhibits peptidyldipeptide hydrolase, the enzyme that con-
verts angiotensin I to angiotensin II and degrades bradykinin. Capto-
pril's antihypertensive action seems to depend on the activity of the 
renin-angiotensin system in relation to the state of sodium baiance.1- 3 
It is not clear, particularly in patients with normal or low plasma 
renin activity, whether captoprillowers blood pressure by eliminating 
the vasoconstrictor angiotensin II or by allowing the vasodilator 
bradykinin to accumulate. We have studied captopril's effect on supine 
and standing blood pressure in an anephric woman in three different 
states of sodium balance. 
Patient, methods, and results 
Captopril (25 mg by mouth) was given to a 36-year-old anephric woman 
on three occasions: one hour after haemodialysis when she was volume and 
sodium overloaded and weighed 62·2 kg; and then two and seven days after 
progressive ultrafiltration, when she weighed 57 ·9 kg and 56· 7 kg respectively. 
Active plasma renin concentrations, measured by radioimmunoassay, ranged 
from 1·2 to 2·9 mU/1 (normal16-40 mU/1) in the three states and did not rise 
after captopril. Angiotensin-convening-enzyme activity was measured by 
spectrophotometric assay of the rate of production of hippuric acid from 
hippuryl-L-histidyl-L-leucine and expressed as a percentage of control 
values derived before captopril was given. Enzyme activity was inhibited by 
56±6% (mean±SE of mean) 30 minutes after captopril was given and by 
92 ± 7 % after 120 minutes. The blood pressure was measured with a random-
zero sphygmomanometer (London School of Hygiene, mk 4, No 7125) to 
avoid digital preference and observer bias. Hean rate was determined from 
a continuous electrocardiograph. 
The figure shows the effect of captopril on blood pressure and heart rate 
in the three different states. The patient was severely hypenensive when she 
weighed 62·2 kg, but captopril had no effect on standing or supine blood 
pressure. When the patient weighed 57·9 kg her supine blood pressure was 
143/90 mm Hg. She did not have postural hypotension before captopril was 
given, but after captopril, although heF supine blood pressure rose by 10 'l'o, 
her blood pressure dropped from 156/101 mm Hg to 98/61 mm Hg on 
standing and she complained of dizziness. When her weight had fallen to 
56·7 kg, captopril caused a 15% drop in supine blood pressure (144/86 mm 
Hg to 128/71 mm Hg), and on standing her blood pressure fell further to 
79/43 mm Hg and she felt that she was going to faint. Again before captopril 
was given there was no postural hypotension. 
Hypertension Unit, Department of Internal Medicine I, University 
Hospital Dijkzigt, Erasmus University, Rotterdam 
A J MAN IN 'T VELD, MD, senior medical registrar 
G J WENTING, MD, senior medical registrar 
MAD H SCHALEKAMP, MD, senior lecturer and consultant physician 
COPYRIGHT @ 'f179 ALL RIGHTS OF REPRODUCTION OF TIDS REPRINT ARE RESERVED 
401/79 IN ALL COUNTRIES OF TilE WORLD 
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Effect of captopril (25 mg by mouth) in an anephric patient in 
three different states of sodium balance on supine and standing 
blood pressure, mean arterial pressure, and heart rate. (Mean 
arterial pressure was calculated from diastolic pressure and 1/3 of 
pulse pressure.) 
Comments 
Our findings show that captopril's effect on blood pressure in an 
anephric patient depends on the state of sodium balance. As little renin 
is available the effect cannot be through elimination of angiotensin II, 
but it may be through accumulation of bradykinin. 4 Others have not 
found any effect of captopril on blood pressure in anephric patients 
and rats, 3 4 but any hypotensive effect may have been masked by 
hypervolaemia. Also the blood pressure response to captopril may be 
partially independent of renin-sodium balance in subjects with a low 
plasma renin activity. If renin is inappropriately low in relation to 
total-body sodium then captopril may produce its effect by potentiat-
ing bradykinin action. Furthermore, our case illustrates that an 
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extrarenal kallikrein-kinin system may be important. The postural 
Kypotension that developed may support a suggestion5 that vasoactive 
peptides may effect venous tone. The fact that heart rate increased 
considerably more when the patient stood in the sodium-depleted 
state suggests that the baroreceptor-induced changes in sympathetic 
tone were appropriate. The postural hypotension may have been 
caused by a fall in venous return and cardiac output caused by 
inhibition of the angiotensin-converting enzyme increasing the 
capacitance of the venous system. 
1 Gavras, H, et al, New Enf{landJournal of Medicine, 1978, 298, 991. 
2 Case, D B, et al, Progress in Cardiovascular Diseases, 1978, 21, 195. 
3 Case, DB, eta/, American Journal of Medicine, 1976, 61, 790. 
4 Thurston, H, and Swales, J D, Circulation Research, 1978, 42, 589. 
5 Turini, G A, et al, Lancet, 1979, 1, 1213. 
(Accepted 7 August 1979) 
Printed in Great Britain by Bourne Offset (lver) Ltd., lver, Bucks. 
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Blood Pressure Response of Nephrectomized Subjects 
and Patients with Essential Hypertension to Ramipril: 
Indirect Evidence That Inhibition of 
Tissue Angiotensin Converting Enzyme Is Important 
GERT J. WENTING, MD, PETER J. BLANKESTIJN, MD, DON POLDERMANS, MD, 
JOS van GEELEN, MD, FRANS H.M. DERKX, MD, ARIE J. MAN in't VELD, MD, 
and MAARTEN A.D.H. SCHALEKAMP, MD 
The kinetics of blood pressure changes and plasma 
angiotensin converting enzyme (ACE) inhibition in 
response to ramipril (HOE 498), 10 mg orally, were 
studied in 6 nephrectomized subjects 12 hours after 
ultrafiltration and in to patients with essential hy-
pertension. Ramipril lowered supine and standing 
blood pressure in both groups, but the effect was 
greater in essential hypertension. The maximal 
Experimental and clinical evidence suggests that the 
antihypertensive action of angiotensin converting en-
zyme [ACE) inhibitors cannot be explained solely by 
blockade of the circulating renin -angiotensin sys-
tem.1~3 Target tissues for blood pressure regulation, 
such as blood vessels, kidney, adrenal gland and brain, 
contain renin, ACE and other components of the re-
nin-angiotensin system, and inhibition of ACE in these 
tissues may contribute to the effect of ACE inhibitors. 
It has even been hypothesized that the primary func-
tion of the circulating renin-angiotensin system is not 
so much to deliver angiotensin II to the tissues but 
rather to deliver angiotensinogen and renin.4 
The kidney is the main, if not the only, source of 
enzymatically active renin in plasma. The level of ac-
tive renin is very low, if not absent, in plasma of ne-
phrectomized subjects. In contrast, plasma angioten-
sinogen is high and the plasma concentration of inac-
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blood pressure response followed the effect on plas-
ma ACE after a lag time of· 3 to 4 hours in both 
groups. These data provide indirect evidence that 
ramipril lowers blood pressure, at least in part, inde-
pendently of its effect on the circulating renin-angio-
tensin system, possibly by acting on tissue ACE. 
(Am J Cardiol 1987;59:920-970) 
tive renin (prorenin] is often within the normal 
range.5•6 It has been proposed that angiotensinogen 
and prorenin may be taken up from plasma by the 
tissues. Prorenin may then be activated and contribute 
to the local formation of angiotensin IF 
The novel compound HOE 498 [ramipril] is a potent 
inhibitor of ACE and penetrates readily into the tis-
sues.8 In view of the possibility that ACE inhibition on 
the tissue level might contribute to the antihyperten-
sive action of ramipril, we studied the kinetics of the 
blood pressure response in relation to the degree of 
inhibition of plasma ACE by this drug both in nephrec-
tomized subjects and in patients with essential hyper-
tension. 
Patients and Methods 
Studies were undertaken in 6 nephrectomized sub-
jects (4 women, 2 men, 29 to 54 years) and in 10 patients 
with essential hypertension (5 women, 5 men, 35 to 59 '· 
years]. Bilateral nephrectomy had been performed 4 
months to 5 years before. The reasons for nephrectomy 
were: intractable renal infection in 4 subjects, uncon-
trollable severe hypertension in 1 subject and recur-
rent renal bleeding [adult polycystic disease] in 1. The 
nephrectomized subjects were receiving maintenance 
19 
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TABLE I Baseline Clinical Data in Nephrectomized Subjects 
Patient 
No. 
Blood Pressure 
(mmHg) 
R 
136/86 130/86 
113/74 123/72 
113/73 113/70 
148/92 139/85 
156/102 144/92 
97/61 108/67 
P = placebo; R = ramipril. 
Heart Rate 
(beats/min) 
R 
88 99 
91 83 
83 89 
86 72 
76 69 
67 67 
hemodialysis, twice a week, with a Fresenius A 2008 C 
dialyzer and a disposable polyacrylonitryl membrane 
kidney. None of these subjects showed clinical or ra-
diologic evidence of congestive heart failure and none 
of them was receiving vasoactive drugs. In the patients 
with essential hypertension, antihypertensive therapy 
had been stopped for at least 2 weeks before the study. 
Sodium intake in these patients was restricted to 50 to 
70 mmol daily and was checked by 24-hour urine 
collection. 
The study was performed on an outpatient basis. 
The nephrectomized subjects were studied in a ran-
domized double-blind placebo-controlled fashion. Ei-
ther 10 mg ramipril or placebo was given by mouth at 
9.30 A.M., 12 hours after a hemodialysis session, during 
which body fluid had been removed until "ideal" body 
weight had been reached. Three subjects began the 
study with active drug and 3 with placebo. Two weeks 
later, the subjects who had been given ramipril re-
ceived placebo, and vice versa. The loss of body 
weight for each dialysis session was 3.1 ± 0.5 kg (mean 
± standard error of the mean) for the subjects who 
received ramipril first, and it was 2.7 ± 0.5 kg for the 
subjects who received placebo first. The difference in 
weight loss was not statistically significant. 
The patients with essential hypertension first re-
ceived placebo and a week later 10 mg of ramipril 
orally. 
Systolic, diastolic and mean blood pressures and 
heart rate were measured automatically (Accutorr TM 
2, Datascope Corp.} every 5 minutes for 1 hour before 
ramipril or placebo was given and for 5 hours there-
after. Standing blood pressure and heart rate were 
measured each hour. Blood was obtained from an in-
dwelling venous catheter. The concentration of enzy-
matically active renin and the total renin concentra-
tion of plasma were measured by radioimmunoassay 
as described previously. 9 Results were expressed as 
,uU/ml, using the international human kidney renin 
standard (MRC 68/356} as a reference. Normal values 
in our laboratory are 10 to 50 ,uU/ml for active renin 
and 60 to 350 ,uU/ml for total renin. Plasma ACE was 
measured by the rate of production of hippuric acid 
from hippuryl-L-histidyl-L-leucine.10 Normal values 
are 7 to 20 mU/ml. 
Data are presented as mean ± standard error of the 
mean, and for statistical comparison the Student's 
paired t test was used. A p value of <0.05 was consid-
ered to indicate a statistically significant difference. 
Active Renin Total Renin Plasma ACE 
(!'Uiml) (~<Uiml) (mU/ml) 
p R R R 
0.4 0.6 89 85 13.4 18.0 
0.1 0.3 24 28 14.2 23.8 
0.4 0.4 38 39 16.2 14.8 
0.2 0.2 25 21 24.0 24.7 
0.7 1.3 133 161 15.0 14.3 
0.4 0.2 10.8 17.6 
The study protocol was approved by the Hospital 
Ethical Review Committee, and informed consent was 
obtained from each patient. 
Results 
Effect on plasma renin, blood pressure and heart 
rate: Clinical data on the nephrectomized subjects be-
fore ramipril and placebo therapy were not different 
(Table I). As expected, active renin in plasma was 
hardly detectable and was unresponsive to ramipril. In 
contrast, the plasma concentration of prorenin ranged 
from low-normal to normal. Supine and standing 
blood pressures did not change with placebo, but de-
creased after ramipril therapy (Fig. 1}. There was no 
significant difference in heart rate between the place-
bo and ramipril periods, and the increments of heart 
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FIGURE 1. Effect of ramipril, 10 mg orally, on su~ine and standing 
blood pressure and heart rate in 6 nephrectomized subjects. Su-
pine, systolic and diastolic blood pressures were significantly lower 
after ramipril (p <0.05). Standing blood pressures were also lower 
(p <0.01). 
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rate on standing were also not different. The decrease 
in blood pressure after ramipril was more pronounced 
in the standing position, but frank orthostatic hypoten-
sion was not observed. Figure 2 shows the changes in 
blood pressure in the nephrectomized subjects in more 
detail. The effect of ramipril on blood pressure in 
these subjects was maximal 4 to 5 hours after drug 
intake. In 3 subjects mean arterial pressure decreased 
by more than 10o/o. 
Active renin in plasma was normal in the patients 
with essential hypertension and showed the expected 
increase after ramipril. Ramiprillowered blood pres-
sure in both the supine and standing position in these 
patients (Fig. 3). Heart rates after ramipril and placebo 
were not significantly different. 
Effect on blood pressure versus effect on plasma 
angiotensin converting enzyme: In both the nephrec-
tomized and essential hypertension subjects, ramipril 
was rapidly absorbed and converted into the bioactive 
compound, as was shown by blockade of plasma ACE 
activity (Fig. 4). Inhibition of ACE was already detect-
able after 30 minutes and was maximal between 1 and 
2 hours after administration. The effect of blood pres-
sure became evident between 1 to 2 hours after drug 
intake and was maximal at 4 to 5 hours in both patient 
groups. Thus, the blood pressure response did not co-
incide with the inhibition of plasma ACE; the maximal 
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FIGURE 2. Individual blood pressure responses of nephrectomized 
subjects to ramipril, 10 mg orally. 
effect on blood pressure followed the effect on plasma 
ACE after a lag time of 3 to 4 hours. 
Discussion 
Ramipril belongs to a new class of orally active, 
non-sulfhydryl pro-drug ACE inhibitors. Enalapril 
also belongs to this class. Ramipril and enalapril have 
a pharmacologic profile similar to that of the ACE 
inhibitor captopril, but they differ from captopril by 
their prolonged action and greater ACE inhibitory po-
tency. Ramipril acts even longer than enalapril and 
may further differ from enalapril in that it has greater 
effect on tissue ACE. It has been reported that in spon-
taneously hypertensive rats the magnitude of blood 
pressure response to the 2 drugs was different and that 
this difference could not be explained by a difference 
in their inhibitory effect on the circulating renin-an-
giotensin system. 3 It was instead related to the degree 
of ACE inhibition in tissues. Ramipril was more potent 
in this respect. Differences in lipid solubility and ex-
tent of hydrolysis of the pro-drug in tissue may be 
important. 
In the present study we gathered some data on ra-
mipril's mode of action by relating its effect on blood 
pressure with its effect on plasma ACE in nephrecto-
mized subjects with very low levels of circulating ac-
tive renin, and in patients with essential hypertension 
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FIGURE 3. Effect of ramipril, 10 mg orally, on supine and standing 
blood pressure and heart rate in 10 patients with essential hyperten-
sion. Supine and standing systolic and diastolic blood pressures 
were significantly lower alter ramipril (p <0.01 ). 
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FIGURE 4. Time course of changes in blood pressure and plasma 
angiotensin converting enzyme (ACE) in response to ramipril, 10 
mg orally, in 6 nephrectomized subjects (black bars) and 10 pa-
tients with essential hypertension (hatched bars). 
with normal renin. In a previous study we showed that 
blood pressure was reduced in fluid-depleted ne-
phrectomized subjects by the ACE inhibitor captopril, 
which was given 1 hour after completion of hemodial-
ysis.11 We interpreted our findings as evidence that the 
effect of captopril on blood pressure may not solely 
depend on its effect on the circulating renin-angioten-
sin system. However, it has been proposed that the 
decrease in blood pressure might have been due to a 
mechanism somehow related to hemodialysis.1z Expo-
sure of blood to the dialysis membrane might trigger 
the production of vasodepressor kinins. Because the 
kinin degrading enzyme, kininase II, is identical with 
ACE, reduced degradation of circulating kinins might 
explain our findings. Leslie et al' 2 administered capto-
pril24 hours after dialysis, and were unable to demon-
strate a hypotensive effect. However, the decrease in 
blood pressure we observed lasted for more then 24 
hours and was progressive in time. Some patients 
showed symptomatic orthostatic hypotension 24 hours 
after captopril, and this was not observed 3 to 4 hours 
after completion of the dialysis procedure, even 
though inhibition of ACE was maximal at that time. In 
our view it is therefore unlikely that circulating kinins 
had contributed to the hypotensive effect of captopril 
in these patients . 
To avoid possible interactions with the hemodialy-
sis procedure, we administered ramipril12 hours after 
completion of hemodialysis. The present results with 
ramipril confirm that ACE inhibitors are capable of 
lowering blood pressure in nephrectomized subjects. 
After ingestion of ramipril, serum ACE decreased rap-
idly in these subjects. It was inhibited by more than 
50o/o, 30 minutes after dosing, and the maximum effect 
was at 1 to 2 hours. Blood pressure, however, de-
creased more gradually and the maximum response 
was after 4 to 5 hours. Thus, there was a considerable 
time lag between the 2 effects. A similar time lag was 
observed in the patients with essential hypertension, 
although the magnitude of the blood pressure response 
was greater in these patients than in nephrectomized 
subjects. 
These findings, taken together, lend further support 
to the hypothesis that ramipril may lower blood pres-
sure, at least in part, independently of its effect on the 
circulating renin-angiotensin system, possibly by act-
ing on tissue ACE. The rapid onset of absorption and 
hydrolysis into the biologically effective dicarboxylic 
acid is somewhat surprising, but our results are sup-
ported by previous pharmacokinetic studies.8•13 
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The hemodynamic effects of captopril were investigated in 22 patients 
with essential hypertension, 22 with hypertension and renal artery stenosis 
and 14 with refractory chronic heart failure. The effects of a first dose of 
captopril, 50 mg orally, were observed for 2 hours, and the effects of re-
peated doses, 450 mg/day in combination with mild dietary sodium re-
striction, for at least 4 weeks. 
Short-term captopril treatment caused similar reductions in blood 
pressure in the three patient groups, that is, 21 ± 3 mm Hg in essential 
hypertension, 29 ± 6 mm Hg in renovascular hypertension and 21 ± 2 mm 
Hg in heart failure (mean ± standard error of the mean) despite large 
differences in pretreatment plasma renin. Heart rate and cardiac output 
did not change in hypertensive patients, a!ld cardiac filling pressures 
decreased. The changes in right atrial pressure, pulmonary artery pressure 
and pulmonary capillary wedge pressure in essential hypertension and 
in renovascular hypertension did not differ. Heart rate decreased and 
cardiac output increased in heart failure, whereas cardiac filling pressures 
decreased. Blood pressure responses to long-term captopril therapy in 
essential and in renovascular hypertension were similar and, as with 
short-term treatment, changes in blood pressure were largely determined 
by changes in peripheral resistance. Several measurements of extra-
cellular fluid volume showed no evidence of fluid retention by the kid-
neys. 
Short-term but not long-term blood pressure responses were correlated 
with pretreatment plasma renin (percent change in mean arterial pressure, 
short-term, versus log renin, r = 0.47, p <0.001, n = 14). Both short- and 
long-term responses of total peripheral resistance were correlated with 
plasma renin (percent change in resistance, short-term versus log renin, 
r = 0.64, p <0.001, n = 40; percent change in resistance, long-term versus 
log renin, r = 0.56, p <0.001, n = 31 ). The correlations were weak and 
probably not important for clinical practice. These data indicate that other 
factors besides circulating renin are important in captopril's hypotensive 
effect. The favorable hemodynamic effects of converting enzyme inhibition 
Jrarrant further consideration of this principle of therapy in the clinical 
management of most forms of hypertension and also in the treatment of 
chronic heart failure. 
The efficacy of captopril in decreasing blood pressure has amply been 
demonstrated. Several but not all centers reported the drug to be more 
effective in hypertension when plasma renin is high rather than low.1·2 
Positive correlations were observed between the decrease in blood 
pressure shortly after a single dose of captopril and pretreatment plasma 
renin.3.4 Such correlations were also recorded after long-term treat-
ment4·5 but again not invariably so.S-10 Theoretically, the change in 
vascular resistance after captopril might correlate more closely with 
pretreatment renin than does the change in blood pressure. Other dif-
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ferences between hemodynamic responses in patients 
with high-renin and low-renin hypertension may exist. 
Comparative studies to explore this possibility are 
scarce. Apart from a study by Atkinson et al.ll indi-
cating that total exchangeable sodium had not changed 
after 6 weeks of captopril therapy in eight patients with 
renal artery stenosis, there are few data on fluid balance 
during long-term captopril treatment. Such information 
is important because it may help to delineate more 
clearly the place of this drug among the antihyperten-
sive drugs now in common use. 
We have collected such data in patients with essential 
hypertension and in those with hypertension associated 
with renal artery stenosis. The results were compared 
with observations in so-called r-efractory chronic heart 
failure. Plasma renin was low or normal in essential 
hypertension, normal or high in renal artery stenosis 
and grossly elevated in most cases with heart failure. 
Methods 
Patient Groups 
Forty-four hypertensive and 15 normotensive pat!ents wit_h 
chronic heart failure were studied after they had given their 
informed consent to the study protocol and procedures. 
Essential hypertension: Twenty-two patients (7 women), 
aged 48 ± 2 years, were studied. Routine investigations in-
cluding intravenous urography and radioisotope renography 
had not revealed any cause for the hypertension. In 17 patients 
previous antihypertensive therapy, if any, was tapered off and 
a placebo was given for at least 3 weeks. Blood pressure on 
placebo was 140 to 200 mm Hg systolic and 95 to 120 mm Hg 
diastolic. Five patients remained on multiple drug therapy. 
In these five patients blood pressure was 160/100 mm Hg or 
higher despite a 2 week course of standard triple therapy, that 
is a combination of a diuretic (hydrochlorothiazide 100 
m'g/day or furosemide 80 mg/day) with a beta-adrenoc~ptor 
blocking agent (propranolol 320 mg/day) and a vasodilator 
(hydralazine 200 mg/day). . 
Hypertension associated with renal artery stenosis 
(renovascular hypertension): This group consis~ed of 22 
patients (9 women), aged 42 ± 4 years. Renal arteriOgraphy 
and renal vein sampling was performed because of abnor-
malities found on routine intravenous urography or radio-
isotope renography, or both. In 18 patients unilateral and in 
4 patients bilateral renal artery stenosis was demonstrate~. 
The renal vein-to-artery ratio of renin on the side of stenosis 
ranged from 1.5 to 4.6. Of these 22 patients, 16 were treated 
by placebo for at least 2 weeks. Blood pressure on J;lace~o w~s 
150 to 200 mm Hg systolic and 95 to 120 mm Hg diastolic. Six 
remained on standard triple therapy for at least 2 weeks. 
Chronic heart failure: Fourteen patients (3 women), aged 
52 ± 2 years, were studied. Nine had ischemic hear~ disease 
and five had valvular disease. 1n four of the latter patients one 
or more prosthetic valves had been placed. All had refractory 
congestive heart failure and were in functional cla_ss I'-: (N~w 
York Heart Association) while under treatment with digoxm, 
a diuretic (furosemide 80 to 120 mg/day) and vasodilators 
(either hydralazine and isosorbide dinitrate or prazosine). 
Study Design 
Patients with hypertension: The study in these patients 
was divided into four phases: an initial outpatient precaptopril 
evaluation during placebo or standard triple therapy (phase 
I), an inpatient captopril titration period (phas~ II), an out-
patient follow-up period of at least 4 weeks durmg captopnl 
monotherapy (450 mg/day) (phase III), and in some patients 
a final period in which a diuretic was added to captopril (phase 
IV). 
All measurements in phase I were made when the patients 
had been recumbent for at least 1 hour. Noninvasive mea-
surements of cardiac output (vide infra) were begun when the 
patients were on placebo or standard triple therapy for at least 
2 weeks. Dietary advice to restrict sodium intake was given 
but adherence to this advice was not rigorously checked. 
However, spot 24 hour urine collections in 30 patients during 
phases I and III gave values of 112 ± 8 and 108 ± 10 mmol of 
sodium, respectively. 
For initiation of captopril treatment in phase II, patients 
were admitted to the hospital for a few days. The hemody-
namic effects of a single first dose of captopril, 50 mg orally. 
were observed for several hours by invasive techniques in 14 
patients with essential hypertension and in 16 with hyper-
tension and renal artery stenosis. None of them had been on 
active drug for at least 3 weeks. Eleven patients on standard 
triple therapy were slowly titrated with increasing doses of 
captopril on an 8 hour schedule, while triple therapy wasta-
pered off. In all patients a final daily dose of 450 mg was 
reached in a few days. 
After discharge all patients were followed up in phase {II 
in the outpatient clinic. Noninvasive measurements of cardiac 
output, which had been performed in phase I, were now re-
peated at weekly intervals. Therapy compliance was checked 
by pill counting. 
In phase IV the hemodynamic effects of adding hydro-
chlorothiazide, 25 to 100 mg/d~y, to captopril, 450 mg/d:>y, 
were studied in patients who d1d not become normotensive 
(150/90 mm Hg or less) on captopril alone. 
Patients with chronic heart failure: All patients were 
admitted to the coronary care unit and the withdrawal of 
previous vasodilator therapy was covered by invasive '?ani-
taring. Twenty-four hours after the last dflse of vasodilator 
and 12 hours after the last dose of diuretic, captopril50 mg was 
given and the effects were observed for several hours. 
Measurements 
Hemodynamics: All hemodynamic studies were performed 
while the patients were in the postabsorptive state and when 
they had been recumbent for at least 1 hour. The short-term 
effects of captopril were monitored invasively and the mea-
surements were begun 1 hour after the catheters had been 
placed. Systemic arterial pressure was measured through a 
catheter introduced into a radial or brachial artery. A Swan-
Ganz flow-directed triple lumen catheter was introduced by 
way of an antecubital vein for recording right atrial, pulmo-
nary artery and pulmonary capillary wedge pressure~. Cardiac 
output was measured in triplicate by thermodilutiOn tech-
nique. 
Blood pressure: Noninvasive methods were used for re-
peated measurements before and during long-term captopril 
treatment. Blood pressure was measured with the London 
School of Hygiene sphygmomanometer to minir:>ize o?server 
bias.I2 Disappearance of sounds was taken as diastolic pres-
sure. 
Cardiac output: This was measured by an indicator dilu-
tion technique using technetium-99m-human serum albumin 
(100 to 200 I'Ci). Time-concentration curves were recorded 
by precordial counting of radioactivity. The counting ~robe, 
which was described previously,l.l was placed perpendicular 
to the chest wall without lateral rotation, over the fifth rib at 
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FIGURE 1. Short-term hemodynamic effects of captopril, 50 
mg orally, in patients with essential hypertension (n = 14), 
hypertension with renal artery stenosis (n = 16) and chronic 
heart failure (n = 14). Data on arterial pressure, heart rate 
and central pressures in heart failure were obtained in 14 
patients; data on cardiac output and peripheral resistance 
in 10. Data relevant to body size were converted to 1.73 m2 
body surface area. MPAP = mean pulmonary artery pressure; 
PCWP = mean pulmonary capillary wedge pressure; RAP 
= right atrial pressure. • p <0.05; •• p <0.01; ••• p 
<0.001. 
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the mi(isternalline with the patient supine. Response curves 
were recorded for 1 to 2 minutes after rapid intravenous in-
jection of the isotope. Additional recordings were made after 
5 and 10 minutes when blood samples were taken. Cardiac 
output was calculated with the Stewart-Hamilton formula. 
From duplicate measurements in 30 subjects with cardiac 
output values ranging from 4 to 12 liters/min the coefficient 
of variation was calculated to be 6 percent. Simultaneous 
measurements of cardiac output by the classical indocyanine 
dilution method and by the isotope method showed good 
agreement (r = 0.92, n = 37). Heart rate was calculated from 
a continuously recorded electrocardiogram. Immediately after 
the precordial time-radioactivity curve was recorded, blood 
pressure was measured in triplicate. Mean blood pressure 
(diastolic pressure + 0.3 X pulse pressure) was used for cal-
culating total peripheral resistance. 
Extracellular fluid volumP was estimated by measuring the 
distribution volume of intravenously injected sodium 'l5S 
sulphate (50 to 60 !LCi) with blood sampling at 0, 30, 60, 80, 100 
and 120 minutes. 14 Blood samples were also drawn for deter-
mination of active plasma renin. The normal range of plasma 
renin is 15 to40 !LU/ml.15 All values relevant to body size were 
converted to 1. 73 m2 body surface area. 
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ESSENTIAL RENAL CONGESTIVE 
HYPERTENSION ARTERY STENOSIS HEART FAILURE 
ARTERIAL PRESSURE mmHg 
~~~~~::: ~~~~~::: Dooo o::: 
HEART RATE beats/min 
~ I ~ ~ i ! ! ! '! ! ~ .. ] 
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~ ... ~ ~:::j 
TOTAL PERIPHERAL RESISTANCE dyn s cm-5 
A Coptopril A Coptopril A Coptopril 
60 120 60 120 60 120 
TIME (min) 
Statistics: Data are presented as mean values± standard 
error of the mean. The t tests for paired and unpaired data 
were used for comparison. 
Results 
Short-Term Studies 
Blood pressure and hemodynamic effects (Fig. 
1): The effects of 50 mg of captopril were maximal at 90 
minutes. At that time mean arterial pressure had de-
creased from 141 ± 6 to 119 ± 7 mm Hg in patients with 
essential hypertension (n = 14), from 143 ± 6 to 114 ± 
5 mm Hg in those with hypertension with renal artery 
stenosis ("renovascular") (n = 16) and from 76 ± 3 to 
54 ± 4 mm Hg in those with chronic heart failure (n = 
14). These responses were not significantly different 
among the three patient groups (p >0.05). Heart rate 
and cardiac output did not change in the two hyper-
tension groups. Heart rate decreased from 90 ± 4 to 82 
± 3 beats/min (p <0.01) in the chronic' heart failure 
group and cardiac output increased from 4.3 ± 0.5 to 5.2 
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FIGURE 2. Long-term hemodynamic effects of captopril, 450 mg/day, 
in patients with essential hypertension (n = 17) and hypertension with 
renal artery stenosis (n = 14). Measurements during captopril therapy 
are compared with those in the last week of placebo treatment. For 
further details see legend to Figure 1. 
± 0.1liters/min (p <0.05). Right atrial pressure, pul-
monary artery pressure and pulmonary capillary wedge 
pressures decreased in the three patient groups. The 
changes in these pressures were greater (p <0.01) in 
chronic heart failure than in essential hypertension and 
renovascular hypertension. 
Total peripheral resistance decreased from 2,170 ± 
90 to 1,880 ± 90 dynes s cm-5 in essential hypertension, 
from 1,980 ± 160 to 1,600 ± 130 dynes s cm-5 in "reno-
vascular" hypertension and from 1,360 ± 210 to 770 ± 
130 dynes s em - 5 in chronic heart failure. The resistance 
changes were greater (p <0.05) in heart failure than in 
the two hypertensive groups. 
Plasma renin: Plasma renin increased from 27 ± 6 
ILU/ml before captopril to 79 ± 30 ILU/ml90 minutes 
after captopril in essential hypertension. It increased 
from 110 ± 21 to 700 ± 120 ILU/ml in renovascular hy-
pertension and from 7 40 ± 330 to 2, 700 ± 870 !l U /ml in 
chronic heart failure. 
Long-Term Studies 
Captopril monotherapy in essential and reno-
vascular hypertension (Fig. 2): Mean blood pressure 
BLOOD 180 
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FIGURE 3. Long-term hemodynamic effects in the two hypertensive 
groups of captopril alone as compared with standard triple therapy (n 
= 11) and with captopril combined with diuretic (n = 1 0). For details 
see text and legend to Figure 1. 
had decreased from 136 ± 4 to 108 ± 2 mm Hg after 4 
weeks of captopril therapy, 450 mg/day, in the essential 
hypertension group (n = 17) and from 135 ± 4 to 105 ± 
3 mm Hg in the renovascular hypertension group (n = 
14). These responses in the two patient groups were not 
significantly different. Heart rate in the essential hy-
pertension group was 76 ± 3 beats per minute before 
captopril and 69 ± 2 after 4 weeks of captopril therapy. 
_Cardiac output was 5.5 ± 0.2liters/min before the drug 
and 4.8 ± 0.2 after 4 weeks. These changes were statis-
tically significant (p <0.05). Stroke volume was not 
significantly altered in the essential hypertension group. 
There were no significant changes in heart rate, cardiac 
output and stroke volume in the renovascular hyper-
tension group. Total peripheral resistance decreased 
from 2,070 ± 130 to 1,830 ± 92 dynes s cm-5 in the es-
sential hypertension group and from 1,940 ± 87 to 1,4 70 
± 69 in the renovascular hypertension group, the change 
in resistance being greater (p <0.01) in the latter 
group. 
Extracellular fluid volume in the essential hyper-
tension group was 14.8liters before captopril and 14.0 
liters after 4 weeks. In the "renovascular" hypertension 
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FIGURE 4. Linear regression analysis of short-term and long-term effects of captopril as related to plasma renin activity. Correlations of short-term 
percent changes in mean arterial pressure with log renin were significant in the group with hypertension and renal artery stenosis (r = 0.53, n = 
16, p <0.05), in the stenosis and essential hypertension groups together {r = 0.43, n = 30, p <0.01) and in the hypertension and heart failure groups 
together (r = 0.47, n = 44, p <0.001) but not in the essential hypertension and heart failure groups separately. Correlations of long-term percent 
changes in mean arterial pressure with log renin were not significant. Correlations of short-term percent changes in total peripheral resistance 
with log renin were significant in the hypertension groups together (n = 0.46, n = 30, p <0.01) and in the hypertension and heart failure groups 
together (r = 0.64, n = 40, p <0.001) but not in the groups separately. Correlations of long-term percent changes in total peripheral resistance 
with log renin were significant in the group with hypertension and renal artery stenosis (r = 0.52, n::::: 14, p <0.05) and in the stenosis and essential 
hypertension groups together (r = 0.56, n = 31, p <0.001) . .6.% :::::percent change; 0 :::::essential hypertension; 0 :::::hypertension with renal 
artery stenosis; f:l. ::::: chronic heart failure. 
group it was 14.2 and 14.1liters, respectively. The dif-
ference was statistically significant (p <0.05) only in the 
essential hypertension group. 
Plasma renin activity increased from 19 ± 4 1-'U/ml 
before captopril to 170 ± 90 1-'U/ml after 4 weeks of 
captopril therapy, 450 mg/day, in the essential hyper-
tension group and from 75 ± 19 to 570 ± 130 1-'U/ml in 
the "renovascular" group. 
Captopril monotherapy versus standard triple 
therapy (Fig. 3): The hemodynamic effects of 4 weeks 
of captopril monotherapy, 450 mg/day, and 4 weeks of 
standard triple therapy were compared in a group of 11 
patients including five with essential hypertension and 
six with hypertension and renal artery stenosis. Systolic 
and diastolic arterial pressures were lower (p <0.05) 
with captopril than with standard triple therapy (Fig. 
3). Moreover, cardiac output was higher (p <0.05) and 
total peripheral resistance was lower (p <0.01) with 
captopril. 
Captopril monotherapy versus captopril plus a 
diuretic (Fig. 3): The hemodynamic profiles of 4 weeks 
of captopril alone, 450 mg/day, and 4 weeks of captoprll 
plus hydrochlorothiazide, 25 to 100 mg/day, were 
compared in 10 patients with essential hypertension 
who did not become normotensive (150/90 mm Hg or 
less) on captopril alone. The addition of hydrochloro-
thiazide to captopril treatment caused a sustained de-
crease in extracellular fluid volume with further re-
duction in blood pressure. Heart rate and cardiac output 
showed no significant changes. Thus, the decrease in 
blood pressure was associated with a parallel decrease 
in total peripheral resistance. 
Correlations between hemodynamic responses 
and pretreatment plasma renin (Fig .. :~): Short-term 
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blood pressure responses 90 minutes after 50 mg of 
captopril in the three groups of patients combined were 
correlated with pretreatment plasma renin (percent 
change in mean arterial pressure versus log renin, p 
<0.001, n = 40). The correlation was rather weak (r = 
0.4 7) and was not significant in the essential hyper-
tension and heart failure groups separately. Short-term 
responses of total peripheral resistance were more 
closely correlated with pretreatment plasma renin 
(percent change in total peripheral resistance versus log 
renin, r = 0.64, p <0.001, n = 40). Long-term responses 
of mean blood pressure were unrelated to pretreatment 
plasma renin, whereas long-term responses of total 
peripheral resistance did correlate with pretreatment 
renin (r = 0.56, p <0.001, n = 31.). 
Discussion 
Blood pressure effects versus plasma renin: The 
hypotensive effects of captopril in essential hyperten-
sion and in hypertension with renal artery stenosis 
("renovascular") appeared to be similar in this study 
despite fourfold higher plasma renin activity in the 
"renovascular" hypertension group. A weak, albeit 
statistically significant correlation was observed be-
tween the short-term hypotensive effect of captopril and 
pretreatment renin in the group with renal artery ste-
nosis and in this group and the essential hypertension 
group together but not in the essential hypertension 
group alone. No such correlations between blood pres-
sure response and renin were observed during long-term 
captopril therapy (Fig. 4). 
The decrease in blood pressure was mainly caused 
by a decrease in peripheral resistance in both hyper-
tension groups. The changes in resistance in the two 
groups together were significantly correlated with 
pretreatment plasma renin both after short-term cap-
topril and after long-term treatment, but again the 
correlations were weak and were not significant in the 
individual groups (Fig. 4). 
Heart rate and cardiac output: Some statistically 
significant differences in the responses of heart rate and 
cardiac output to long-term captopril therapy between 
the two groups of hypertensive patients emerged. Heart 
rate and cardiac output decreased in those with essen-
tial hypertension and not in those with "renovascular" 
hypertension, but here again the differences were 
smalL 
Blood pressure and hemodynamic effects in heart 
failure: Plasma renin can be low, normal or high in 
chronic heart failure. 16 In our patients it ranged from 
30 to 4,600!-'U/ml (normal less than 40). By increasing 
unilateral vascular resistance the grossly elevated 
plasma renin in most of our patients might have con-
tributed to the maintenance of a relatively normal blood 
pressure in the presence oflow cardiac output. However, 
despite the wide range of renin values, the effect of 
captopril on peripheral resistance was only weakly 
correlated with pretreatment renin values (Fig. 4). 
Blood pressure was already low in some patients with 
heart failure and a further decrease in pressure might 
have been deleterious, but captopril was well tolerated 
by these patients. They had no chest pain and there 
were no electrocardiographic changes suggestive of in-
creased cardiac ischemia. Within 30 minutes after the 
intake of captopril the patients were less dyspneic. In-
deed, hemodynamic measurements showed improve-
ment: heart rate decreased and cardiac output increased 
in the presence of marked reduction in cardiac filling 
pressures. These results agree with those of previous 
reports on the short-term effects of captopril in heart 
failure_l7-1B 
Mechanisms of captopril's cardiovascular ef-
fects: The most important hemodynamic effect of 
captopril is arteriolar dilatation. The arterioles are the 
major resistance to blood flow and form by far the 
largest contribution to total peripheral resistance. 
Therefore, correlations between captopril's effect on 
total peripheral resistance and pretreatment plasma 
renin support the contention that blockade of plasma 
renin-mediated angiotensin II formation is a component 
of captopril-induced arteriolar dilatation. However, the 
correlation coefficients in our analysis were rather small 
and indicate that other factors besides circulating renin 
are important. The observed reduction in cardiac filling 
pressures has been considered to reflect a dilatory effect 
of captopril on capacitance vessels, However, it is more 
likely that reduced cardiac filling pressures are an ex-
pression of improved cardiac performance. Our data do 
not provide definite evidence for either possibility. 
Although captopril produces vasodilatation, it does 
not cause reflex tachycardia. From experiments in 
animals19 some evidence indicates that the set-point, 
but not the sensitivity, of the arterial baroreflex is al-
tered by converting enzyme inhibition. In man the 
baroreflex-mediated responses to upright posture seem 
unimpaired by captopril20; postural hypotension is 
seldom seen with this drug. 
Extracellular fluid volume: role of angiotensin 
and aldosterone: Captopril does not cause fluid re-
tention by the kidneys and again this contrasts with 
some other vasodilators. The decrease in extracellular 
fluid volume observed in some of our hypertensive pa-
tients and the absence of fluid retention in all can be 
explained, at least in part, by reduced angiotensin II 
formation, because this peptide is known to promote 
renal sodium and water retention both through its direct 
actions on the kidney and through aldosterone. A sim-
ilar mechanism could underlie the favorable hemody-
namic response to the combination of captopril with a 
diuretic. Our patients showed a sustained reduction of 
extracellular fluid volume after hydrochlorothiazide had 
been added to captopril, and this was associated with 
a decrease in total peripheral resistance. Presumably 
inhibition of angiotensin I conversion in these patients 
has prevented the compensatory increase in angiotensin 
II and aldosterone, which can limit the therapeutic ef-
fect of a diuretic, 21 •22 
A 20 percent reduction in both systolic and diastolic 
blood pressures was observed in our hypertensive pa-
tients with captopril as the only drug in combination 
with mild dietary sodium restriction. This response is 
as good or even better than the blood pressure responses 
to thiazide diuretics and beta-receptor blocking 
agents. 
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Therapeutic implications: Captopril is an effective 
antihypertendve agent with a favorable hemodynamic 
profile. The hemodynamic responses in essential hy-
pertension with low or normal plasma renin and in hy-
pertension associated with renal artery stenosis with 
normal or high renin are very similar. The long-term 
hemodynamic effects of converting enzyme inhibition 
that have been observed in patients with hypertension 
warrant further consideration of captopril as a treat-
RENIN AND THE HEMODYNAMIC EFFECTS OF CAPTOPRIL-WENTING ET AL. 
ment of choice in most forms of clinical hypertension. 
In severe or refractory chronic heart failure cardiac 
function can improve with captopril, but further studies 
are required to define its place in the long-term treat-
ment of heart failure. 
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Effects of captopril in acute and chronic heart failure 
Correlations with plasma levels of noradrenaline, renin, and 
aldosterone 
G J WENTING, A J MAN IN 'T VELD, A J WOITTIEZ, F BOOMSMA, K LAIRD-MEETER, M L 
SIMOONS, P G HUGENHOLTZ, MAD H SCHALEKAMP 
From the Departments of Internal Medicine I and Cardiology, Universicy Hospital Dijkzigr, Erasmus Universicy 
Rorrerdam, Rorrerdam, The Nerherlands 
SUMMARY The angiotensin-converting enzyme inhibitor, captopril, was given to 19 patients with 
severe heart failure. Seven patients had acute myocardial infarction and the remainder had chronic 
myocardial damage caused by ischaemia or valvular disease. Cardiac filling pressures were raised in all, 
the pulmonary capillary "wedge" pressure being 17 mmHg or more. Captopril, 50 _mg orally, raised 
stroke volume and cardiac output, and reduced heart rate, cardiac filling pressures, systemic arterial 
pressure, and the plasma concentrations of aldosterone and noradrenaline. These changes were 
attended by clinical improvement. Decrements in cardiac filling pressures, systemic arterial pressure, 
and total peripheral resistance were positively correlated with pretreatment plasma renin. Long-term 
treatment with captopril was offered to 14 patients. Four patients with severe coronary disease died 
suddenly after initial clinical improvement. In nine patients haemodynamic measurements were 
repeated after three months. The results showed sustained effects on cardiac output and filling 
oressures but there was no loss of body weight. The haemodynarnic effects were at least as good as with 
previous vasodilators. The fall in systemic arterial pressure, however, was greater with captopril. 
Captopril may become a valuable adjunct to the treatment of acute and chronic heart failure, but more 
information about its effect on coronary blood flow is required. 
The acute beneficial response to vasodilators in patients 
with congestive heart failure is well documented.'-' By 
lowering vascular tone and left ventricular wall tension, 
these agents improve myocardial contraction and 
reduce raised filling pressures of the heart. It is now 
also clear that such a favourable effect is not restricted 
to drugs that cause vasodilatation because of their 
direct relaxing effect on vascular smooth muscle. Com-
parable haemodynamic responses are observed with 
drugs that reduce sympathetic vascular tone,' 6 act by 
interruption of the renin-angiotensin-aldosterone 
cascade,? 8 or block serotonergic vascular mechanisms.9 
Because so many different neurohumoral factors are 
involved in the circulatory homeostasis ofhearc failure, 
however, it is likely that benefits from intervention in 
one regulatory system are lost by compensatory acti-
vation of other systems. In this regard it is significant 
that, as compared with the abundance of data on the 
acute benefits of vasodilatory treatment, little is known 
about its long-term efficacy .10 11 Experiments with 
.-\c~.:epred for pubhcauon 50ctober 19H2 
65 
32 
hydralazine" 13 and prazosin 1+-lo suggest that only part 
of the initial response is maintained. Weight gain, 
oedema, and increases in the plasma levels of renin, 
aldosterone, and noradrenaline have been found to 
accompany tolerance to these drugs. In contrast, the 
vasodilatory response to inhibitors of angiotensin-
converting enzyme is not accompanied by increased 
sympathetic activity17 and aldosteroJle productionl.< 
nor by renal sodium and water retention. 19 Indeed, 
good results have been obtained with the use .of the 
orally active angiotensin-convening enzyme inhibitor, 
captopril, even in patients with congestive heart failure 
refractory to conventional treatment. 20-21 The role of 
the renin-angiotensin system in heart failure, however, 
is not fully understood, 24 25 and information about the 
long-term cardiovascular and humoral effects of 
captopril in heart failure is fragmentary. 
With these uncertainties in mind we have studied the 
acute and long-term effects of captopril in normo-
tensive patients with heart failure and pulmonary con-
gestion. We have tried to correlate these effects with 
measurements of the plasma levels of noradrenaline, 
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renin, and aldosterone. These measurements were con-
sidered a rough index of the involvement of the 
sympathetic nervous system and the renin-angiotensin 
system in our patients. Two groups of patients were 
studied. In one group heart failure was an acute con-
dition occurring in the course of myocardial infarction. 
Plasma noradrenaline was r:iised in these patients but 
plasma renin and aldosterone were normal or low in 
most of them. In a second group heart failure was a 
chronic treatment-resistant condition, and most 
patients had high plasma noradrenaline as well as high 
plasma renin and aldosterone. 
Patients and methods 
Nineteen patients with normal blood pressure with 
heart failure were studied. On the basis of onset and 
duration of this condition the patients were divided 
into two groups. Acute pump failure resulting from 
transmural myocardial infarction was the cause of 
pulmonary congestion and shortness of breath in the 
seven patients of group 1 (Table 1). Criteria for 
inclusion were: mean pulmonary capillary wedge 
pressure higher than 17 mmHg and systolic arterial 
pressure between 90 and ISO mmHg. Captopril was 
given to four patients within 12 hours after the onset of 
myocardial infarction. Digoxin, diuretics, or other 
vasoactive agents were not used and the interval 
between the last sedative or pain relieving agent and 
captopril was at least one hour. Intravenous lignocaine 
for arrhythmia was necessary in two patients and this 
was continued during the study. The clinical condition 
of three patients (Table I, cases 5, 6, and 7) was such 
that initial treatment with intravenous dopamine and 
nitroprusside was indicated. Two to three days after 
the onset of myocardial infarction, these patients were 
weaned from intravenous therapy. Recurrence of 
pulmonary congestion and raised cardiac filling 
pressures, however, made additional treatment 
desirable. Captopril was then chosen as an oral sub-
stitute for the nitroprusside infusion they had received 
before. Treatment with dopamine and nitroprusside 
was stopped at least I2 hours before captopril was 
given. Group 2 consisted of 12 patients suffering from 
refractory congestive heart failure for at least two years 
(Table 2). The aetiology of ventricular failure was 
secondary to ischaemic heart disease and previous 
myocardial infarction in seven patients. Three of them 
had undergone coronary bypass surgery. Persistent 
poor ventricular function despite aortic or mitral valve 
Table I Clinical characteristics of patients with acute myocardial infarction 
Case Age Sex Weight Height Localisation of CKpeak Time beween onset Therapy (mgjd) 
No. (y) (kg) (m) myocardial infarction value(Ujl) MI and start 
capropril (h) Digoxin F rusemide 
I 71 M 69 1·75 Anterolateral 210 4 
2 55 M 76 1·74 Anteroseptal 870 5 
3 59 M 72 1·64 Anterior 1200 10 
4 57 M 81 1·72 Inferior 345 12 
5 45 M 60 1·78 Posterior 1600 30 0·250 240 
6 62 M 90 1·76 Anteroseptal 940 52 0·250 200 
7 57 F 67 1·69 Anteroseptal 1500 72 0·250 !60 
Note: CK, serum creatine kinase (normal value 5-30 U/1); !vii, myocardial infarction. 
Table2 Clinical characteristics and echocardiographic findings in patients with chronic heart failure 
Case Age Sex Weight Height Diagnosis and NYHA Echocardiographic Therapy (mgjd) 
No. (y) (kg) (m) duration of chronic class dimensions ( mm) 
heart failure (y) 
LA LA/AoLVD LVS Dig Fru Spir Hyd I so Pra Nif 
8 64 M 72 1·68 IHD 3 IV so 1·43 85 70 0·125 320 ISO 200 80 
9 49 F 72 1·63 IHD 2 IV 52 1-63 70 55 240 100 100 80 
10 63 M 61 1·79 IHDCB 3 IV 45 1·50 78 68 0·125 120 so 40 
II 62 M 76 1·82 VHDMV 2 III 72 1·89 70 60 0·250 320 200 80 
12 54 M 67 1·75 IHDCB 2 IV 60 2·00 75 60 0·250 120 100 80 40 
13 67 M 66 1·68 IHD 2 IV 60 1·71 100 90 0·250 80 100 
14 54 M 58 1·75 VHDA+MV 3 IV 63 1·70 90 85 0·250 160 so 200 80 
IS 74 F 60 1·69 VHDMV 6 IV 65 1·86 60 45 0·125 320 so 
16 59 F 65 1·68 VHDAV 2 IV 55 1·38 so 35 0· 125 80 so 16 
17 46 M 78 1·80 IHDCB 3 IV 65 2·32 62 so 0·250 120 200 80 
18 64 F 73 1.66 VHDMV 5 IV 70 1-89 70 60 0·250 160 100 
19 46 M 79 1-68 IHDCB 5 III 45 1·66 73 59 0·250 80 80 40 
IHD, ischaemic heart disease; VHD, valvular hean disease; CB, coronary bypass; MV, prosthetic mitral valve; AV, prosthetic aortic valve; 
echocardiographic dimensions: LA, left atrial dimension (normal2.0-40 mm); Ao, aonic root diameter(normal20-40 mm); LA/Ao, ratio between 
left atrial dimension and aortic diameter (normal I); LVD, left ventricular end-diastolic dimension (normal3()-55 mm); LVS, left ventricular 
end-systolic dimension (normal value variable); Dig, digoxin; Fru, frusemide; Hyd, hydralazine; !so, isosorbide nitrate; Pr.a, prazosin; Nif, 
nifedipine. 
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replacement was the cause of heart failure in five 
patients. All complained about shortness of breath at 
rest despite extensive treatment with dietary sodium 
restriction, digoxin, diuretics, and hydralazine-
isosorbide dinitrate combinations or prazosin. 
Captopril was given to this treatment-resistant group 
24 to 36 hours after the vasodilators or prazosin had 
been stopped. 
HAEMODYNAMIC EVALUATION 
The patients of group 1 were admitted to the coronary 
care unit. A Swan-Ganz thermodilution catheter was 
positioned in the pulmonary artery and a small Teflon 
cannula was placed into a radial artery. When stable 
baseline haemodynamic measurements had been 
obtained, captopril, 50 mg, was given by mouth, and 
its effect was followed for several hours. In the patients 
of group 2 invasive haemodynamic monitoring was 
started during the use of previous vasodilators. For this 
purpose the patients were transferred to the coronary 
care unit from the general ward where they had been 
admitted some days before in order to optimise medical 
and dietary treatment. Vasodilators or prazosin were 
then stopped and the withdrawal period of at least 24 
hours was covered by invasive monitoring. Digoxin 
and diurectics were continued, but at least si.x hours 
was left between administration of these drugs and the 
start of captopril. With the evaluation of the first dose 
of captopril the invasive first part of the study was 
finished. After treatment lasting three months nine 
patients of group 2 were readmitted to the coronary 
care unit for invasive monitoring of the long-term 
effects of captopril. 
.\lEAS URE.\\E:--:Ts 
Heart rate (HR), systemic arterial pressure, and 
pulmonary arterial pressure were continuously 
monitored. Triplicate cardiac output measurements by 
the thermodilution technique were performed at 
frequent intervals and at that time integrated mean 
values for systemic arterial pressure (MAP), right 
atrial pressure (RAP), pulmonary arterial pressure, 
(PAP) and pulmonary capillary "wedge" pressure 
(PCWP) were also taken. Pressures and cardiac output 
were measured with the patient in a semisupine 
position and the transducers were zeroed at mid-
thoracic level. Cardiac output was corrected for body 
surface area and tabulated as cardiac index (CI). The 
following variables were derived: total peripheral 
resistance in kPafs per 1 as TPR=(MAP-RAP)/CI, 
pulmonary vascular resistance in kPa/s per 1 as 
PVR=(PAP-PCWP)/CI, cardiac work index in ]/min 
as CWI=(MAP-PCWP)xCI, and stroke work index 
in J as SWI=(MAP-PCWP)xSI, where SI is stroke 
volume index. 
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OTHER MEASUREMENTS AND STATISTICS 
Estimations of cardiac chamber size were made by 
means of M-mode echocardiograms obtained with an 
ECHO-cardioVISOR SE(Organon Technica, The 
Netherlands) interfaced to a Honeywell LS 6 strip 
chart recorder. The dimensions of left atrium, aorta, 
and left ventricle during end-systole and end-diastole 
were taken with standard positions of the transducer as 
described previously. 20 Arterial and mixed venous 
oxygen saturations were measured by oximetry. The 
arteriovenous oxy~en difference (AV-02) in mmol/1 was 
calculated as AV-02 =(A'",-PA,",) x Hb x 1·01, where 
.-\ar and P A'"' are the arterial and pulmonarv an erial 
(mixed venous) oxygen saturations and Hb is the 
haemoglobin content in mmol/1, while 1·01 is the bind-
ing capacity in mmol 02 of 1 mmol Hb. 
Plasma levels of active renin2' and aldosterone2' 
were measured by radioimmunoassay. The normal 
range for renin in ourlaboratory is 15 to 45 J.LL; /mi. For 
aldosterone it is 100 to 500 pmol/1. A radioenzymatic 
technique was used for determining plasma nor-
adrenaline.'" The normal range is 1 to 3 nmol/1. Data 
are given as mean ± SEM. Plasma levels of renin, 
aldosterone, and noradrenaline were nor distributed 
normally. Mean values and standard errors were there-
fore calculated after log transformation. Statistical 
analysis was performed using Student's ttest for paired 
data. Linear regression analysis was used for calcu-
lation of correlation coefficients. Statistical significance 
was accepted at the 95% confidence level. 
Results 
PRE-CAPTOPRIL EVALUATIO:--: 
Patients with myocardial infarcrion 
Pre-captopril values of arterial pressure were somewhat 
higher and central pressures were lower than in the 
patients with chronic heart failure (Tables 3 and 41. 
Though plasma noradrenaline was raised in all cases, 
plasma renin and aldosterone were normal in the pre-
viously untreated cases (Table 5, cases Ito 4). 
Patients with chronic congestive heart failure 
The severity of heart failure was nor only reflected by 
their symptoms, as expressed according to the New 
York Heart Association (NYHA) classification30 but the 
advanced stage of cardiac dilatation was also disclosed 
by echocardiography (Table 2). Both left atrium and 
left ventricular cavity dimensions were much 
increased. Moreover, filling pressures of either side of 
the heart were high, that is right atrial pressure 14±2 
mmHg and pulmonary capillary "wedge" pressure 
25±2 mmHg, while cardiac index was low. The mean 
value for cardiac index of2·6±0·4ljmin is probably an 
overestimation because it does not include three very 
serious cases, in which no reliable cardiac output 
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Table3 H aemodynamic responses ro captopril in patients with acute myocardial infarction 
Case Heart Heart rate Mean pressure ( mmlig) Cardiac index Resisumce (kPafs per I) 
No. rhythm (beats/min) (1/min) 
Arterial Right arrial Pulm. artery Pulm. cap. Systemic Pulmonary 
Before After "wedge'' Before Aftq 
Before After Before After Before After Before After Before Aftq 
Before After 
I SR 90 86 117 107 9 6 29 19 20 11 2·9 3·4 298 238 25 19 
2 SR 86 84 95 91 13 8 28 28 19 16 2·1 2-2 312 302 34 44 
3 SR 91 80 113 93 12 7 31 24 26 16 2·8 2·9 289 237 14 22 
4 SR 58 56 87 79 9 8 27 26 24 20 2·8 3·1 223 183 9 16 
5 AF 105 78 79 62 13 8 30 23 27 18 1·7 2·4 311 180 14 17 
6 SR 94 90 62 50 17 II 38 33 23 16 
7 SR 109 102 98 90 5 0 27 17 17 11 2·3 2-7 324 267 35 18 
Mean 90 82 93 82 11 7 30 24 22 15 2·4 2·8 293 235 22 23 
±SEM 6 5 7 7 I I I 2 I I 0·2 0·2 15 19 5 4 
p <0·05 <0·01 <0·001 <0·01 <0·001 <0·01 <0·01 NS 
Nate: Values presented are those obtained before and 90 minutes after administration of captopril, 50 mg. SR, sinus rhythm; AF, atrial fibrillation. 
I kPa/s per I= 10 dyn s cm-5. 
measurements could be obtained. Systemic arterial 
pressure was already low before captopril, systolic 
114±4 mmHg and diastolic 62±3 mmHg, and, despite 
extensive use of digoxin, the mean value for heart rate 
exceeded 80 beats/min. The plasma levels of renin, 
aldosterone, and noradrenaline were grossly raised 
(Table 5). Kidney function was moderately impaired as 
indicated by a serum creatinine of 133 ± 14 ,umol/1; the 
range was 81 to 253 ,umol/1, with a value above 100 
JLIDOl/1 in eight patients. 
ACUTE EFFECTS OF CAPTOPRIL 
H aemodynamics 
Captopril improved resting haemodynamics both in 
the patients with heart failure caused by acute myo-
cardial infarction (Table 3) and the patients with 
chronic heart failure (Table 4). 
Changes in systemic arterial pressure, heart rate, 
cardiac output, and filling pressures were not much 
different for the two groups. Therefore in Fig. l to 3 
the data of both groups have been pooled. Despite 
decrements in systolic arterial pressure, from 121 ±6 to 
96±6 rnmHg, and in diastolic pressure, from 66±3 to 
52 ±4 mmHg, heart rate was also lowered by captopril, 
from 88±3 to 80±3 beats/min (p<O·OS, Fig. l). These 
effects became apparent after IS minutes, while the 
peak effects occurred between 90 and lOS minutes. In 
eight patients systolic arterial pressure fell below 90 
mmHg and in four below 75 mmHg. The fall in arterial 
pressure was well tolerated. One patient complained 
about blurred vision at a time when his systolic arterial 
pressure was 65 mmHg. No hypotensive period, how-
ever, was associated with the onset or worsening of 
angina or electrocardiographic abnormalities. Triple 
Table4 A cure haemodynamic responses co captopril in patients with chronic heart failure 
Case Heart Heart rate Mean pressure (mmHg) Cardiac index Resistance (kPajs per l) 
No. rhythm (beats/min) (1/min) 
Arterial Right atrial Pulm. artery Pulm. cap. Systemic Pulmonary 
Before After ''wedge" Before After 
Before After Before After Before After Before After Before After 
Before After 
8 SR Ill 89 74 34 12 3 50 24 34 10 2·3 2·4 216 103 56 47 
9 SR 88 85 85 65 5 -I 38 29 23 II "1·9 2·1 337 251 63 69 
10 SR 84 72 72 48 13 2 41 25 27 16 1·3 2-6 363 142 86 28 
11 AF 75 76 74 65 10 8 29 26 !8 13 3·3 3·5 !56 130 27 30 
12 SR 99 96 88 66 17 8 44 36 30 23 1·6 2-2 355 211 70 47 
13 AF 104 90 83 67 16 9 38 30 27 19 
14 AF 71 65 66 36 12 5 26 17 18 9 1·7 2·9 254 86 38 22 
15 PM 74 74 65 30 20 8 44 31 24 14 2-8 3·1 129 57 57 44 
16 AF 87 85 66 51 18 9 34 20 20 12 4·7 4·7 82 72 24 14 
17 SR 82 81 93 79 27 25 45 38 33 28 
18 SR 77 64 87 71 II 7 36 25 21 13 
19 SR 81 80 70 51 6 -I 30 16 20 10 3·6 3·6 142 116 22 13 
Mean 86 80 77 55 14 7 38 26 25 15 2·6 3·0 226 130 49 35 
±SEM 4 3 3 5 2 2 2 2 2 2 0·4 0·3 36 21 8 6 
p <0·01 <0·001 <0·001 <0·001 <0·001 <0·05 <0·01 <0·05 
Note: Values presented are those obtained before and 90 minutes after administration of captopril, 50 mg. PM, pacemaker rhythm. Other 
abbreviations as in Table 3. 
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TableS Hormone levels before captopril 
Case Plasma renin Plasma Plasma 
No. (p.Ufml) aldosterone noradrenaline (pmol/1) (rmwl/1) 
I 6 166 3-3 
2 14 222 7·2 
3 27 332 4·3 
4 9 Ill 4·5 
5 1700 9970 20·1 
6 540 2270 17·5 
7 
8 990 943 18·3 
9 30 665 3·7 
10 4600 10500 14·6 
11 88 860 2-3 
12 68 2520 13·9 
13 200 1270 6·5 
14 1400 4700 4·5 
!5 58 277 2·4 
16 330 1770 10·2 
17 140 9690 6·8 
18 110 8860 9·2 
19 78 1220 2·7 
Note: Plasma noradrenaline, I nmol/1 ~ 169 ng/1. 
Plasma aldosterone, I pmol/1' ~ 360 pg/1. 
product, that is the product of systolic arterial 
mmHg 
90 
80 
70 
60 
MEAN ARTERIAL PRESSURE 
n=15 
1/min CARDIAC INDEX • STROKE INDEX o 
3.2 
2.8 
2.4 
kPa.s.l- 1 
300 
TOTAL PERIPHERAL VASCULAR RESISTANCE 
69 
ml 
40 
34 
28 
pressure, heart rate, and pulmonary capillary "wedge" 250 
pressure divided by 1000, fell from 253±19 to 119±13 
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Fig. 1 Responses of systemic arterial pressure and heart rate to a 
single dose of captopril (50 mg) in IO patients with heart failure. 
The fall in both systolic and diastolic arterial pressure was already 
significant (p<O·O I) IS minutes after captopril. The fall in heart 
rate became significant (p<O·O I) after 30 minutes. 
200 
150 
-30 30 60 90 120 
TIME (min) 
Fig. 2 Effects of captopril (50 mg) on cardiac index, stroke 
index, mean arterial pressure, and total peripheral resistance. The 
peak effects were significant at p<O·O I. 
(p<O·OOl) presumably leading to a diminished myo-
cardial oxygen demand. 
The fall in mean arterial pressure of 25±4% was 
associated with a fall in total peripheral resistance of 
30±5% (Fig. 2). Cardiac output rose by an increase in 
stroke volume. This increase in flow was also reflected 
in the accompanying change in arteriovenous oxygen 
difference. It fell significantly from 3·1 ±0· 3 mmol/1 
before captopril to 2·7±0·2 mmol/1 one hour after 
captopril (p<0·05) and to 2·6±0·2 mmol/1 two hours 
after captopril (p<0-05). The amount of work 
performed by the heart did not change. Cardiac work 
and stroke work indices before captopril were 
20·26±2·26 J/min and 0·24±0·03 J, respectively, and 
90 minutes after captopril they were -19·61 ±2·58 J/min 
and 0· 25 ±0·03 J. 
Captopril caused parallel decrements in mean 
pulmonary arterial pressure, pulmonary capillary 
"wedge" pressure, and right atrial pressure (Fig. 3). 
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Fig. 3 Cupropril (50 mg) caused concurrent decrements in mean 
pulmonary arterial, pulmonary capillary "wedge", and right 
atrial pressures. After 30 minuces all changes were signzficanr at 
p<O·OI. 
Pulmonary vascular resistance fell from 38±6 to 30±4 
kPa/s per l (p<0·05). These changes were most 
pronounced in the chronic heart failure group (Table 
4). 
Plasma renin rose and plasma aldosterone fell after 
captopril (Fig. 4) as expected. More surprising was the 
change in plasma noradrenaline; it fell from a mean 
value of 6·09 nmol/1 before captopril to 5 ·4 nmolfl after 
one hour (p<0·5) and to 4·5 nmol/1 after two hours 
(p<O·Ol). The higher the pretreatment value of nor-
adrenaline, the greater was its decrement (Fig. 5). 
Interrelations berween humoralfacrors, baseline 
haemodynamics, and capropril-induced changes 
Pretreatment plasma noradrenaline was directly corre-
lated with pretreatment plasma renin and aldosterone 
(Table 6). Heart rate before captopril was directly 
correlated with noradrenaline, suggesting that the high 
plasma level of noradrenaline indeed reflected an 
increased sympathetic tone in these patients. Of the 
flow measurements, pretreatment stroke volume was 
inversely correlated to plasma noradrenaline but not to 
renin, whereas cardiac performance, expressed as 
cardiac work or stroke work, was inversely correlated 
both with noradrenaline and with renin and also with 
plasma aldosterone. Total peripheral resistance before 
captopril, however, was unrelated to the plasma levels 
of noradrenaline and renin. The decrease in mean and 
diastolic systemic arterial pressure after captopril but 
not the decrease in systolic pressure was correlated to 
pretreatment renin (Fig. 6, Table 7), which suggests 
that part of the pressure drop was prevented by the 
observed rise in stroke volume. The decrease in total 
peripheral resistance after captopril was directly corre-
lated to the pretreatment plasma levels of noradrena-
line, renin, and aldosterone. 
CLINICAL COURSE 
Patients with myocardial infarcrion 
After the first dose of captopril all patients experienced 
a reduction in dyspnoea and orthopnoea and in some 
Table 6 Correlatirms between pretreatment haemodynamic variables and pretreatment lwmume levels 
Baseline values of No. Versus baseline 1.-•alues of 
Log plasma renin Log plasma aldoscerane Log p/asrrw noradrenaltne 
p p p 
Arterial pressure systolic } -0·69 <0·001 -0·65 <0·01 -0·51 <0·05 diastolic 18 -0·42 NS -0·10 } NS -0·09 } NS mean -0·65 <0·01 -0·37 -0·19 
Heart rate 18 +0·33 NS +0·21 NS +0·60 <0·01 
Cardiac index- } 14 -0·31 NS -0·37 NS -0·40 } NS Cardiac work index -0·69 <0·01 -0·64 <0·01 -0-49 
Stroke index } 14 -0·39 NS -0·47 NS -0·56 <0·05 Stroke work index -0·73 <0·01 -0·72 <0·01 -0·62 <0·05 
Mean right atrial pressure } +0·24 } +0·34 } +0·30 } NS Mean pulmonary artery pressure 18 +0·31 NS +0·29 NS +0·40 Mean pulmonary capillary "wedge" pressure +0·28 +0·27 +0·52 <0·05 
Total peripheral vascular resistance } 14 +0·11 } NS +0·29 } NS +0·43 } NS Pulmonary vascular resistance +0·39 +0·37 +0·26 
Log plasma renin } Log plasma aldosterone 18 +0·78 <0·001 Log plasma noradrenaline +0·62 <0·01 +0·56 <0·05 
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Fig. 4 Neurohumoral responses to captopril (50 mg) in 18 
patients with heart failure. Both plasma noradrenaline and 
aldosterone fell (p<O·O I) after 60 minutes, whereas plasma renin 
rose (p<O·Ol). 
the annoying non-productive cough as a sign of 
imminent lung oedema disappeared. Signs of heart 
failure gradually faded away in four patients (cases I to 
4) and cessation of captopril after a few doses was well 
tolerated. The course of their myocardial infarction 
was further uneventful. The three patients with more 
severe pump failure, who had previously been treated 
with dopamine and nitroprusside, remained on 
captopril. The dose was gradually increased to !00 mg 
three times a day, and digoxin and diuretics were con-
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tinued. One of them, case 5, remained in a critical 
condition and died after a few days. The two others 
improved clinically and could be mobilised. Three days 
after discharge from the hospital, 25 days after the 
onset of myocardial infarction, case 6 died suddenly. 
Case 7 was found dead one month after myocardial 
infarction. At a visit to the outpatient clinic some days 
before her death the blood pressure was 95/75 mmHg 
while she was taking 300 mg captopril and 160 mg 
frusemide. At that time she had no complaints and 
there were no signs of central or peripheral congestion. 
Patients with chronic heart failure 
After haemodynamic assessment of the first dose of 
captopril, which was 50 mg, long-term treatment was 
instituted, initially with doses that ranged from 12·5 to 
50 mg three times a day, depending on kidney function 
and on the blood pressure response at the time of the 
first dose. In case IS captopril treatment had to be 
stopped after a few doses because of rapid deterioration 
of pre-existent mild renal insufficiency, with oliguria. 
Cases 8 and 14 had supine systolic arterial pressure 
levels that were persistently below 80 mmHg at a daily 
dose of ISO mg. They complained about blurred vision. 
In these patients the dose was reduced to 75 mg. In the 
remaining patients the dose of captopril was gradually 
increased to 300 mg per day, but in three (cases 9, II, 
and 17) this led to an increase in serum creatinine, 
which was reversed by reducing the dose to 75 mg. 
All patients showed symptomatic improvement 
which was mainly the result of a lessening of dyspnoea. 
In two patients a pleural effusion, which was refractory 
to treatment, disappeared in a few weeks. Captopril 
treatment, however, did not result in loss of weight; it 
was 70·4±2-4 kg before captopril and 71·5 ±2·5 kg 
after one week (n= 10). Two patients (cases 8 and !0) 
died in the first month of treatment. Ultimately, nine 
patients completed a thr~e month treatment period. 
Long-term haemodynamic effects of captopril and com-
parison with previous vasodilatory regimens 
In Fig. 7 haemodynamic measurements obtained from 
repeat right heart catheterisation after three months of 
captopril treatment were compared with those taken at 
the start of the study. Our study had been designed in 
such a way that we were able not only to compare 
long-term effects of captopril with its acute effects bur 
also with the long-term effects of previous vasodilatory 
treatment. The significant haemodynamic improve-
ment after the first dose of captopril was maintained in 
the long run. After three months of captopril, systemic 
arterial pressure, pulmonary arterial pressure, 
pulmonary capillary "wedge" pressure, cardiac index, 
and total peripheral resistance all still differed signifi-
cantly from values measured shortly before captopril 
was given. The haemodynamic profile with chronic 
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Fig. 5 Correlation of maximal decrease in plasma noradrenaline after capwpril (50 mg) with the 
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Fig. 6 Correlations between pretreatment plasma renin and the percentage changes of mean arterial 
pressure and IOta! peripheral resistance 90 minutes after captopril (50 mg). 
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Fig. 7 Bar graphs representing haemodynamic variables measured during the different study phases in the nine patients (cases 9, 11-14, 
16-19, see Table 2), who had captoprilfor three months. 
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m acute effecrs of captopril, 50 mg 
§§ long rerm effeas of capropril 
The a cure effecrs ofcaptopril in rhese nine parienrswere comparable wirh rhe responses in rhe v.'hole group ( F1g. 2 and 3 ). Fhe a cure <'ffecrs 
of captopril were maintained during long-term trearmenz. When the haemodynamic effecrs of rhe previously used vasodilarors were 
compared with long-term captopril significant differences were found for sysremic arterial pressure (systolic and diastolic, p<O·OO I) and 
pulmonary arterial pressure (systolic and diastolic, p<O·O I). 
captopril was not much different from that with 
previous vasodilating treatment but systemic arterial 
pressure was lower with chronic captopriL Though at 
first we did not intend to change the dose of the 
diuretics, it became clear from frequent determinations 
of serum potassium that the dose of the aldosterone 
antagonist, spironolactone, could be diminished and 
finally stopped in all patients. The doses of frusemide 
and digoxin were not altered. Before captopril serum 
potassium was 4·0±0·2 mmol/1 at a time when nearly 
40 
all patients were taking spironolactone (Table 2). 
Evaluation at three months showed serum potassium 
was 4·4±0·3 mmol/1, with no patient on spironolactone 
or oral potassium supplements. Serum creatinine rose 
from 120± II ,umolfl (range 96 to 175 ,umol/1) to 
128± 11 ,umol/1 (range 76 to 160 ,umol/1) after three 
months on captopri1 (p<0-01). No significant change 
in body weight occurred during long-term captopril 
treatment; body weight was 70·2±2·9 kg after three 
months as compared with 71·6±2·2 kg before 
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Table 7 Correlations between captopril-induced haemodynamic changes (90 min) and pretreatment hormone levels 
Changes after capropril No. Versus baseline values of 
(0-90min) 
Log plasma renin Log plasma a/dQsrerone Log plasma noradrenaline 
Anerial pressure systolic 1 } 0·05 cliastolic 1 18 0·62 mean1 0·46 
Heart rate 1 18 0·58 
Carcliac index T } 14 0·57 Carcliac work index - 0·06 
Stroke index T } 14 0·65 Stroke work index- 0·03 
Mean right atrial pressure 1 } 0·48 Mean pulmonary artery pressure 1 18 0·47 Mean pulmonary capillary "wedge" ressure 1 0·40 
Total peripheral vascular resistance } 14 0·71 Pulmonary vascular resistance ! 0·61 
Plasma renin T } 0·80 Plasma aldosterone 1 18 0·51 Plasma noradrenaline 1 0·59 
captopril. No patient developed skin rash, proteinuria, 
or leucopenia. 
Discussion 
It was remarkable how effective a single dose of 
captopril was in our patient~ whether or not they were 
in acute or chronic failure. As total peripheral 
resistance fell, the heart was relieved and stroke volume 
and cardiac output rose. Captopril also had a distinct 
effect on the preload of the heart as indicated by the 
decrease in cardiac filling pressures. Our study gives no 
detailed insight into the mechanism of this decrease. 
The fall in right atrial pressure has been reported to 
precede the fall in pulmonary arterial pressure and 
pulmonary capillary "wedge" pressure.' This suggests 
that an effect of captopril on venous tone rather than an 
improvement of forward output of the heart is respons-
ible for the observed decrease in cardiac filling 
pressures. In our study, however, the changes in filling 
pressures of the right and left side of the heart occurred 
synchronously. 
Plasma renin is often high in heart failure but not 
invariably so. In our series it was increased in most 
patients with chronic heart failure who were on 
diuretics. whereas it was normal or even low in the 
patients with acute myocardial infarction who were not 
on diuretics. Thus, stimulation of the renin angiotensin 
system in.normotensive heart failure might be a conse-
quence of treatment rather thaq a consequence of the 
disease. This seems. to contrast with sympathetic 
activity as reflected by plasma noradrenaline. High 
concentrations of noradrenaline were observed 
whether or not the patients had been on diuretics. The 
effect of captopril on peripheral resistance was 
positively correlated with pretreatment plasma renin, 
as were the effects on stroke volume, cardiac output, 
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p p p 
NS O.z? } 0·09 } <0·01 0·39 NS 0·34 NS <0·05 0·21 0·07 
<0·05 0·41 NS 0·63 <0·01 
<0·05 0·58 <0·05 0·30 } NS NS 0·14 NS 0·24 
<0·05 0·71 <0·01 0·40 } NS NS 0·16 NS 0·35 
<0·05 0·18 } 0·26 } <0·05 0·24 NS 0·26 NS <0·05 O·ll 0·26 
<0·01 0·71 <0·01 0·51 <0·05 
<0·05 0·60 <0·05 0·36 NS 
<0·001 0·64 <0·01 0·61 <0·01 
<0·05 0·82 <0·001 0·46 <0·05 
<0·05 0·35 NS 0·77 <0·001 
and cardiac filling pressures. The correlations, how-
ever, were weak, and the changes in the patients with 
normal or moderately raised renin were nearly as great 
as in those with grossly raised renin. 
A notable feature of the cardiovascular actions of 
captopril is its apparent ·interference with baroreflex 
function. Heart rate did not rise in our patients despite 
a drop in systemic arterial pressure. This has also been 
reported by others. 31 32 Attenuation of circulatory 
reflexes in congestive heart failure has been proposed as 
an underlying mechanism. 3 Heart rate, however, is also 
not increased when arterial pressure is lowered by 
captopril in subjects with normal heart function. 33 
From experiments in dogs, Hatton et al. 34 concluded 
that captopril displaced the setpoint of the arterial 
baroreflex to a lower pressure without modifying the 
sensitivity of the reflex. 
Ideally the decrease in vascular resistance after 
captopril should be balanced by an increase in cardiac 
output so that perfusion pressure of the different 
organs is maintained. Clearlv this ideal was not met. 
Systemic arterial pressure fell, in some cases to an 
alarmingly low level with the potential danger of a 
deleterious effect on coronary blood flow. On the other 
hand, the decrease in heart rate and the concomitant 
reductions in cardiac filling pressures and systemic 
arterial pressure and· thereby in left vascular wall 
tension suggest that myocardial oxygen demand is 
diminished by captopril. 
Of the 14 patients on long-term captopril, four died 
within a month after initial clinical improvement. They 
had ischaemic heart disease. In congestive heart failure 
the cutaneous, splanchnic, and renal vascular beds are 
particularly prone to neurohumorally induced vaso-
constriction_]' In this way, for instance during 
exercise, blood flow is shunted from the renal and 
splanchnic circulation to that of skeletal muscle, heart, 
Capwpril and heart failure 
and brain. It is therefore conceivable that in our 
patients who died suddenly captopril interfered with 
the normal redistribution of blood flow during 
exercise, which may have led to myocardial ischaemia. 
The relatively high doses of captopril we have used 
may have contributed to the low systemic arterial 
pressure in our patients. Symptomatic hypotension, 
however, has also been observed with doses as low as 
6·25 mg. 32 Our study does not give an indication of 
what the optimal dose of captopril should be, but 
recent experience in patients wirh heart failure and in 
patients with severe hypertension suggests that 
captopril in daily doses not higher than 75 mg is 
effective when combined with a diureticY 36 Such a 
regimen might reduce the incidence of side effects. The 
side effects that occur most frequently are skin rash, 
loss of taste, proteinuria, and leucopenia. These were 
not encountered in our small series of patients. 
In conclusion, oral angiotensin-convertine enzyme 
inhibition by captopril has a profound effect on cardio-
circulatory control mechanisms, which are altered 
during heart failure. Heart rate, total peripheral 
resistance, cardiac filling pressures, and the increased 
plasma concentrations of aldosterone and noradrena-
line are lowered while stroke volume is increased. In 
some patients the beneficial acute effects are main-
tained in the long run. During treatment of heart 
failure with high ceiling diuretics such as frusemide 
and ethacrynic acid in combination with captopril, 
potassium supplements or aldL'Sterone antagonists are 
no longer needed. In the majority of our severe cases, 
combined treatment with frusemide and captopril 
resulted in a low systemic arterial pressure. This may 
compromise coronary circulation, particularly during 
exercise. Before captopril can be recommended as a 
useful drug for the treatment of heart failure, particu-
larly in coronary artery disease, more insight into its 
effects on coronary blood flow is required. 
We thank Dr P Pigott and Dr J Hill (Squibb) for 
providing the captopril tablets. 
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Asynchronous Changes in Prorenin and Renin Secretion 
after Captopril in Patients with Renal Artery Stenosis 
FRANS H.M. DERKX, M.D., LIES TAN-TJIONG, M.D., GERT J. WENTING, M.D., 
FRANs BooMSMA. PH.D., ARIE J. MAN IN 'T VELD, M.D., AND MAARTEN A.D.H. ScHALEKAMP, M.D. 
SUMMARY An assay of plasma prorenin was developed in which the conversion to renin occurred 
under apparently optimal conditions. Some characteristics of the assay were 1) pro renin was activated 
by Sepharose-bound trypsin at 4°C; 2) the concentration of activator was not critical provided that 
incubation was prolonged until renin activity had reached a plateau; and 3) this plateau was stable and 
had the same height as after maximal activation with acid, pepsin, plasmin or urokinase. Maximal 
activity with Sepharose-bound trypsin at 4°C was higher than with cryoactivation, and optimal 
conditions were more readily reproduced than with trypsin at 37°C or with acid-activation. The assay 
was used for measurements in peripheral and renal vein plasma after captopril in hypertensive 
patients with unilateral renal artery stenosis. Peripheral renin rose within 30 minutes after a first dose 
of captopril, 50 mg orally, and it remained high with chronic treatment. In contrast, peripheral 
prorenin fell initially and rose after 4 hours. These changes in peripheral plasma were related to 
changes in the secretion rates of the two forms of renin from the affected kidney. Thus chronic, but not 
acute, stimulation of renin release was associated with an increased secretion rate of prorenin. The 
late rise in prorenin is probably an indication of enhanced synthesis in the kidney, so that more 
pro renin is available for conversion. The data suggest that prorenin is indeed a biosynthetic precursor 
of renin and that, at least under certain circumstances, a major proportion of circulating prorenin 
originates from the kidney. (Hypertension 5: 244-256, 1983) 
KEv WoRDS • captopril • converting enzyme 
renal artery stenosis • renin 
A BOUT 80% of the renin in normal human plasma is thought to circulate in an inactive form.'-' Inactive renin is often called "pro-
renin" because it can be converted in vitro to active 
renin.' It is not certain that prorenin is a precursor of 
naturally occurring renin. however. 
Activation of the factor XU-kallikrein pathway 
causes irreversible prorenin-to-renin conversion after 
dialysis of plasma against acid followed by restoration 
of pH to neutral (acid-activation)'· 6 and possibly also 
in plasma that is stored at low temperature ( cryoactiva-
tion)7 Prorenin can also be activated by adding tryp-
sin' or pepsin9· 10 to plasma. These exogenous activa-
tors act independently of factor XII and kallikrein. 
From the Department of Internal Medicine I. Dijkzigt Hospital. 
Erasmus University. Rotterdam. The Netherlands. 
Supported-by grants from the Dutch Kidney Foundation and the 
Foundation for Medical Research (FUNGO). 
Address for reprints: Maaiten A.D.H. Schalekamp. Department 
of Internal Medicine I. room P 434. University Hospital Dijkzigt. 
Dr. Molewaterplein 40. 3015 GD Rotterdam. The Netherlands. 
Received for publication April 28. 1982: revision accepted Sep-
tember I 0. 1982 
244 
46 
prorenin • 
Prorenin is measured by functional assays in which 
prorenin is converted to renin. The difference in renin 
activity before and after activation is taken as a meas-
ure. The implicit assumptions are that all prorenin mol-
ecules are converted and that one molecule of activated 
prorenin has the same enzymatic activity as one mole-
cule of naturally occurring renin. Cryoactivation, 
however, often leads to incomplete prorenin-to-renin 
conversion.' Acid activation appears more complete 
but careful adjustment of pH is of critical impor-
tance. II." For trypsin activation, high concentrations 
of trypsin are required to overcome the inhibitors in 
plasma but such high concentrations may destroy 
renin.'· "· 14 Trypsin may also attack renin substrate and 
may interfere with the radioimmunoassay of angioten-
sin I, the final step in the assay of renin. Soybean 
trypsin inhibitor (SBTI) has therefore been used to 
prevent this. However, some commercial SBTI prep-
arations appear to have angiotensinase activity result-
ing in considerable loss of angiotensin I during the 
~ssay." 
The present paper describes an assay of prorenin in 
which it is activated by trypsin that is bound to Sephar-
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ose. The immobilized activator can quantitatively be 
removed by centrifugation. Optimal conditions were 
worked out for activation in plasma and the results 
were compared with maximal acid activation and with 
maximal activation by pepsin, plasmin and the plas-
minogen activator urokinase. The behavior of natural-
ly occurring active renin on gel filtration and dye affin-
ity chromatography columns was compared with that 
of prorenin activated by immobilized trypsin. Some 
enzymatic properties of the two forms of renin were 
also compared. The assay was then applied to a study 
of the effects of angiotensin converting enzyme inhibi-
tion by captopril on peripheral and renal vein plasma 
prorenin in patients with unilateral renal artery 
stenosis. 
Materials and Methods 
Reagents 
Trypsin from bovine pancreas, 2 x crystallized, 
was purchased from Sigma, St. Louis, Missouri. Its 
specific activity was 12,000 a-N-benzoyl-L-arginine-
ethyl ester (BAEE) units/mg of protein. Pepsin A, 
specific activity 3200 units/mg of protein, was also 
from Sigma. Activator-free highly purified human 
plasmin, specific activity 19 casein units/mg of pro-
tein, was a product of Kabi, Stockholm. Sweden. Uro-
kinase was the urokinase reference standard of Leo. 
Copenhagen, Denmark. Aprotinin (Trasylol) was ob-
tained from Bayer, Leverkusen, West Germany. 
Ile5-Angiotensin I (AI) from Serva, Heidelberg, 
West Germany, was dissolved in Tris/acetate buffer of 
pH 7.5 (vide infra) and stored at - 20°C at a concentra-
tion of 40 1-1-M. Its strength was tested by bioassay in 
the rat against Val'-AII (Hypertens·in) from Ciba-
Geigy. Basel, Switzerland. When allowance was 
made for the impurities present in the Ile5-AI prepara-
tion as stated by the manufacturer. the pressor activi-
ties ofVal'-AII and Ile5-AI on a molar base were found 
to be equal. I I Renin substrate was prepared from sheep 
plasma. which was taken 4-5 days after bilateral neph-
rectomy. I6 It was dissolved in phosphate buffer pH 7.5 
and stored at - 20oC at a concentration of 5 1-1-M. 
expressed as the maximal quantity of Ile5-AI equiv-
alents that could be generated in the presence of a large 
excess of renin. Renin substrate prepared from human 
plasmai 6 was also used in some experiments. A human 
kidney renin standard. lot MRC 68/356, was kindly 
supplied by the WHO International Laboratory for 
Biological Standards, London, England. This standard 
was dissolved in phosphate buffer pH 7.5 containing 
0.35% bovine serum albumin. It could be stored at 
- 20°C at a concentration of 10.000 fLUnits/ml for up 
to 3 months without loss of activity. 1251-labeled Ile5-AI 
and anti-lie'-AI rabbit antiserum were prepared as de-
scribed previously. 11 Radioactive AI in 0.05 M acetic 
acid, containing 0.1% bovine serum albumin, 0.0 I% 
thiomersalate, 0.00 I% neomycin sulphate and 0.1 M 
NaCI, was stored in 0.25 ml portions at - 20°C. 
CNBr-activated Sepharose 4B, Sephadex G-100, 
Blue Sepharose CL-6B, Blue Dextran 2000, and the 
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molecular weight markers for gel chromatography, ri-
bonuclease A (Mr 13,700), chymotrypsinogen A (Mr 
25,000), ovalbumin (Mr 43,000), and human serum 
albumin (Mr 67 ,000) were purchased from Pharmacia, 
Uppsala, Sweden. I"C-ovalbumin (Mr 46,000) and 
I"C-bovine serum albumin (Mr 69,000) were also used 
as molecular weight markers and were obtained from 
the Radiochemical Centre, Amersham, England. 
Buffer Solutions 
Phosphate Buffer, pH 7.5 
This buffer contained 12.2 mM Na H, P04 , 86.7 
mM Na2 HP04 , 75.9 mM NaCI and 1.0 mM disodium 
ethylenediamine-tetraacetate (EDT A). 
Glycine!HCI Buffers, pH 3.3 or pH 4.0 
These buffers contained 50 mM glycine. 94.9 mM 
NaCI, and 5.1 mM EDTA. The pH was adjusted with 
concentrated HCI. 
Tris/Acetate Buffer, pH 7.5 
This buffer contained 0.1 M Tris. 0.35% bovine 
serum albumin, 0.1% lysozyme, and 0.2% neomycin 
sulphate. The pH was adjusted with glacial acetic acid. 
Preparation of Plasma 
Blood was collected in chilled plastic tubes contain-
ing EDTA in a final concentration of 5 mM. It was 
centrifuged at 3000 x g and 4°C immediately after 
collection. Plasma was kept frozen at - 20°C before 
use. 
Preparation of Immobilized Trypsin and Pepsin 
The enzymes were covalently bound to CNBr-acti-
vated Sepharose 4B in a ratio of 30-40 mg of protein 
per g of dry Sepharose according to the directions of 
the manufacturer. In this manner more than 97% of 
protein was bound to Sepharose. Sepharose-bound 
trypsin was diluted in phosphate buffer pH 7.5. Sus-
pensions of Sepharose-bound pepsin were stored in 
glycine/HCI buffer pH 3.3. 
Activation of ·Pro renin 
Activation by Immobilized Trypsin 
Dilutions of Sepharose-bound trypsin (I 00 1-1-l, 0.05 
- 4.0 mg trypsin) were added to I ml plasma. The 
mixtures were incubated at 37° and at 4°C for various 
time periods as indicated in the results section. Trypsin 
was removed by centrifugation. The supernatants were 
checked for amidolytic activity with the chromogenic 
substrate N-benzyol-L-isoleucyl-L-glutamylglycyl-L-
arginine-p-nitroanilide (S 2222, Kabi, Stockholm, 
Sweden). For this purpose 0.1 ml of the supernatant of 
the incubates was mixed with 0.2 mM substrate (about 
10 times Km for trypsin) in 0.1 M Tris/HCl buffer pH 
8.2 in a total volume of 1.0 mi. The linear release ofp-
nitroaniline was followed for l-2 minutes at 405 nm in 
a 1-cm semi-microcuvette at 37"C. With this method 
the remaining trypsin activity in the supernatants was 
found to be less than 0.1% of the original activity in the 
incubates. 
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Acid Activation 
Plasma samples (2 ml) were dialyzed against gly-
cine/HCl buffer pH 3.3 for 24 hat 4°C, followed by 
dialysis against phosphate buffer pH 7.5, containing 
6% polyvinylpyrrolidone, again for 24 hours at 4°C. 
Polyvinylpyrrolidone had been added to the buffer to 
prevent dilution of the plasma due to colloid-osmosis. 
The dialysis bags were emptied in calibrated plastic 
tubes and rinsed with phosphate buffer pH 7.5 and the 
volume was adjusted to 2 ml with the same buffer. 
Activation by Immobilized Pepsin 
Plasma samples (2 ml) were dialyzed against gly-
cine/HCl buffer pH 3.3 for 24 hat 4°C. To I ml of the 
dialyzed plasma was added Sepharose-bound pepsin 
(100 ~-tl, 0.3 mg pepsin). The mixture was incubated at 
32°C for various time periods, as indicated in the Re-
sults. Pepsin was removed by centrifugation and pH 
was restored to 7.5 with I M NaOH. 
Activation by Plasmin and Urokinase 
Plasmin was dissolved at a concentration of 20 ca-
sein units/ml in phosphate buffer pH 7.5. Urokinase 
was dissolved in this buffer at a concentration of 1000 
Ploug units/mi. The plasma samples were dialyzed 
against glycine/HCl buffer pH 4.0 for 24 hours at 4°C 
and pH was restored to 7.5 with I M NaOH. The 
activator solutions (I 00 ILl) were added to I ml of the 
pH 4.0-pretreated samples and incubated at 4°C for 
various time periods as indicated in the Results. 
Assay of Naturally Occurring Renin and Prorenin that is 
Activated In Vitro 
For this assay, 0.1 0-0.25-ml samples were added to 
0.5 ml of renin substrate, and the volume was adjusted 
to 1.0 ml with phosphate buffer pH 7.5. The final 
concentration of renin substrate in the mixture was 2.5 
~-tM Ile'-Al equivalents, which corresponds to about 
I 0 times km (see Results). After addition of protease 
inhibitors, i.e., 10 ~-tl of0.34 M 8-hydroxyquinoline, 5 
~-tl of 0.28 M phenylmethylsulphonyl-fluoride in eth-
anol, and 10 ~-tl aprotinin (10,000 kallikrein-inhibiting 
units/ml), the mixtures were incubated at 37°C. The 
incubation time was 3 hours except when stated other-
wise. The renin-containing samples had been diluted 
in such a way that no more than 5% of the substrate 
was cleaved during incubation. Parallel incubations at 
4°C served as blanks. Incubations of dilutions of stan-
dard human kidney renin at 37° and 4°C were run in 
each assay batch. The concentration of homologous 
substrate in the incubation mixtures was less than 0.2 
~-tM lle'-AI equivalents. Previous studies have shown 
that this concentration of homologous substrate did not 
interfere with the reaction of renin and the heterolo-
gous substrate. 11 The reaction was stopped by adding 
I ml of 0.15 M NaCI followed by heating for I 0 min-
utes in a boiling water bath. The precipitate was re-
moved by centrifugation. The concentration of AI in 
the supernatant was measured by radioimmunoassay, 
using 125I-labeled Ile'-AI and rabbit anti-lle'-AI anti-
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serum." Renin concentration is expressed as micro-
units of the renin standard per ml (~-tUiml). Prorenin 
was measured as the difference between the renin con-
centration after activation of the test sample ("total 
renin") and the co10centration before activation. For 
routine measurements in plasma, 1.0 ml plasma was 
incubated with I 00 ~-tl Sepharose-bound trypsin in a 
final concentration of 0.25 mg trypsin/ml for 24 hours 
at 4°C. The reasons why this procedure was selected 
are presented and discussed in the results and discus-
sion sections. 
Interassay variability was evaluated by weekly mea-
surements of naturally occurring active renin and pro-
renin in a normal plasma pool (stored at - 20°C) dur-
ing a 9-month period. The mean value of naturally 
occurring active renin was 27 ~-tUiml (36 assays) with a 
standard deviation of 3 ~-tUiml (coefficient of variation 
II%). The mean value of "total renin" was 254 ~-tUi 
ml, with a standard deviation of 26~-tUiml (coefficient 
of variation 10%). The mean value of prorenin was 
227 ~-tUiml with a standard deviation of 24 ~-tUiml 
(coefficient of variation II%). In normal plasma the 
contribution of naturally occurring active renin to total 
renin is small but it becomes greater after stimulation 
of renin release. The coefficient of variation of pro-
renin measurements then also becomes greater since 
prorenin is taken as the difference between total renin 
and naturally occurring active renin. 
In 17 healthy men (aged 24-45 years) who were 
recumbent for at least I hour before blood sampling, 
naturally occurring renin had a mean value of 23 ~-tU/ 
ml (antilog of arithmetic mean after logarithmic trans-
formation of data) with a range of 14 to 43~-tU/ml. The 
mean value of prorenin was 196~-tU/ml with a range of 
138 to 312~-tUiml; the mean value of the proportion of 
renin that was in the active form was 10.9%, with a 
range of 4.3% to 17.5%. 
Gel Filtration 
Untreated plasma (2 ml) or trypsin-activated plasma 
(2 ml) was applied to 2.6 X 90 em columns of Sepha-
dex G-100 equilibrated with 0.01 M Tris/HCl buffer 
pH 7.0 containing 0.15 M NaCl and I mM EDTA. The 
same buffer was used for elution. Flow rate was adjust-
ed to 10 ml/hr and 1.5-ml fractions were collected. The 
columns were calibrated with ribonuclease A, chymo-
trypsinogen A, human albumin and ovalbumin. Blue 
dextran 2000 was used for determining void volume. 
14C-ovalbumin and 14C-BSA were used as internal 
standards. Gel filtration was carried out at 4°C. 
Affinity Chromatography 
Untreated plasma ( 4 ml) or trypsin-activated plasma 
(4 ml) was applied to 1.6 x 25 em columns of Blue 
Sepharose CL-6B equilibrated with 0.02 M phosphate 
buffer pH 7 .1. Elution was performed with this buffer 
in 3 steps, i.e., without added NaCI, with 0.2 M NaCl 
and with 1.4 M NaCI added to the buffer. 17 Flow rate 
was 50 to 60 ml!hr and 2.5-ml fractions were collect-
ed. Affinity chromatography was carried out at 4°C. 
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Studies in Patients 
Fifty-four hypertensive patients were studied after 
they had given their informed consent. All had unilat-
eral renal artery stenosis as demonstrated by renal ar-
teriography. Treatment was stopped at least 3 weeks 
before the studies began. The patients were recumbent 
for at least one hour before blood sampling. 
Group I (n = 14) 
Renal arteriography had already been performed be-
fore this study. The patients received a first dose of 
captopril, 50 mg orally. Peripheral venous blood was 
sampled from an indwelling needle for renin and pro-
renin measurements before and at different time inter-
vals after captopril. Renin before captopril was 8! fLU/ 
ml (antilog of arithmetic mean after logarithmic trans-
formation of data) with a range of !9 to 250 fLV/m!, 
and prorenin was 190 fLU/ml with a range of 77 to 4! 0 
fLV/m!. The patients were then treated with captopril, 
50 mg 3 times a day. and blood was taken after I, 2, 
and 4 weeks l-2 hours after the morning dose. 
Group 2 (n = 15) 
Blood was sampled from both renal veins and from 
the abdominal aorta before and 30 minutes after a first 
dose of captopril, 50 mg, just before renal arteriog-
raphy. Because some time elapsed between sampling 
of the renal vein of one side and sampling at the other 
side, two aortic samples were taken each at exactly the 
same time that a renal vein sample was collected. Pe-
ripheral vein renin before captopril was 51 fLV/m! 
(range !6--!90 fLV/m!) and prorenin was !70 fLV/m! 
(range 57-320 fLVIm!). 
Group 3 (n = 15) 
Blood was sampled from both renal veins and from 
the abdominal aorta !6 hours after a first dose of capto-
pril, 50 mg, just before renal arteriography. This time 
interval was chosen because studies in Group I had 
shown that peripheral prorenin was significantly in-
creased after !6 hours. Peripheral vein renin before 
captopril was 58 fLU/ml (range !5-480 fLVIm!) and 
prorenin was !30 fLV/m! (range 20-490 fLVIm!). 
Group 4 (n = 10) 
Blood was sampled from both renal veins and from 
the abdominal aorta while the patients were taking 
captopril, 50 mg three times a day, for 2 weeks. Sam-
pling occurred l-2 hours after the last 50 mg dose and 
just before renal arteriography. Peripheral vein renin 
before captopril was 66 fLVIm! (range 30-360 fLV/m!) 
and prorenin was 2!0 fLVIm! (range 72-520 fLU/ml). 
Results 
Activation of Plasma Prorenin by Immobilized Trypsin: 
Selection of Optimal Conditions 
Normal plasma pool was incubated at 4o and 37°C 
with Sepharose,bound trypsin at concentrations rang-
ing from 0.05 to 0.50 mg per ml of plasma at 4°C and 
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from 0.05 to 4.0 mg/ml at 37° C. The results at 4° and 
3TC were markedly different (fig. !). First, the reac-
tion velocity was higher at 3T C than at 4°C, but for a 
given trypsin concentration, the maximum level of 
renin activity ultimately obtained was higher at 4°C 
than at 37°C. Second, with trypsin concentrations 
ranging from 0.12 to 0.50 mg/ml, this maximum of 
renin activity was independent of trypsin concentration 
during incubation at 4°C and not at 37°C. Third, very 
high concentrations of trypsin were required at 37° C 
for approaching the maximal renin activity obtained at 
4°C but these high concentrations also caused inactiva-
tion or destruction of renin. 
As shown in figure l, with the use of 0.25 mg 
trypsin per ml of plasma at 37°C. activation had 
reached its maximum after 2 hours of incubation, and 
at that time the renin activity was about half the maxi-
mum obtained with the same concentration of trypsin 
at 4°C. With this concentration of trypsin the genera-
tion of active renin at 3TC had stopped because not 
enough uninhibited trypsin was left. This was demon-
strated by the following experiments. Plasma (I ml) 
was incubated with Sepharose-bound trypsin (I 00 fLl) 
in a concentration of 0.25 mg trypsin per ml of plasma 
for 4 hours at 3TC. After incubation the plasma was 
separated from the activator by centrifugation. The 
supernatant was transferred to a new tube and renin 
was measured; it was 140 fLU/ml as compared to 32 
fLU/ml before incubation with trypsin. The supernatant 
was mixed with fresh Sepharose-bound trypsin, again 
in a concentration of 0.25 mg/ml, whereas the trypsin 
pellet was resuspended in fresh plasma (I ml). The 
mixtures were then incubated for 24 hours at 4oC and 
renin was measured. Newly added trypsin caused fur-
ther generation of active renin to its maximal value of 
250 fLV/m! in the supernatant but addition of fresh 
plasma to the precipitate was without effect. In con-
trast, at 4oC maximal activation of prorenin was ob-
tained while active trypsin was still present. This was 
shown as follows: plasma ( l ml) was incubated with 
Sepharose-bound trypsin (I 00 fLl) in a concentration of 
0.25 mg/ml for 24 hours at 4°C. Plasma was then 
separated from the activator by centrifugation. The 
supernatant was transferred to a new test tube and renin 
was measured; it was 240 fLV/m! as compared to 34 
fLVIm! before incubation with trypsin. Fresh plasma (I 
ml) was added to the trypsin pellet and mixed. Renin 
was generated during subsequent incubation at 4°C, 
whereas no further activation occurred after addition of 
fresh trypsin to the supernatant. It is therefore very 
likely that at 4oC all the prorenin that could be convert-
ed by trypsin was indeed converted. 
Recovery of Prorenin and Renin during Incubation with 
Immobilized Trypsin 
The possibility that some loss of prorenin has oc-
curred during trypsin treatment at 4dC cannot be ex-
cluded but the fact that the same maximum of renin 
activity was reached irrespective of the trypsin concen-
tration in the incubate argues against such a loss of 
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FIGURE I. Activation of prorenin in a pool of normal plasma by immobilized trypsin at 4°C (left) and 37'C 
(right). The concentrations of trypsin. in mglml of plasma. are indicated. Results are the means of three 
experiments. 
prorenin. Renin activity decreased with prolonged in-
cubation with trypsin at 3rC but not at 4°C, thereby 
indicating that active renin was inactivated or de-
stroyed at 37°C. This was substantiated by the follow-
ing experiment (fig. 2). Standard human kidney renin 
( 1000 ~-tU/ml) in phosphate buffer pH 7.5 was incu-
:::-1200 
.,.;_ 
::J 
-=1000 
c 
·c 
~ 
800 
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200 
Incubation time (hours) 
.,......._. D---4 without trypsin 
o--o o--o with trypsin 
4°C 
40( 
37°C 
FtGURE 2. Inactivation or destruction of human kidney renin 
(MRC standard) by immobilized trypsin (0.25 mg!ml of incu-
bate) at4°C (closed squares) and at 37'C (open circles). Con-
trols without trypsin are shown as closed symbols. 
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bated at 4° and 37°C with Sepharose-bound trypsin in a 
concentration of 0.25 mg/ml. After various time inter-
vals trypsin was removed by centrifugation, and renin 
activity in the supernatant was determined. Incubation 
for 24 hours at 4°C had practically no effect on renin 
activity but at 37°C renin was rapidly inactivated or 
destroyed. It should be noted that these incubates are 
free of trypsin inhibitors, so that the concentration of 
uninhibited trypsin is higher under these circumstances 
than when the same quantity of trypsin is added to 
plasma. 
As shown in figure 2, at 37°C some destruction of 
renin occurred in the absence of trypsin. This may be 
due to a change in pH; in some examples it rose during 
24 hours of incubation at 37°C from 7.4 to maximally 
8.1. Renin has been reported to be destroyed at this 
temperature at alkaline pH 3 
Recovery of Angiotensin I in Trypsin-Treated Plasma 
Aliquots of normal plasma (I ml), to which lie'-AI 
had been added in a final concentration of 0.04 ~-tM, 
were incubated for 24 hat 4°C with immobilized tryp-
sin (I 00 ~-tl) in a concentration of 0.25 mg/ml or with 
phosphate buffer pH 7.5 (I 00 ~-tl). After incubation the 
immobilized trypsin was removed by centrifugation 
and 0.5 ml of the plasma samples was incubated with 
0.5 ml of sheep renin substrate in the presence of 
protease inhibitors as described in the methods section. 
The recovery of added Ile5- AI was 98 ± I 0. I% in 
trypsin-treated plasma and 98 ± 9.3% in untreated 
plasma (mean ± SEM, n = 5). 
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FIGURE 3. Comparison between various activation procedures: (a) incubation of a pool of normal plasma with 
immobili=ed trypsin (0.25 mglml of plasma) at4°C; (b) dialysis at pH 3.3 followed by dialysis ar pH 7.5 both ar 
4°C; (c) incubation with plasmin (2 casein unitslm/) or urokinase ( IOO Pioug unitslm/) at 4°C following dialysis at 
pH 4.0 and restoration of pH by I M NaOH; and (d) incubation with pepsin (0.3 mglml) at pH 3.3 and 32°C 
followed by restoration of pH by I M NaOH. Results are the mean of three experiments. 
Comparison between Trypsin Activation of Prorenin and 
other Activation Procedures 
The following procedures were compared (fig. 3): 
I) incubation of normal plasma pool at4°C with immo-
bilized trypsin (0.25 mg/ml): 2) dialysis for 24 hours at 
pH 3.3 and 4°C followed by dialysis at pH 7.5 again at 
4°C: 3) dialysis for 24 hours at pH 4.0 and 4°C fol-
lowed by restoration of pH to 7.5 with I M NaOH and 
incubation at 4°C with plasmin (2 casein units/ml) or 
with urokinase (I 00 Ploug units/mil: and 4) dialysis for 
24 hours at pH 3.3 and 4°C followed by incubation at 
32oC with immobilized pepsin (0.3 mg/ml) and subse-
quent restoration of pH to 7.5 with l M NaOH. The 
maximum levels of renin activity obtained with each of 
these procedures appeared not different. This is an 
indication that all the prorenin that could be converted 
to active renin by proteolytic attack was indeed 
converted. 
Comparison between Trypsin-Activated Prorenin 
and Naturally Occurring Renin 
Gel Filtration 
The eluates were treated with trypsin for measuring 
prorenin. The conditions were the same as for plasma, 
i.e., incubation with immobilized trypsin (0.25 mg/ 
ml) for 24 hours at 4°C. We have not rigorously 
checked whether the conditions chosen for plasma 
were also appropriate for measuring prorenin in the 
column eluates. They probably are because, when nor-
mal plasma was treated with immobilized trypsin (0.25 
51 
mg/ml) for 24 hours at 4°C before it was subjected to 
chromatography, the quantity of renin in the eluate was 
the same as when native plasma was applied to the 
column and the eluate was subsequently treated with 
trypsin. This quantity was 15 times higher than the 
quantity of renin that was recovered from the column, 
when trypsin-treatment had been omitted both before 
and after chromatography. The factor of 15, as found 
in the column eluates, was the same as the ratio be-
tween total renin and naturally occurring active renin 
in the plasma itself. 
When plasma was activated prror to chromatog-
raphy, only active renin was recovered from the col-
umn, with its peak appearing at the same elution vol-
ume as the peak of naturally occurring active renin 
(fig. 4). Mr of naturally occurring active renin was 
49,000 and Mr ofprorenin was 56,000 (mean value of 
three experiments). 
Dye-Ligand Affinity Chromatography 
The eluates were treated with immobilized trypsin in 
the same way as after gel filtration. When native plas-
ma was subjected to affinity chromatography. the bulk 
of active renin passed through the column, while pro-
renin was eluted with 0.2 M NaCI. The quantity of 
renin that was recovered after trypsin~treatment of the 
eluate was about 15 times higher than before trypsin-
treatment, which agrees with the ratio between total 
renin and naturally occurring active renin in the plasma 
itself. This suggests that the method of trypsin-treat-
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FIGURE 4. Gel filtration on Sephadex G-1 00 of untreated nor-
mal plasma and of plasma treated with immobilized tl)psin 
!0.25 mg!ml) for 24 hours at 4°C. The molecular weight mark-
ers 14C bovine serum albumin (Mr 69,000) and 14C-ovalbumin 
(Mr46,000) were used as internal standards. Renin was deter-
mined in the eluate before (closed circles) and after (open 
circles) incubation with immobilized tl)'psin. Calculated Mr-
mlues: plasma prorenin 56,000. plasma renin 49,000 and hu-
man kidney renin (MRC standard) 42,000. 
ment was appropriate for measuring prorenin in the 
column eluates. 
When plasma had been activated by trypsin prior to 
chromatography. all the renin appeared to pass through 
the column. since no renin was detected both before 
and after trypsin treatment of the eluates at 0.2 M NaCI 
and at 1.4 M NaCI (fig. 5). 
Enzyme Kinetics of Naturally Occurring Renin and 
Prorenin that is Activated by Trypsin 
Under the conditions of the renin assay the genera-
tion of AI from sheep renin substrate by both forms of 
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FIGURE 5. Affinity chromatography on Blue Sepharose of un-
treated normal plasma and of plasma treated with immobilized 
trypsin (0.25 mglml!Jor 24 hours at4°C. Renin was determined 
in the eluate before (closed circles) and after incubation with 
immobilized trypsin (open circles). 
renin proceeded linearly with time and was proportion-
al to the concentration of active renin. The activity of 
human kidney renin (MRC standard) was not influ-
enced by the addition of untreated or trypsin-treated 
normal plasma, indicating that substances interfering 
with the reaction between renin and its substrate were 
absent. 
Active renin was isolated from plasma of a patient 
with hypertension and renal artery stenosis. The con-
centration of naturally occurring renin in this plasma 
was very high. 1200 f.LU/ml. Renin was isolated by 
Sephadex G-1 00 gel filtration and further purified by 
DEAE-Sepharose ion exchange chromatography10· 1" 
followed by affinity chromatography on Blue-Sephar-
ose." The preparation was free of renin substrate and 
prore·nin. Prorenin was isolated from normal plasma 
by Sephadex-G-100 gel filtration followed by chroma-
tography on Blue Sepharose. The preparation was free 
of renin substrate and renin. Prorenin was then activat-
ed with immobilized trypsin as described above. The 
renin preparations were incubated with sheep renin 
substrate for I hour at 37"C and AI that had been 
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formed was determined for constructing Lineweaver-
Burk plots (fig. 6). Km-values for naturally occurring 
plasma renin and standard human kidney renin and for 
plasma prorenin that was activated by trypsin appeared 
similar; they ranged from 0.21 to 0.28 J.LM. 
pH-Optimum Curves of Naturally Occurring Renin and 
Prorenin that is Activated by Trypsin 
The sources of naturally occurring renin and of pro-
renin that was activated by trypsin were the same as in 
the previous experiment. The renin preparations and 
sheep renin substrate were dialyzed for 24 hours at 4°C 
against phosphate buffers with pH values ranging from 
4.5 to 9.0. The renin preparations were then incubated 
with sheep renin substrate or with human renin sub-
strate at these various pH-values for I hour at 37°C. 
The concentrations of sheep substrate in these incu-
bates was 2.5 J.LM AI equivalents/ml, and the concen-
tration of human substrate was 0.4 J.LM AI equivalents/ 
mi. The pH optimum curves of naturally occurring 
renin and of prorenin that was activated by trypsin 
appeared not different (fig. 7). The pH-optimum was 
7.5 for the reaction with sheep substrate and 5.8 with 
human substrate. 
Measurements of Plasma Renin and Prorenin in Patients 
Group I 
Results are shown in figure 8. Renin in peripheral 
plasma rose within 30 minutes after the first dose of 
captopril and reached a peak value after 1-2 hours. It 
remained high with chronic treatment. Prorenin fell 
initially (p < 0.05; paired t test) but with long-term 
treatment it reached a value as high or higher than 
renin. 
Groups 2, 3, and 4 
Basal values of peripheral vein renin and prorenin 
were comparable in the three groups (see Methods 
section). Blood pressure fell from 208 ± 6/112 ± 5 
mm Hg to 164 ± I 0/94 ± 6 mm Hg 30 minutes after 
captopril in Group 2. Blood pressure was 211 ± 7/110 
± 6 mm Hg before captopril and 198 ± 8/104 ± 7 
mm Hg 16 hours after captopril in Group 3. In Group 4 
blood pressure was 202 ± 9/109 ± 4 mm Hg before 
captopril and 143 ± 6/91 ± 5 mm Hg 1-2 hours after 
the last dose of captopril. Data collected at the time of 
renal vein sampling are shown ·in figure 9 and in table 
I. Renin in the renal vein on the affected side, but not 
contralaterally, was higher than in the aorta before 
captopril and 30 minutes after a first dose of captopril 
(p < 0.001, Group 2), and at 16 hours after a first dose 
of captopril (p < O.OOL Group 3), and also with 
chronic captopril treatment (p < 0.001, Group 4). 
Prorenin in the renal vein on the affected side was 
significantly higher than in the aorta before and 16 
hours after a first dose of captopril (p < 0.05 and p < 
0.0 I in Groups 2 and 3 respectively), and also with 
chronic captopril treatment (p < 0.01, Group 4). Con-
tralaterally the pro{enin levels in the renal vein and 
aorta were not different neither before captopril nor 
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FIGURE 6. Enzyme kineticsofnaturallyoccurring active plas-
ma renin (closed circles), tr.vpsin-activated plasma prorenin 
(open circles) and human kidney renin (MRC standard, trian-
gles). The renins were incubated at 37°C with sheep renin 
substrate for 5, 10, 20, 30, and 60 minutes. v = initial velocity 
in p..M angiotensin I per hour. s = substrate concentration in 
11-M angiotensin 1-equiva!ents. 
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FIGURE 8. Effects of a first dose of captopril, 50 mg orally, and of chronic captopril treatment, 50 mg three times 
a day, on blood pressure and on renin and prorenin in peripheral plasma. Prorenin at 30 and 60 minutes after the 
first dose of captopril was significantly below the control value (p < 0.05, paired ttest). At4 and 16 hours it was 
above control (p < 0.001 ). During chronic treatment blood was sampled 1 to 2 hours after the morning dose of 
captopril. Prorenin in these samples was 3 times higher than control (p < 0.001 ). Values in normal plasma 
(n=17) are 23 1-'Uiml (range 14-43 1-'Uim/)for renin and 196 !-'Uiml (range 138-312 1-'U/m/)for prorenin. 
TABLE I. Renin and Prorenin in Plasma of Renal Vein and Aorta in Patients with Renal Artery Stenosis 
"'Log renin (!'-Uiml) 
Blood Affected side Contralateral 
Patient Study· sampling Renal Renal 
group* design time Aorta vein Aorta vein 
Group 2 Captopril 50 mg Before first dose of 1.73 2.09 1.72 1.79 
(n = 15) single dose captopril 0.10 0.10 0.09 0.09 
30 min after first 2.66 3.12 2.70 2.71 
dose of captopril 0.11 0.13 0.11 0.10 
Group 3 Captopril 50 mg 16 hrs after first 2.02 2.37 2.01 2.01 
(n = 15) single dose dose of captopril 0.15 0.19 0.15 0.15 
Group 4 Captopril 50 mg t.i.d. 1-2 hrs after last 2.91 3.42 2.89 2.89 
(n = 10) for 2 wks dose of captopril 0.13 0.12 0.12 0.13 
*For details see Methods section. 'fp < 0.05. !;p < 0.01. *P < 0.001 for difference from 1.00. 
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TABLE I. 
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AFFECTED SIDE 
RENIN (fJU/ml) PRO RENIN (fJU/ml) 
3200 CJ Renal Artery 1600 
2800 IZl Renal Vein 1400 
2400 1200 
2000 1000 
1600 800 
1200 600 
800 400 
400 I 200 --1?/l ~ 
CONTRALATERAL SIDE 
RENIN (fJU/ml) PRO RENIN (fJU/ml) 1200 2400 
2000 1000 
1600 800 
1200 600 
800 400 
400 200 
A c D A c D 
A: before first dose of captopri I } group 2 B: 30 min after first dose of captopri I 
C: 16 h after first dose of captopril 
-group 3 
D: during chronic captopril treatment } group 4 1 - 2 h after I ast dose 
FIGURE 9. Effects of a first dose of captopril, 50 mg orally, and of chronic captopril treatment, 50 mg three rimes 
a day, on plasma renin and prorenin in the renal vein and the abdominal aorta. Statistics of these data and details 
on study design are presented in table I. 
(Continued) 
10Log prorcnin (J.<.U/ml) Renal vein-to-aorta Renal vein-to-aorta 
Affected side Contralateral ratio of renin ratio of prorenin 
Renal Renal Affected Contra- Affected Contra-
Aorta vein Aorta vein side lateral side lateral 
2.23 2.26 2.21 2.21 2.38§ 1.16 1.19t 1.04 
0.04 0.06 0.06 0.06 0.21 0.09 0.08 0.08 
2.02 1.93 2.01 1.89 3.25§ 1.05 1.14 1.04 
0.09 0.20 0.14 0.19 0.50 0.05 0.26 0.13 
2.41 2.57 2.41 2.42 2.72§ 1.00 1.53:1: 1.03 
0.13 0.13 0.12 0.13 0.50 0.02 0.16 0.03 
2.99 3.16 3.01 3.02 3.39§ 1.00 !.Sot 1.03 
0.06 0.06 0.05 0.05 0.48 0.03 0.11 0.02 
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after captopril. High levels of renin were measured in 
the aorta 30 min after a single dose of captopril and 
with chronic treatment. High levels of prorenin were 
measured in the aorta with chronic captopril. This is in 
agreement with the measurement of peripheral vein 
renin in Group I. 
Discussion 
Methodological Aspects 
For the results of functional assays of pro renin to be 
valid. conversion of the prorenin in the test sample 
should be complete and the enzymatic activities of 
equimolar quantities of activated prorenin and natural-
ly occurring renin should not diffBr. These criteria are 
likely to be met when immobilized trypsin is used for 
prorenin activation in human plasma under the assay 
conditions we have worked out. Several lines of evi-
dence support this conclusion. First, identical results 
were obtained with acid-activation. with activation by 
pepsin, plasmin, and urokinase and with immobilized 
trypsin, provided that optimal conditions were select-
ed. A plateau of maximal renin activity was obtained. 
and the level of this plateau had the same height with 
each of these procedures. 
Second, Km-values and pH-optimum curves for the 
reactions of trypsin-activated prorenin and naturally 
occurring renin with sheep renin substrate did not ap-
pear different. Third, the behavior of trypsin-activated 
prorenin on SephadexcG 100 and Blue Sepharose chro-
matography columns was similar to that of naturally 
occurring renin. The Mr-values· of naturally occurring 
active renin (49,000) and prorenin (56.000) as estimat-
ed by gel filtration. are in agreement with those report-
ed by others 19• 20 and confirm that the Mr of these plas-
ma renins is greater than the Mr of human kidney renin 
(42.000). 
Maximal activation of prorenin was observed, when 
plasma was incubated with trypsin at4°C. Other work-
ers have incubated at 37°C. 14 Our results indicate that it 
is difficult, if not impossible, to obtain complete acti-
vation of prorenin at this temperature. Moreover. the 
results at 37"C are strongly dependent on the concen-
tration of trypsin and on the incubation time. At 4°C 
these variables are less critical. provided that incuba-
tion is prolonged until renin activity has reached a 
plateau. At 37"C a larger proportion of added trypsin is 
inhibited by plasma than at 4°C, and at 37"C the re-
maining uninhibited trypsin causes progressive inacti-
vation or destruction of renin. Both the inhibition of 
trypsin. which leads to incomplete activation of pro-
renin. and the inactivation of renin by trypsin are the 
cause of measuring falsely low prorenin values. Low 
values have also been obtained after cryoactivation. It 
is therefore not surprising that the results of prorenin 
measurements reported in the literature are widely 
different. A literature search showed that the mea-
sured percentage of renin in normal plasma is 
highest with cryoactivation (35%-53% ), '· 21 - 23 where-
as it is intermediate with acid-activation (20%-
56 
50%),1.'· 10• 11 ·"· 22 • 2+-32 and lowest with trypsin (12%-
34% ). 3· 12· 14·" In our study. II% of the renin in normal 
plasma was in the active form. 
The methodological difficulties are amplified when 
prorenin is measured after maneuvers that are known 
to increase circulating renin. The accuracy of renin 
assays expressed as absolute values is inversely corre-
lated to the height of the measured value. Thus. the 
higher the renin. the less accurate is its measurement. 
This causes problems particularly when the difference 
in renin before and after activation of plasma is small. 
It explains why there is confusion on whether. after 
certain stimuli. increments in circulating renin are as-
sociated with decrements in prorenin.'· 2· "· 27 · 30 · "· 34• 35 
Changes in Prorenin after Captopril 
As shown by the present study on patients with renal 
artery stenosis, stimulation of renin release by angio-
tensin converting enzyme inhibition with captopril 
causes a precipitous rise in circulating renin with ini-
tially no change or even a fall in prorenin. Later also 
prorenin begins to rise. A transient fall in plasma pro-
renin after captopril has recently been reported. 36 · 17 
whereas earlier studies had failed to demonstrate such 
a faiL'"40 
Before stimulation with captopril we found a renal 
vein-to-aorta prorenin ratio of 1.19 ± 0.08 (mean ± 
SEM) on the affected side and of 1.04 ± 0.08 contrala-
terally; the value on the affected side was just signifi-
cantly different from 1.00 (p < 0.05). Also in earlier 
studies renal secretion of prorenin was difficult to dem-
onstrate under basal conditions. 2• tt. 25 · n. 41 It has there-
fore been postulated that prorenin is formed by extra-
renal inactivation of intrarenally produced renin. 
However. since prorenin appears to have a longer plas-
ma half-life than renin.'' a relatively low secretion rate 
of prorenin may suffice to maintain a relatively high 
plasma leveL It is possible therefore that the vena-
arterial difference in prorenin across the kidney is often 
too small to detect with an assay that has an accuracy 
that is not better than I 0%. 
After acute stimulation with captopril the secretion 
of prorenin by the affected kidney was not significantly 
increased, despite a tenfold. rise in the secretion of 
renin. With chronic stimulatio.n however. the venoar-
terial difference in prorenin became large enough to be 
easily detectable. Thus it appears that the kidney is 
indeed capable of secreting prorenin. This finding is 
probably not an artifact since secretion could be dem-
onstrated on the affected side but not contralaterally. In 
fact, our data indicate that the changes in peripheral 
prorenin concentration after captopril are a conse-
quence. at least in part. of corresponding changes in 
the rate of prorenin secretion from the affected kidney. 
Both the concentration of prorenin in peripheral plas-
ma and its secretion are increased with prolonged stim-
ulation of rea in release but not with acute stimulation. 
An extrarenal source of plasma prorenin. however. 
cannot be entirely ignored since low to normal concen-
trations of prorenin are present in the plasma of neph-
rectomized subjects. 11 ·" "' 
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This pattern of changes in renin and prorenin after 
captopril is similar to that of insulin and proinsulin 
following an oral glucose load; insulin rises within a 
few minutes but proinsulin begins to rise not earlier 
than after I -2 hours. 43 The late rise in proinsulin is a 
manifestation of an increased rate of synthesis in the 
pancreas. More prohormone is then available for con-
version to the active hormone before it is released into 
the circulation. These points of resemblance between 
the two hormonal systems should not distract from the 
fact that under normal basal conditions the concentra-
tion of insulin in peripheral plasma is 8-9 times higher 
than that of proinsulin, whereas the reverse is true for 
renin and prorenin. 
Our results do not answer the question whether or 
not prorenin is a storage form of renin but they do 
suggest that prorenin enters the circulation either by 
leakage from the juxtaglomerular cells or by corelease 
before it is converted to renin. In conclusion, these 
data indicate that prorenin is indeed a biosynthetic 
precursor of renin and that under some circumstances, 
if not mostly, a major proportion of prorenin in the 
circulation originates from the kidney. 
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Split renal function after captopril in unilateral renal 
artery stenosis 
G J WENTING, H L TAN-TJIONG, F H M DERKX, J H B DEBRUYN, A J MAN IN 'T VELD, 
MAD H SCHALEKAMP 
Abstract 
The renal extraction ratios of 1311-sod.ium iodohippurate 
("'1-Hippuran) and "'1-tha!amate were gready reduced 
on the affected side by 50 mg captopril in seven out of 
14 patients with unilateral renal artery stenosis. With 
long term captopril 150 mg daily the uptake of "mTc-
diethyleDetriaminepenta-acetic acid by the affected 
kidney which was determined by scintillati'>n cam.era renogr~phy, became almost zero in these seven patie~ts, 
indicating severe reduction of the glomerular filtration 
rate. Function of the affected kidney returned on dis-
continuing treatm.ent. The reduced extraction of sodium 
iodohippurate probably reflected a shortened plasma 
transit time through the kidney due to intrarenal vaso-
dilatation. The reduced extraction of thalamate re-
flected a low filtration fraction, suggesting that the 
vasodilatation was, at least in part, at the level of the 
postglomerular arterioles. Captopril had little effect on 
the contralateral kidney and on the kidneys of 17 patients 
with essential hypertension, and serum creatinine 
concentrations showed m.inor changes. 
Radioisotope renography should be performed after 
beginning captopril treatment in patients with renal 
artery stenosis. This is also recommended for patients 
Oven captopril as a third line drug when renal artery 
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stenosis has not been excluded. Hypertension in these 
patients is often severe and difficult to controL Renal 
artery disease is not rare in this difficult group and 
finding seriously impaired renal function on one side 
during captopril treatment may be diagnostic. 
Introduction 
Captopril is now widely used for severe hypertension, including 
that associated with renal artery stenosis.1 - 4 Renal failure, 
however, may occur in patients receiving captopril who have 
bilateral renal artery stenosis or a stenosis affecting a solitary 
functioning kidney.:; -l (} Increase in systemic arterial pressure, 
dilatation of preglomerular arterioles, postglomerular vaso-
constriction, and possibly other mechanisms may help to 
maintain glomerular filtration when renal perfusion is com-
promised by artery stenosis.11 12 Some of these mechanisms 
depend, at least in part, on an intact renin-angiotensin system. 
Converting enzyme inhibition, by interfering with angiotensin II 
formation, has therefore the potential to disturb the fine balance 
between pressure and flow required for optimal regulation of 
glomerular filtration in renal artery disease. In unilateral 
disease such an effect may easily go unnoticed because of the 
functional reserve of the opposite kidney. 
We report on the effects of captopril on split renal function 
in these patients. 
Patients and methods 
Thirty one hypertensive patients were selected from a larger 
series of consecutive patients because they were shown to have 
unilateral renal artery stenosis on renal arteriography (n=l4; table I) 
or because their renal arteries were found to be normal on both 
sides (n -.17). The patients were admitted to this hospital for a 
diagnostic work up because their hypertension was difficult to 
control; they remained hypertensive despite combined treatment 
with high doses of diuretics, [3 blockers, hydralazine, and in some 
cases also methyldopa. Results of urine analysis, serum electrolyte, 
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urea, and creatinine concentrations, and urinary excretion of vanillyl-
mandelic acid were normal. Medication had been stopped for at least 
two weeks before renal function studies and renal vein catheterisation. 
The renal arteriogram was made after renal vein sampling in the 
same session. 
t:nr-Sodium iodohippurate (1 31 1-Hippuran) and ~~~I-thalamate 
were administered by constant infusion into an arm vein. Mter 
reaching the steady state blood samples were taken simultaneously 
from the abdominal aorta and the renal vein. Samples from the same 
iites were used for renin measurements. The extraction ratio of 
1311-sodium iodohippurate (EH) and of 1251-thalamate (ET) and the 
aortic and renal vein plasma renin values were measured 10-15 minutes 
before captopril and 30-45 minutes after 50 mg of this drug. Blood 
samples were also taken at 15 minute intervals from a peripheral 
vein for estimating total renal clearance of sodium iodohippurate and 
thalam.ate.ln J.1 All blood samples were centrifuged immediately and 
radioactivity measured in plasma. Single-kidney extraction ratio 
(extraction efficiency) was calculated as (A-V)/A x 100%, where 
A =activity in abdominal aorta and V =activity in renal vein. The 
clearance of sodium iodohippurate was taken as a measure of total 
effective renal plasma flow, and the clearance of thalamate was 
taken as a measure of total glomerular filtration rate. 
The single kidney uptake of 1111mTc-diethylenetriaminepenta-acetic 
acid (1111mTc-DTPA) was determined by scintillation camera reno-
graphyY' Approximately 5-10 mCi oomTc-DTPA was injected 
intravenously. Lightpen "regions of interest" corresponding to the 
left and right kidneys were traced on the display screen using the 
three minute summation image. Time activity curves of each kidney 
region were displayed. Counting rates from the kidney areas were 
corrected for background activity using a region of interest between 
the kidneys. Single kidney function was estimated from the radio-
activity over the kidney regions 60-120 seconds after injection and 
expressed as activity ratio--that is, right/(right +left). This ratio is 
a measure of the single kidney's contribution to total glomerular 
filtration rate. HI The kidney scans were made before treatment and 
after three to five weeks of captopril 150 mg daily. 
The concentration of active renin in plasma was measured by 
radioimmunoassay.17 Blood pressure was measured intra-arterially in 
the acute study during renal vein catheterisation and indirectly with 
the London School of Hygiene sphygmomanometer in the long 
term study. 
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Grouped data are presented as means (SEM in parentheses), and 
differences were analysed for statistical significance by Student's r 
tests for paired and unpaired data. 
Results 
Values of EH and ET were significantly decreased after captopril 
on both sides both in patients with unilateral renal artery stenosis 
and in essential hypertension (table II; fig 1). The effects ofcaptopril 
on kidneys with a stenotic artery were much greater than on kidneys 
with normal arteries. The renal extraction ratio of a substance equals 
its renal clearance divided by the renal plasma flow. Thus ET = 
clearance of thalamate/true renal plasma flow, or glomerular filtration 
rate/true renal plasma :flow-that is, filtration fraction. Our results 
therefore indicate that the single kidney filtration fraction was lowered 
by captopril, particularly when the kidney was affected by renal 
artery stenosis. 
Since the clearance of sodium iodohippurate did not change after 
captopril (table II; fig 2) and EH =clearance of sodium iodohippurate/ 
true renal plasma flow, the observed reduction of EH after captopril 
implies that true renal plasma flow and therefore the total renal 
blood flow was increased. 
As shown in figure 3, 1111mTc-DTPA uptake by the affected kidney 
became almost zero after captopril in seven patients with unilateral 
renal artery stenosis (group 1) and was essentially unchanged in the 
remaining seven patients with renal artery stenosis (group 2). It was 
also unchanged in the patients with essential hypertension. Reductions 
in Ea and ET after the first dose of 50 mg captopril were greater in 
group 1 than in group 2 (table II). Serum creatinine concentration 
rose significantly during long term captopril in group 1 but not in 
group 2 (table III). Neither the changes in blood pressure nor the 
pressure levels that were reached after captopril were, however, 
different in the two groups. None of the patients developed trouble-
some proteinuria. 
The loss of renal function after captopril in group 1 appeared not 
to be due to irreversible parenchymal damage. In four patients 
DTPA uptake was restored one to two weeks after captopril had 
been stopped (figure 4 gives an example). By that time the plasma 
creatinine concentration had also returned to its original value. The 
TABLE 1-Clini.:al data on patients with unilateral renal artery stenosis 
Case No 
8 
9 
10 
11 
12 
13 
14 
Ago 
(years) 
47 
57 
56 
64 
47 
31 
57 
68 
57 
58 
65 
25 
68 
50 
S= Cause of renal artery stenosis 
M Atherosclerosis 
Group 1 
M Atherosclerosis 
M Atherosclerosis 
M Atherosclerosis 
M Atherosclerosis 
F Fibromuscular hyperplasia 
M Atherosclerosis 
F Atherosclerosis 
Group 2 
M Atherosclerosis 
M Atherosclerosis 
M Atherosclerosis 
F Fibromuscular hyperplasia 
M Atherosclerosis 
F Atherosclerosis 
Renal vein to artery renin ratio 
Plasma renin 
mUflt Affected kidney Contralateral kidney 
233 5·97 0·92 
61 3·29 1·02 
37 2·42 0•94 
38 1·58 1·12 
37 1·71 1·17 
23 2·65 0·88 
480 1·39 0·91 
178 5·81 0·89 
353 2·09 0·81 
75 3·08 1·03 
208 2·20 1-40 
34 1·53 1·04 
40 1·36 1·55 
42 2·17 0·96 
Patients separated into two groups based on effect of captopril on uptake of ••mTc-diethyJenetriaminepenta-acetic acid by affected 
kidney r see text). 
+Normal range 5-45 mU/1. 
TABLE rr-Acute ~ifccts of captopril in patients with unilateral renal artery stenosis (group 1 v group 2). Values are means (SEM in parentheses) 
p Values for differences between 
M.ean arterial prellsure (mm Hgl 
Total effective renal plasma flow (ml'min1 
Total glomerular filtration rate (.ml/minl 
Si~~~i~k~dfoed~hi~r;~~~~~ (~.~;o uf { ~~~~:~~t~~~~k)idney 
Si~~;~;~~~ccr.,~.~traction ratio of { ~~~~:~~t~~~~~~d~!:Y 
Group 1 (cases 1-7) 
Before captopril After captopril 
139 (5} 
333 {35) 
95 (6) 
60 (7) 
75 (3) 
tR (11 
24 (2) 
114 (4)*** 
343 (42) 
82 (7)** 
2Q (7)* .. 
71 (3) 
6 (1)* .. 
22 (3) 
60 
Group 2 (cases 8-14) groups 1 and 2 
Before captopril After captopril Before captopril After captopril 
137 (10) 110 (10) .. NS NS 
320 (46) 328 (48) NS NS 
87 (8) 81 (7)* NS NS 
64 (5) 53 (9)* NS <0·001 
74 (3) 70 (5) NS NS 
17 (2) 13 (3) ... NS --0·001 
22 (2) 19 (3) NS NS 
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TABLE III-Long term effects of captopn"l in pat£enrs with unilateral renal artery stenosis (group 1 v group 2). Values are means (SEM in parentheses) 
Group 1 (cases 1-7) Group 2 (cases 8-14) 
p Values for differences between 
groups 1 and 2 
Before captopril After captopril Before captopril After captopril Before captopril After captopril 
Mean arterial pressure (mm Hg) 
Serum creatinine (!llllol/l) 
143 (7) 
100 (6) 
111 (6)'" ... 
122 (9) .. 
140 (8) 
113 (12) 
114 (5)••• 
116 (12) 
NS 
NS 
NS 
NS 
Uptake of ••mTc-DTPA by affected kidney ("~ of total 
uptake) 
NS =Not significant. 
34 (3) ...::: 10 
••g~~!,;lo~;·!i~~~~!fin·onal unirs-Creatinine: 1 !J.mol/1.::::0·01 mg/100 ml. 
remaining three patients were not restudied after discontinuation of 
captopril treatment, but DTPA kidney scans after reconstructive 
vascular surgery showed improved uptake on the affected side. 
Discussion 
This study shows that in a substantial number of potients 
with unilateral renal artery stenosis the renal extraction ratio 
of both "'!-sodium iodohippurate (EH) and "'1-thalamate (ET) 
is greatly reduced on the affected side when captopril is given 
as the only drug. The fall in E H may be explained by a shortened 
plasma transit time through the kidney due to intrarenal vaso-
dilatation. This has also been observed with vasodilatation 
induced by other agents. 111 ET equals filtration fraction, and the 
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FIG 1-Effect of 50 mg captopnl on renal extraction efficiencies of laq_ 
sodium iodohippurate (EH) and I:!:>I-thalamate (Er) in 14 patient!. with 
unilateral renal artery stenosis and 17 patients with es!.ential hypertension 
In patients with renal artery stenosis changes in EH and E 1 were s1gniticant 
on both sides (p< O·on. Changes in essentml hypertension were also sig-
nificant (p< 0·05). 
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FIG 2-Effect of 50 mg captopril on total clearances of 131 1-sodium iodo-
hippurate (effective renal plasma flow) and 12:>1-thalamate (glomerular 
filtration rate) in 14 patients with unilateral renal artery stenosis and 17 
patients with essential hypertension. Effect of captopril after 60 minutes 
was significant for systolic and diastolic intra-anerial pressure (p<O·OOl) 
and for renin (p<O·Ol). 
fall in ET after captopril may reflect the dilatation of post-
glomerular arterioles. In Captopril also lowered E H and ET of 
kidneys with a normal artery but the changes were not as 
great as for kidneys with artery stenosis. In our patients the 
fact that the decrease in EH on both sides was not associated 
with a decrease in total clearance of sodium iodohippurate is 
further support for vasodilatation in the kidney, probably on 
the affected as well as the non-affected side. Increase in total 
renal blood ftow and decrease in total filtration fraction after 
captopril have bet!n reported in patients with essential hyper-
tension.1 ~ In those studies the clearance of para-aminohippurate 
was used as an estimate of renal plasma ftow with the implicit 
assumption that the renal extraction efficiency was high and 
remained constant. This, however, may be misleading, as 
shown by our results; the effects of captopril on renal blood 
flow and filtration fraction would be grossly underestimated in 
some patients. 
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Other significant findings were the changes in the uumTc~ 
DTPA kidney scans showing a decrease in glomerular filtration 
rate during long term captopril treatment. This was seen only 
with kidneys affected by artery stenosis. It also appeared to be 
an all or none phenomenon-that is, the uptake of DTPA by 
Renal artery stenosis Essential 
~ ~ _byRertensJon 
170 ~ 150 Mean arterial ~ pressure (mmHg) 130 110j 
90 
60 f---f 
40 
' 
~ 
DTPA uptake ( '/,) 
-20 
"-----------
Affected Affected Right 
kidney kidney kidney 
FIG 3-Effect of long term captopril 150 mg daily on blood 
pressure and single kidney uptake of 1!UrnTc-DTPA in 14 patients 
with unilateral renal artery stenosis and 17 patients with essential 
hypertension, Patients with renal artery stenosis divided into 
two groups according to change in DTPA uptake (see table III 
for statistics). Values in patients with essential hypertension pre-
sented as means and SEM. Mean arterial pressure calculated as 
diastolic pressure~ 0·3Xpulse pressure. London School of 
Hygiene sphygmomanometer used. Three consecutive readings 
with patient in recumbent position were averaged. Effect of 
captopril on mean arterial pressure in patients with essential 
hypertension was not different from effect in two groups of 
patients with renal artery stenosis. 
the affected kidney became either almost zero or showed little 
change. The deterioration in renal function was observed in 
half of our patients, but this high incidence may have been 
related to selection; all had been referred to us because of severe 
hypertension that was difficult to controL 
Deterioration of renal function does not occur only with 
captopril, 2 0 but conceivably converting enzyme inhibitors may 
be especially likely to cause this complication. Acute converting 
enzyme inhibition with captopril or angiotensin II blockade 
with saralasin caused renal failure in rats with chronic two 
kidney, two clip hypertension pretreated with. frusemide. 21 By 
contrast, the _.direct smooth muscle relaxants minoxidil and 
dihydralazine did not have this effect, despite a similar fall in 
systemic arterial pressure. Such findings have also been reported 
in a few patients with bilateral renal artery stenosis or with a 
stenotic artery to a solitary functioning kidney. 7 - 9 Most of 
these patients had been treated with captopril in combination 
with other drugs, particularly diuretics. More work is needed to 
establish whether captopril either alone or combined with a 
diuretic is more harmful for the kidney affected by artery 
stenosis than other antihypertensive drugs. 
The effect of captopril on systemic arterial pressure in our 
patients who responded with loss of filtration on the affected 
side was not greater than in those who maintained filtration. 
Thus the degree of reduction in blood pressure is probably not 
BRITISH MEDICAL JOURNAL 
the only factor determining whether or not renal function can 
be maintained during captopril. Experimental constriction of a 
renal artery is known to be followed by vasoconstriction within 
the affected kidney, and there is good evidence that the post-
glomerular vascular resistance is increased so that filtration 
pressure is restored and glomerular filtration rate is maintained. 
This mechanism is impaired by converting enzyme inhibition, 
and filtration pressure may fall, particularly when systemic 
arterial pressure also falls.11 12 Increased glomerular blood flow 
after intrarenal vasodilatati ...... n may partly compensate for this. 22 
When filtration pressure falls below a critical level, however, 
the kidney stops filtering. It is tempting to assume that this 
occurred in some of our patients. It was the patients with the 
greatest reductions in EH and ET after captopril who responded 
with loSs of filtration. Presumably these were the patients with 
the most severe artery stenosis. An alternative or additional 
mechanism contribUting to the fall in glomerular filtration rate 
might be that a critically severe stenosis of a large artery be-
comes more severe after dilatation of the distal vascular bed. 23 24 
This has been reported in renal artery stenosis induced by 
cuff constrictors in intact instrumented dogs. ~jj 
Fortunately, in none of our patients were the effects of 
captopril on renal function associated with irreversible damage 
No treatment 
.,a._.__.:.:;· 
During coptopril 
Ott captopril 
,, 
S Time- ( milutes ) lO 15 
PIG 4--Sequential 99 rnTc-DTPA kidney scans in patient with unilateral 
renal anery stenosis (case 3; table I) before captopril, after four weeks of 
captopril 150 mg daily, and one week after ::.topping captopril. Time after 
radioisotope injection indicated. 
to the renal parenchyma. DTPA uptake was restored by 
discontinuing captopril or after reconstructive vascular surgery. 
Radioisotope renography should be performed in any patient 
with renal artery stenosis who is taking captopril. Perhaps we 
should go even further. Until now captapril has been used in 
hypertension mainly as a third line drug when other drugs have 
failed. Renovascular hypertension is not uncommon in this 
difficult group. Hence radioisotope renography should probably 
be performed in every patient who has been given captopril 
because of poor response to other drugs when the possibility of 
renal artery stenosis has not been excluded. We believe that 
finding seVerely impaired renal function on one side during 
captopril treatment calls for withdrawing the drug or perhaps 
lowering the dose. In such cases renal artery stenosis is likely 
to be the underlying disease. 
We thank Mr P P M van de Kooy, department of nuclear medicine, 
Erasmus University, for his help in analysing the kidney scans. We 
also thank Dr A J van Seyen, department of radiology, who analysed 
the arteriograms. 
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Risks of angiotensin converting enzyme inhibition in renal 
artery stenosis 
GERT J. WENTING, FRANS H. M. DERKX, LIES H. TAN-TJIONG, ANDRIES J. VAN SEYEN, 
ARIE J. MAN IN'T VELD, and MAARTEN A. D. H. ScHALEKAMP 
Departments of Internal Medicine I and ROntgenology, University Hospital Rotterdam-Dijkzigt, Erasmus University, Rotterdam, The 
Netherlands 
ACE inhibitors are now widely used in the treatment of 
severe hypertension, including hypertension associated with 
renal artery stenosis. Several authors have reported on deteri-
oration of renal function upon institution of angiotensin con-
verting enzyme (ACE) inhibition in patients characterized by 
having marked degrees of bilateral renal artery stenosis or a 
stenosis affecting a solitary functioning kidney. These effects 
have been considered to be associated with a profound fall in 
arterial pressure by some authors [1--4] but not by others [5-7]. 
To date, the exact mechanism behind this loss of renal 
function has not been clarified, but the current explanation is 
that autoregulation of glomerular filtration depends on an intact 
renin-angiotensin system [8]. ACE inhibition, by interfering 
with angiotensin 11 formation, has therefore the potential to 
disturb the balance between the pressure and flow required for 
optimal regulation of glomerular filtration in renal artery dis-
ease. In unilateral disease, adverse effects of ACE inhibition 
may easily go unnoticed because ofthe functional reserve of the 
opposite nonstenotic kidney. We therefore studied split renal 
function in 25 patients with hypertension and unilateral renal 
artery disease. In one patient with a stenosis of a saphenous-
vein graft to a solitary functioning kidney, we further tried to 
elucidate the mechanism involved in the shutdown of glomeru-
lar filtration during ACE inhibition. 
Patients and methods 
Twenty-five patients (10 male, 15 female; aged 16-66 years) 
with unilateral renal artery stenosis on renal arteriography and 
near-normal overall renal function were studied. The cause of 
the renal artery stenosis was classified, according to the arteri-
ographic appearance, as due to either atheroma (21 patients) or 
fibromuscular dysplasia (4 patients). One patient (a heavy 
smoker, male, aged 62 years) had had an aorto-iliac graft and a 
saphenous-vein graft had been anastomosed to the prosthesis 
and end to end to the right renal artery beyond the occluded 
portion. A small contracted nonfunctioning kidney was re-
moved in the same session. Blood pressure was initially well 
controlled without hypotensive drugs but the recurrence of 
Received for publication July 9, 1986 
© 1987 by the International Society of Nephrology 
severe hypertension suggested re-stenosis. Aortography showed 
a tight stenosis of the saphenous-vein graft. In all patients, 
previous antihypertensive treatment was withdrawn for at least 
one week. The patients were admitted to hospital for detailed 
measurements of blood pressure, and for renal function studies 
and renal vein catherization. Renal arteriography was per-
formed after renal vein sampling. 
131 I-sodium iodohippurate (131!-hippuran) and 125!-thalamate 
were administered by constant infusion into an arm vein. After 
reaching the steady state, blood samples were taken simulta-
neously from the abdominal aorta. and the renal vein. Samples 
from the same sites were used for renin measurements. The 
extraction ratio of 131!-hippuran (EH) and of 125!-thalamate (Ey), 
and the aortic and renal vein plasma renins, were measured 
10-15 min before, and 30--45 min after, administration of 50 mg 
of captopril. 
Blood samples were also taken at 15-min intervals from a 
peripheral vein for estimating total renal clearance of sodium 
iodohippurate and thalamate [9. 10]. All blood samples were 
centrifuged immediately and radioactivity was measured in 
plasma. Single-kidney extraction ratio (extraction efficiency) 
was calculated as [(A - V)/A x 100%)], where A is the activity 
in abdominal aorta and V is the activity in renal vein. The 
clearance of sodium iodohippurate was taken as a measure of 
total effective renal plasma flow, and the clearance of thalamate 
was taken as a measure of total glomerular filtration rate (GFR). 
The single kidney uptake of 99mTc-diethylenetriaminepenta-
acetic acid C9mTc-DTPA) was determined by scintillation cam-
era renography [11]. Approximately 5-10 mCi 99mTc-DTPA was 
injected intravenously. Light-pen "regions of interest" corre-
sponding to the left and right kidneys were traced on the display 
screen using the three-minute summation image. Time activity 
curves of each kidney region were displayed. Counting rates 
from the kidney areas were corrected for background activity 
using a region of interest between the kidneys. Single kidney 
function was estimated from the radioactivity over the kidney 
regions 60-120 seconds after injection and expressed as activity 
ratio-'--that is, right/ (right + left). This ratio is a measure of the 
single kidney's contribution to total GFR [12]. The kidney scans 
were made in 14 patients before treatment and after 3-5 weeks 
of captopril 150 mg daily. The concentration of active renin in 
plasma was measured by radioimmunoassay [13]. Blood pres-
sure was measured intraarterially in the acute study during 
S-180 
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______ T_able 1. Acute effects of 50 mg captopril in 25 patients with hypertension and unilateral renal artery stenosis ·------
P values Before captopril After captopril 
~~----~----------------------~~------~----------
Arterial pressure. mm Hg 205 ::±: 6/114 ::±: 3 161 ::±: 6/84 ± 5 <0.001/<0.001 
Total effective renal plasma flow. mllmin 328 ± 24 340 ::±: 32 NS 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
Total glomerular filtration rate, mllmin 91 ::±: 4 85 ::±: 5 
Single-kidney extraction ratio of J Affected kidney 54 ::±: 5 34 ::±: 4 
sodium iodohippurate, % l Contralateral kidney 74 ::±: 2 66 ± 3 
Single-kidney extraction ratio of J Affected kidney 15 ± 2 8 ± I 
thalamate, % l Contralateral kidney 22 ± 1 18 ± I 
10 100 1,000 10,000 10 100 1,000 10,000 
Aorta reryin, f.LUiml 
Fig. 1. Acute effect of 50 mg captopril on the plasma concentration of 
active renin in blood from the renal veins and aorta. Symbols are: (0) 
before captopril. {8) after captopril. 
renal vein catherization and indirectly with the London School 
of Hygiene sphygmomanometer in the long-term study. 
Grouped data are presented as means :!: SEM and differences 
were analysed for statistical signficance by Student's t tests for 
paired data. 
Results 
Acute effects of captopril 
Renal vein renins. Before captopril treatment, the plasma 
concentration of active renin was higher in blood from the renal 
vein of the stenotic kidney than from the aorta (Fig. 1). the renal 
vein-to-aorta renin ratio (VIA) being 2.86:!: 0.28. Veno-arterial 
differences for active renin across the contralateral kidney were 
small. VIA being 1.09 :!: 0.06. After the first dose of 50 mg 
captopril, VIA of the stenotic side rose to 3.70 :!: 0.46 (P < 
0.01). 
No change of VIA was found for the contralateral side, with 
VIA ·remaining 1.03 :!: 0.03. Renin in peripheral plasma rose 
from 100 :!: 20 to 607 :!: 98 ILUiml. 
Blood pressure and renal function. Despite a fall in blood 
pressure, the overall clearance of sodium iodohippurate and 
thalamate was not much altered (Table I). However, captopril 
had a pronounced. and sometimes dramatic, effect on the 
extraction efficiency of the stenotic kidney for these radiolabels 
(Figs. 2 and 3). EH fell by more than 20% in 9 patients. The renal 
extraction ratio of a substance equals its renal clearance divided 
by the renal plasma flow. Thus ET = clearance of thalamateltrue 
renal plasma flow, or GFR/true renal plasma flow, that is, 
filtration fraction. Our results therefore demonstrate that the 
single kidney filtration fraction was lowered by captopril, 
particularly when the kidney was affected by renal artery 
stenotic side % 100r-------------~~~~~-----------, 
10 15 20 25 
Patients 
Fig. 2. Acute effect of 50 m}? captopril on the extraction efficiency of 
131 /-sodium iodohippurate of the stenotic kidney. Open bars before 
captopril, hatched bars during captopril treatment. 
stenotic side % 30,-------------~~~~~-------------, 
25 
10 15 20 25 
Patients 
Fig. 3. Acute effect of 50 mR captopril on the extraction efficiencv of 
125/-tha/amare of the stenotic kidney. Open bars before captoPril. 
hatched bars during captopril treatment. 
stenosis. Since the overall clearance of sodium iodohippurate 
did not change after captopril treatment and EH = clearance of 
sodium iodohippurateltrue renal plasma flow, the observed 
reduction of EH after captopril implies that true renal plasma 
flow and therefore the total renal blood flow was increased. It 
is. however, possible that in some cases the blood flow of the 
nonaffected kidney is increased, whereas the flow of the af-
fected kidney is decreased. 
65 
S-182 Wenting et a/ 
~ 
~ 
~250 80 ~ 
0 
E systolic "' E 70; i 200 60 E ~ 
~ 50 ~ 
c. 0 
-g 150 40-5-
0 mean .,; iii 30 ~ : 
100 20 ·) 
diastolic 
10 ~ 
50 a: 
80 -~ 240 E 
"' 
* 
E f 60 2ooz 
160~ ~ ERPF 
~ 40 120 0 
-~ 
20 
w 
60 50 
50 40 
-~ E 
30 c 8 
rl 30 E 
~ 20 :g 20 ~ 
u 
10 10 
0 0 
-90 -60 -30 30 60 90 
Time, min 
Fig. 4. Acute effect of 50 mg captoprif in a patient with a tight stenosis 
of a saphenous-vein bypass graft to the right artery of a solitary 
functioning kidney. 
Function of a solitary kidney. Data on blood pressure, urine 
production, GFR, and renal haemodynamics after a single dose 
of 50 mg captopril in the patient with a tight stenosis of the 
saphenous-vein bypass are shown in Fig. 4. The fall in blood 
pressure after captopril was modest, but renal perfusion and 
glomerular filtration almost ceased. Although captopril proba-
bly had a vasodilatory effect within the .kidney, vascular resist-
ance over the total circuit, including the bypass. rose. 
Long-term effects of captopri/ 
As shown in Fig. 5, 99mTc-DTPA uptake by the affected 
kidney almost ceased after captopril treatment in seven patients 
(group I), but was essentially unchanged in the remaining group 
Renal artery 
stenosis 
group 1 group 2 
tn 170 
J: 
E 
E 
1150 
~ 130 
·~ 
1i 
~ 110 
~ 
90 
60 
~ 
0~ 
' 
b<! ~ 0. 40 ~.: a.~ ~~.s 
~~ 20 ~ c -
:Q<t: o-......_.. ~c. ~t:; 
"'' c u 
·- f-UlE 
~ affected affected 
kidney kidney 
Fig. 5. Effect of long-term captopril, 150 mg daily, on blood pressure 
and single kidney uptake of 99mTc-DTPA in 14 patients with unilateral 
renal artery stenosis. Patients with renal artery stenosis divided into 
two groups according to change in DTPA uptake, Mean arterial 
pressure calculated as diastolic pressure + 0.3 x pulse pressure. 
(group 2). Neither the changes in blood pressure nor the 
pressure levels that were reached after captopril treatment 
were, however, different in the two groups (Fig. 5). Reduction 
in EH and ET after the first dose of 50 mg captopril were 
correlated to the changes in 99mTc-DTPA uptake (r = 0.78, P < 
0.01, and r = 0.72. P < 0.01, respectively). Serum creatinine 
concentration rose significantly from 100 ± 6 to 122 ± 9 .umol/l 
(P < 0.01) in group I but not in group 2 (113 ± 12 .umol!l before 
captopril, 116 ± 12 .umolll during captopril). The loss of renal 
function after captopril treatment in group I appeared not 
associated with irreversible parenchymal damage. In 4 patients, 
DTPA uptake was restored after captopril had been stopped 
and serum creatinine had also returned to its original value. The 
remaining three patients were not restudied after discontinua-
tion of captopril treatment but DTP A kidney scans after recon-
structive vascular surgery showed improved uptake on the 
affected side. 
Discussion 
The present study extends earlier observations [14] that, in a 
substantial number of patients with unilateral renal artery 
stenosis. the renal extraction ratio of both 131!-sodium iodohip-
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purate (EH) and 1251-thalamate (ET) is greatly reduced on the 
affected side wher. captopril is given as the only drug. The fall 
in EH may be explained by a shortened plasma transit time 
through the kidney due to intrarenal vasodilatation. This has 
also been observed with vasodilatation induced by other agents 
[15]. ET reflects filtration fraction. and the fall in ET after 
captopril treatment may result from the dilatation of postglom-
erular arterioles [16]. Captopril also lowered EH and ET of the 
contralateral kidney. but the changes were small and compara-
ble to those found in patients with essential hypertension [13]. 
Other significant findings were the changes in 99mTc-DTPA 
kidney scans showing a decrease in GFR during long-term 
captopril treatment. This was seen only with kidneys affected 
by artery stenosis. It also appeared to be an all or none 
phenomenon-that is. the uptake of DTPA by the affected 
kidney either became almost zero or showed little change. The 
effect of captopril on systemic arterial pressure in our patients 
who responded with loss of filtration on the affected side was 
not greater in those who maintained filtration. Thus the degree 
of reduction in blood pressure is probably not a decisive factor 
determining whether or not renal function can be maintained 
during captopril treatment. Experimental constriction of a renal 
artery is known to be followed by vasoconstriction within the 
affected kidney, and there is good evidence that the postglom-
erular vascular resistance is increased (by local formation of 
angiotensin II) so that filtration pressure is restored and 
glomerular filtration rate is maintained. This mechanism is 
impaired by ACE inhibition, and filtration pressure may fall. 
Increased glomerular blood flow, after intrarenal vasodilata-
tion. may partly compensate for this [17]. When filtration 
pressure falls below a critical level, however. the kidney stops 
filtering. It is tempting to assume that this occurred in some of 
our patients. An alternative or additional mechanism contribut-
ing to the fall in GFR might be that a critically severe stenosis 
of a large artery becomes more severe after dilatation of the 
distal vascular bed [18, 19]. This has been reported in renal 
artery stenosis induced by cuff constrictors in intact. instru-
mented dogs [20]. The rise in vascular resistance over the total 
renal circuit in our patient with the tight stenosis of the 
saphenous-vein graft suggests that this rheological phenomenon 
also occurs in humans. It is clear that, in exceptional cases, EH 
will also fall as a result of severe reduction of renal perfusion. · 
Fortunately, in none of our patients were the effects of captopril 
on renal function associated with irreversible damage to the 
renal parenchyma. However, the consequences of a long-term, 
captopril-mediated reduction in GFR are unknown. When renal 
blood flow is gravely compromised. renal artery thrombosis 
may occur [21]. We recommend that radioisotope renography 
should be performed after beginning ACE inhibition in patients 
with renal artery stenosis. This is also recommended for pa-
tients given captopril as a third-line drug when renal artery 
stenosis has not been excluded. Hypertension in these patients 
is often severe and difficult to control. Renal artery disease is 
not rare in this difficult group, and finding seriously impaired 
renal function on one side during captopril treatment may be 
diagnostic. 
Reprint requests to Professor M.A.D.f!. Schalekamp, De?.a~tment of 
Internal Medicine. University Hosprtal Rorterdam-Duk;:.rgt, Dr. 
Molewaterplein 40, 3015 GD Rotterdam, The Netherlands 
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DIAGNOSTIC TOOL 
Captopril test for diagnosis of renovascular hypertension. 
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AJ, Schalekamp MADH. 
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Captopril treatment does not improve renal vein lateralization. 
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CAPTOPRIL TEST FOR DIAGNOSIS OF 
RENAL ARTERY STENOSIS 
Summary 
One hundred seventy-nine patients were selected for a diagnostic work-up of 
renovascular hypertension from a consecutive series of hypertensive subjects referred to a 
single outpatient clinic between January 1978 and January 1985. Selection criteria were: 
1. diastolic blood pressure 120 mm Hg or above in patients of 40 yr or younger, 
irrespective of whether or not they were on treatment; and/or 2. diastolic blood pressure of 
100 mm Hg or above despite a combination therapy with at least three drugs. 
Diagnosis of renal artery stenosis was made by renal angiography. The response of blood 
pressure and the plasma concentration of naturally occurring active renin, one hour after 50 
mg captopril orally, were assessed. Before the test, the patients had been off drug treatment 
for at least two weeks. The predictive value of the test was 0.92 using a renin concentration 
of 200 !J.U/ml or above as criterion for a positive test. The predictive value of a negative 
test was 0.81. Using the blood pressure response as a criterion, the predictive values were 
lower. Predictive values were not improved by combining the renin level with the blood 
pressure response. The prevalence of renal artery stenosis in our patients with severe or 
therapy-resistant hypertension was 50% (unilateral stenosis 34%). Plasma renin one hour 
after 50 mg captopril (captopril test) is a useful criterion for selecting cases forrenal 
angiography, at least in a hypertension clinic where a patient population is seen with a 
similarly high prevalence of renal artery stenosis. 
Introduction 
There are no clinical characteristics that can be used to differentiate unequivocally 
bet.veen p~tients with essential hypertension and patients with hypertension due to renal 
artery st~nosis (3). Renal angiography is the only effective technique for demonstrating the 
presence of a stenotic lesion in the renal artery. Obviously, this technique cannot be used 
for screening the hypertensive population for renal artery disease. Several procedures, such 
as intravenous urography and radioisotope renography have been used for selecting 
patients for renal angiography. However, the values of these diagnostic tests has been 
disputed (3). 
Plasma renin activity and the plasma concentration of active renin is higher on average in 
patients with renal artery stenosis than in patients with essential hypertension but there is a 
large overlap between the two groups. This might be related, at least in part, to the fact that 
renin measurements were not always performed under strictly standardized conditions 
(sodium intake, posture, antihypertensive treatment). 
Until recently, the saralasin infusion test has been advocated as a diagnostic tool in 
patients with suspected renal artery stenosis. Blood pressure generally falls after infusion 
of this competitive angiotensin II antagonist when plasma renin is high, but not when it is 
normal or low. The discriminatory value of this test as a diagnostic indicator of renin-
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dependent hypertension however, is also disputed (7, 8). 
Inhibition of angiotensin-converting enzyme is another possibility to inferfere with the 
renin-angiotensin system. In this paper we have tried to answer the following question: Are 
measurements of plasma active renin under strictly standardized conditions before and 
after a single oral dose of the angiotensin-converting enzyme inhibitor captopril (50 mg) of 
any use for diagnosing renal artery stenosis ? 
Patients and methods 
Patients 
The 179 patients in this study were selected from a larger consecutive series of caucasian 
hypertensive subjects referred to our outpatient clinic between January 1978 and January 
1985. Inclusion criteria for this study were: 
1. diastolic blood pressure repeatedly 120 mm Hg or above in patients of 40 yrs or 
younger, irrespective of whether or not they were under antihypertensive therapy; and/or 
2. diastolic blood pressure of 100 mm Hg or above, despite a combination therapy with at 
least three different antihypertensive drugs. 
The patients were hospitalized during the time of the study and had a sodium intake 
between 50 and 70 mmoles per day. Antihypertensive therapy was stopped at least two 
weeks before the study. All patients underwent renal angiography at the end of the study. 
The distinction between fibromuscular dysplasia and atherosclerotic disease was made by 
angiography criteria (2). The patients had given their informed consent. 
Sixty-two patients had unilateral renal artery stenosis and 28 had bilateral renal artery 
stenosis. In 10 of these patients, renal artery stenosis was due to fibromuscular dysplasia 
and in the remainder to atherosclerotic lesions.No abnormalities were found in 89 patients, 
and this group was considered to have essential hypertension. 
Captopril test 
The test was performed while the patients were recumbent after one hour bed rest. 
Captopril, 50 mg was given by mouth. Blood pressure was measured every 5 min with an 
automatic oscillometric device (Accutor, Datascope, Paramus, NJ, USA) from 30 min 
before to 4 hours after captopril administration. Blood samples for renin measurements 
were taken from an indwelling catheter in a forearm vein at -30 min, 0 min, 30 min, 1 hr, 2 
hrs and 4 hrs after captopril. The first blood sample was taken between 11 and 12 a.m. 
Renin measurements 
Blood was collected in chilled plastic tubes containing EDTA in a final concentration of 
5 mM. It was centrifuged at 3000 g for 10 min at 4 oc immediately after collection. Plasma 
was stored at -20°C. Naturally occurring active renin was measured as described before 
(4, 5). For this assay 0.1-0.25 ml plasma was added to 0.5 ml purified sheep renin-
substrate, to which the appropriate enzyme inhibitors were added. The volume was 
adjusted to 1.0 ml with 0.1 M sodium phosphate buffer, pH 7.5, containing 0.05 M NaCl. 
The final concentration of sheep renin-substrate in the incubation mixture was 1.5 J..!M, 
which corresponds with approximately 6xKm. The samples were incubated at 37°C for 
periods up to one hour. The rea_ction was stopped by pipetting 50 J.!l aliquots into prechilled 
plastic tubes placed on melting ice. The quantity of angiotensin I that was generated during 
incubation was measured by radioimmunoassay. The zero-incubation time was taken as the 
blank. The concentration of enzymatically active renin is expressed as microunits per ml of 
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plasma {Jl.U/ml), using as a reference the human kidney renin standard 68/356 of the 
Medical Research Council (MRC) National Institute for Biological Standards and Control 
(London, UK) (1) 
Statistics 
The best trade-off between sensitivity and specificity for the various test criteria was 
determined from a Receiver Operator Characteristic Curve (6). 
Results 
Peripheral vein renin unde:r: basal conditions 
The peripheral vein renin levels of enzymatically active renin in untreated patients with 
unilateral renal artery stenosis, bilateral renal artery stenosis and essential hypertension, 
who were off antihypertensive therapy for at least two weeks are shown in Figure 1. 
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Figure 1: Active renin in the peripheral vein of patients who were off antihypertensive 
therapy for at least 2 weeks. EHT = essential hypertension. URAS = unilateral renal 
artery stenosis. BIRAS =bilateral renal artery stenosis. 
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The normal renin level in our laboratory is between 15-45 J.!U/ml. Basal renin did not 
discriminate for renal artery stenosis. Half of the patients with renal artery stenosis had 
renin values within the normal range. The predictive values of a positive test (renin~ 45 
J.!U/ml) and a negative test are given in Table 1. 
TABLEl. Diagnostic value of different tests 
Test criterion Specificity Sensitivity P(D+T+) P(D-T-) 
Renin before captopril ( ~ 45 J.!U/ml) 0.43 0.90 0.81 0.61 
Decrease in systolic BP one hour after 
captopril ( ~ 30 mm Hg) 0.66 0.77 0.74 0.68 
Renin one hour after 
captopril ( ~ 200 J.!U/ml) 0:84 0.93 0.92 0.81 
Decrease in systolic BB x renin after 
captopril ( ~ 5000 mm Hg.JlU/ml) 0.85 0.92 0.94 0.81 
P(D+ T +) = predictive value of positive test= chance for someone with positive test (T +) to 
have renal artery stenosis (D+). 
P(D-T-) = predictive value of negative test= chance for someone with negative test (T-) to 
have essential hypertension (D-). 
Captopril test 
The decrease in blood pressure in response to captopril cannot be used as a diagnostic 
test (Figure 2 and Table 1). 
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Figure 2: Effects (mean±SEM) of a single dose of oral captopril, 50 mg,on blood pressure 
and peripheral vein active renin. EHT = essential hypertension. URAS = unilateral renal 
artery stenosis.BIRAS = bilateral renal artery stenosis. 
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The best criterion for predicting renal artery stenosis was a plasma renin level of more 
than 200 J..LU/ml one hour after captopril (Figure 3 and Table 1). The predicted value of a 
positive test was 0.92, and the predictive value of a negative test was 0.81 (Table 1 ). 
Combining the renin levels 1 hour after captopril with the blood pressure response caused 
no improvement in predictive values (Table 1). 
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Figure 3: Active renin in the peripheral vein 1 hour after 50 mg captoprilEHT = essential 
hypertension. URAS = unilaceral renal artery stenosis. BIRAS = bilateral renal artery 
stenosis. 
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Discussion 
The diagnostic specificity of measurements of the peripheral vein renin under basal 
conditions is low, even when these conditions are carefully standardized as in this study. 
Also the blood pressure response to captopril is not of much diagnostic value. Both the 
specificity and the sensitivity of this effect were low. The discriminative power of 
peripheral vein renin measurements are improved when the blood samples are taken after 
stimulation of renin release by captopril. Renin values one hour after this drug showed 
little overlap between patients with renal artery stenosis and those with essential 
hypertension. 
In our population of patients with severe or therapy-resistant hypertension the prevalence 
of renal artery stenosis was 50%. 
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Figure 4: Relationship between prevalence of renal artery stenosis and predictive values 
of renin (closed lines) and captopril renin (dotted lines). P(D+IT +) = change for someone 
with positive test( renin ~45 p.U/ml; captopril renin~ 200 p.Uiml) to have renal artery 
stenosis. P(D+IT-) =chance for someone with negative test to have renal artery stenosis. 
Note that the predictive values of plasma renin greatly improved after stimulation ofrenin 
by captopril. Calculations were made on the basis of a specificity of0.84 and a sensitivity 
of0.93. Prevalence of renal artery stenosis in our patient population however was high, 
approximately 50% (see also Table 1 ). D+ =Disease (renal artery stenosis) present; 
D- =Disease (renal artery stenosis) absent; T +=Test positive; T- =Test negative. 
Figure 4 shows a computer-calculated relationship (6) between the prevalence of renal 
artery stenosis and the predictive value of a positive captopril test(;?: 200 J.!U/ml). It can 
been seen that in a population with a prevalence of 30%, the predictive value of a positive 
test would be 0.83. In the same case the predictive value of a negative test would be 0.72. 
These are still acceptable values. 
Our results indicate that the captopril test is useful for selecting patients for renal 
angiography. 
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CAPTOPRIL TREATMENT DOES NOT 
IMPROVE RENAL VEIN RENIN 
LATERALIZATION. MEASUREMENT OF 
RENIN WITH MONOCLONAL RENIN 
ANTIBODIES. 
ABSTRACT 
The renal vein-to-artery (VIA) renin ratios were determined in 160 patients with essential 
hypertension (EHT) and 116 with unilateral renal artery stenosis (URAS). Drug treatment 
was stopped for two weeks in 76 EHT and 75 URAS. The remaining patients were on 
captopril50 mg tid for 14 days. Renin was measured by direct asay using monoclonal 
renin antibodies as well as indirect assay. The renal VI A renin ratios obtained with the two 
assays were not different. In untreated EHT V /A was 1.285 ± 0.029 (right kidney, mean± 
sem) and 1.296 ± 0.028 (left). In untreated URAS it was 3.008 ± 0.211 on the affected side 
and 1.049 ± 0.028 contralaterally. With captopril treatment peripheral plasma renin rose by 
a factor of 3 in EHT and by a factor of 7 in URAS. The renal VI A renin ratios on both 
sides were not altered by captopril treatment, both in URAS and EHT. The renal V/A 
difference rather than VI A ratio is a measure of renal secretion of renin. Provided the 
clearance rate of renin is not altered by captopril the VI A ratio will only increase after this 
drug when renal plasma flow is decreased. Our findings are in accordance with the 
experience that generally renal perfusion is well maintained during converting enzyme 
inhibitor treatment. 
INTRODUCTION 
An elevated renal vein-to-artery (V/A) ratio of renin on the affected side, together with 
contralateral suppression, is considered to be a useful index of the functional importance of 
unilateral renal artery stenosis in patients with renovascular hypertension (1-3). The renal 
VI A ratio of renin is also used for predicting the outcome of surgical correction ( 4-8). A 
variety of stimuli of the renal secretion of renin, such as low sodium diet (9,10), head-up 
tilting (10,11) and treatment with a diuretic (9), vasodilator (12), saralasin (13) or 
angiotensin-converting enzyme inhibitors (14-16), have been advocated to improve the 
diagnostic value of VI A renin measurements. 
However, the renal V-A difference rather than the VI A ratio is a measure of renin 
secretion, and there is no a priori reason for expecting VI A to increase after stimulation of 
renin secretion. The V-A difference cannot be used in clinical practice, because of the large 
variability of this difference. This variability is partly due to the fact that the standard 
deviation of repeated renin measurements is large as compared to the V-A difference, 
which is often small. Whereas the renal V/A will not increase necessarily with an increase 
in renin secretion, VI A , at a given rate of secretion, will increase with a decrease in renal 
plasma flow (2). Although renal plasma flow is generally well maintained during treatment 
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with angiotensin-converting enzyme inhibitors, lowering of the systemic blood pressure by 
these drugs may impair renal perfusion, particularly when the renal artery is affected by 
stenotic disease (17). 
We therefore decided to perform a prospective study on the usefulness of captopril as a 
diagnostic tool for increasing the renal VI A ratio of renin in patients with renal artery 
stenosis. A second issue we wanted to address was the method of renin assay. In most 
studies the PRA method is used. In this method angiotensin I (ANG I) generated from 
endogenous renin substrate is measured by RIA. The rate of ANG I generation in this 
method depends not only on the concentration of renin but also on that of renin substrate. 
The latter may be decreased due to increased consumption when large amounts of ANG I 
are produced, as may occur during converting enzyme inhibitor treatment (18). In patients 
with renal artery stenosis this may lead to an erroneously low V/A ratio on the affected 
side, particularly, when the renal vein renin level on that side is very high. 
We therefore measured ANG I generation in the presence of saturating amounts of 
exogeneous substrate and compared this indirect RIA with a novel direct RIA using a 
monoclonal renin antibody that recognizes renin and does not bind to its precursor, 
prorenin. 
PATIENTS AND METHODS 
Patients. 
Patients who were referred for the diagnostic work-up of renal artery stenosis were 
studied. These include: 
1) patients, 40 yr or less, with a diastolic blood pressure of at least 105 mm Hg in the 
absence of any drug treatment, and 2) patients, regardless of age, with a diastolic blood 
pressure of at least 105 mm Hg despite treatment with at least 3 different classes of 
antihypertensive drugs. 
Patients with a small contracted kidney not caused by renal artery stenosis and patients 
whose kidneys were affected by pyelonephritis, tuberculosis or radiation were not 
included. Patients with bilateral renal artery stenosis were also not included. This report 
deals with data on 276 consecutive cases. 
Renal vein blood sampling. 
In 151 patients (75 with unilateral renal artery stenosis) antihypertensive drugs were 
stopped for at least 14 days before the patients were taken into hospital. Captopril was 
given to 125 patients (41 with unilateral renal artery stenosis) for 14 days in a dose of 50 
mg three times daily. After the patients were admitted to the hospital they were put on a 
diet containing 60-90 mmol sodium per day. After 3 days the renal veins were sequentially 
catheterized which a single catheter via the Seldinger technique. Arterial blood samples 
were obtained via a catheter in the abdominal aorta. In patients receiving captopril, renal 
vein sampling was performed 5-6 hours after dosing. Since plasma renin may change 
during the catheterization procedure and since it takes some time to move the catheter from 
one renal vein to the other, the arterial samples were collected at exactly the same time as 
the corresponding renal vein samples. The position of the catheters was checked by 
measuring 0 2 saturation of blood. Renal angiography was performed immediately after the 
sampling procedure had been finished. Blood for renin measurements was collected in 
tubes containing 0.1 volume of 0.13 M trisodium citrate to which soybean trypsin inhibitor 
(Sigma, StLouis, Mo,USA), 10 mg/ml, had been added. The blood samples were 
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immediately centrifuged at 3000 g for 10 min at room temperature, and plasma was stored 
at -20°C. Renal angiography showed that renal artery stenosis (more than 70%) was caused 
by atherosclerosis in 106 patients and by fibromuscular dysplasia in 10. The remainder had 
essential hypertension and no abnormality of the renal arteries. The patient data are 
summarized in Table 1. 
Table 1. Patient groups 
Diagnosis Female/Male 
Unilateral renal 
artery stenosis 
fibromuscular 10/0 
dysplasia 
atherosclerosis 30/76 
Essential 65/95 
hypertension 
Results are expressed as mean ± sem 
Renin assays. 
Age 
yr 
31.8 ± 3. 
50.0± 1.3 
46.2± 1.1 
Duration 
of hypertension 
yr 
2.9 ± 1.0 
4.0±0.6 
7.9±0.6 
Renin was measured by an immunoradiometric assay using the monoclonal antibodies 
3E8 and 4G 1 (Diagnostic Pasteur, Marnes la Coquette, France). The characteristics of these 
antibodies have been described elsewhere (19). Antibody 3E8 recognized both renin and 
prorenin and was covalently bound to a magnetic solid phase (Magno gel, Diagnostic 
Pasteur). Antibody 4G 1 specifically recognized the catalytic site of active renin and did not 
bind to prorenin. This antibody was labelled with iodine 125 using the chloramine-T 
method. Details of this direct renin assay have been described elsewhere (20-21). Results 
are expressed as pg/ml, using highly purified human kidney renin (Ciba Geigy, Basle, 
Switzerland) as a standard. The MRC human kidney renin standard 68/356 (Medical 
Research Council, National Institute for Biological Standards and Control, London, UK) 
was also run in each assay batch. One pg of the Ciba Geigy standard corresponded with 0.7 
J-LU of the MRC standard. 
In the enzyme-kinetic assay of renin (indirect renin assay) the velocity of ANG I 
generation, in the presence of saturating amounts of sheep renin substrate, was measured 
by RIA of ANG I (22). Results are expressed as J-LU of the MRC standard per ml. The renal 
vein and artery plasma samples from each patient were always run in the same assay batch. 
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RESULTS 
Comparison between direct and indirect renin assays. 
The direct assay of renin is less sensitive than the indirect assay, the lower limit of 
detection being 7 ~U/ml (10 pglml) and 0.4 ~U/ml respectively. For a plasma pool with a 
renin level of 25 pglml, the within- and between-assay variability coefficient of variation 
(CV) of the direct assay was 11 and 16% respectively, and for a plasma pool with high 
renin content, 90 pglml, it was 6 and 8%, which is similar to the CV of the indirect assay. 
The results of the direct and indirect renin assays in the patients with renal artery stenosis 
and essential hypertension are presented in Fig. I. 
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Fig .1. Coffelation between the results of direct and indirect renin measurements in 
patients with unilateral renal artery stenosis or essential hypertension. In the direct assay 
renin was measured by an immunoradiometric technique using highly specific monoclonal 
renin antibodies. In the indirect assay renin was measured by the enzyme-ldnetic method 
and the generated angiotensin I was quantitated by RIA. The renal artery stenosis group 
consisted of 16 patients on captopril, 50 mg tid for two weeks, and 16 on no drugs. The 
essential hypertension group consisted of 12 patients on captopril and 12 on no drugs. 
Continuous line is the line of identity. Results are expressed as mean and sem. 
By measuring renin both with the direct and the indirect assay, the enzymatic activity of 
renin can be expressed as ~U per pg. From Fig. I it appears that, in patients with unilateral 
renal artery stenosis, renin, expressed in this way, in the ipsilateral renal vein was not 
different from, that in the contralateral vein and in the aorta, and this was also true for 
patients with essential hypertension. Thus, there was no evidence for the existence of 
substances in plasma interfering with the action of renin on its substrate. The VI A renin 
ratios calculated from the results of the direct assay were not different from those of the 
indirect assay (Fig.2). 
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VIA J.S 
RENIN 
RATIO 
UNILATERAL RENAL ARTERY STENOSIS ESSENTIAL HYPERTENSION 
IPSILATERAL 
lndlr..:t dk..:t Indirect dl.-..ct 
Fig.2. The renal vein-to-artery (VIA) renin ratio in patients with unilateral renal artery 
stenosis or essential hypertension. The VIA ratios were calculated from the results of both 
the direct and indirect renin assays. Closed bars: patients on captopril, 50 mg tid for two 
weeks. Open bars: patients on no drugs. For numbers of patients see legend of Fig.l. 
Results are expressed as mean± sem. 
Effect of captopril on the VI A ratio of renin. 
The effects of two-week captopril treatment on peripheral vein renin and on serum 
creatinine, creatinine clearance and blood pressure in patients with renal artery stenosis or 
essential hypertension are summarized in Table 2. 
Table 2. Effects of captopril 
Number Serum Creatinine Blood pressure Peripheral plasma 
Diagnosis Capto- of creatinine clearance systolic diastolic renin 
pril patients j.I.IllOI/1 ml/min mmHg mmHg J.!.U/ml 
Renal artery no 75 112±4 76±3 192±2 114±2 53.2(21.0-135) 
stenosis yes 41 134±8* 63±4* 163 ± 3** 99 ±2** 359(124-1040)** 
Essential no 76 102±5 83±4 191 ±6 116±4 17.6(7.1-43.8) 
hypertension yes 84 122±9* 70±5* 162± 5* 102±4** 50.6(13.1-195)** 
Data on creatinine and blood pressure are expressed as mean ± sem. Statistical analysis for 
the renin measurements was performed after logarithmic transformation of the results in 
order to obtain a Gaussian distribution. Results are expressed as geometric mean (between 
brackets geometric mean minus SD and geometric mean plus SD). 
* P<0.01, ** P<0.001 from untreated patients (unpaired t-test) 
Captopril caused a decrease in creatinine clearance, a fall in blood pressure and a rise in 
renin. The effects on creatinine and blood pressure were similar in the two groups. 
In contrast, the increase in renin was much greater in the patients with renal artery stenosis. 
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The best trade-off between sensitivity and specificity of measurements of peripheral 
plasma renin for predicting renal artery stenosis was determined from a Receiver Operator 
Characteristic Curve. The best trade-off was obtained with a renin level of 45 J.!U/ml or 
higher in the untreated patients and 200 J.1U/ml or higher in the captopril group. 
The sensitivity of measurements of unstimulated peripheral plasma renin as a test for 
predicting renal artery stenosis was 0.49 with a specificity of 0.89. The sensitivity of 
measurements of captopril-stimulated renin to predict renal artery stenosis was 0.70 and 
the specificity 0.84. Thus, when using peripheral renin as a criterion, it is the sensitivity of 
this test that is markedly improved by captopril treatment 
In essential hypertension the VI A renin ratio of the right kidney was 1.285 ± 0.029 (mean 
± sem) in the untreated patients and 1.298 ± 0.030 in the group treated with captopril 
(Fig.2).The V /A renin ratio on the left side was not different from that on the right. The 
V/Arenin ratio was 3.008 ± 0.211 on the affected side and 1.049 ± 0.028 contralaterally in 
the untreated patients with unilateral renal artery stenosis (Fig.2) 
In the captopril-treated patients the V/A renin ratio was 2.991 ± 0.215 and 1.035 ± 0.017 
respectively, which again was not different from the VI A ratios in the untreated patients. A 
VI A renin ratio on the affected side of 1.50 or more is considered to indicate renal artery 
stenosis on that side (1-3). Figure 3 shows that 93% of the patients with renal artery 
stenosis satisfied this criterion on the affected side, as compared to only two patients (2%) 
on the unaffected side. In contrast, 17% of the patients with essential hypertension had a 
V/A ratio of 1.50 or more on the right side and 16% had this increased ratio on the left 
side. If one defines contralateral suppression as a V/A ratio of 1.10 or less, 77% of the 
renal artery stenosis patients had contralateral suppression, whereas 18% of the patients 
with essential hypertension had a suppressed ratio on the right side and 20% on the left 
100 
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Fig.3. The cumulative distribution curve of the VIA renin ratio in patients with unilateral 
renal artery stenosis. Broken line: patients (n=41) on captopril, 50 mg tid. Continuous 
line: patients (n=75) on no drugs. 
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DISCUSSION 
In this study we employed a new immunoradiometric assay to measure renin. This direct 
assay of renin makes use of a highly specific monoclonal antibody that recognizes active 
renin but not prorenin (19). This assay has some advantages over the indirect assay: 1) The 
procedure does not involve an incubation step for generating ANG I; the problems of 
incomplete recovery of ANG I and non-optimal pH during incubation are therefore 
circumvented, 2) results are not influenced by the concentration of renin substrate (23), and 
3) one technician can easily handle up to 100 samples in one day; the indirect renin assay 
takes at least two days. 
A disadvantage of the direct renin assay is its lower sensitivity, which makes it difficult 
to measure low-normal levels. In the case of renal vein measurements this problem can be 
solved by stimulating the secretion of renin, for instance with captopril, prior to sampling. 
With such stimulation both types of assay produce comparable results. 
With captopril treatment we found a 6- to 7-fold increase in peripheral vein renin in 
patients with unilateral renal artery stenosis. In these patients nearly all renin is secreted by 
the affected kidney and, because the increase in peripheral renin is caused by a parallel 
increase in renin secretion, the VIA renin ratio of this kidney will not be altered by 
captopril as long as renal plasma flow remains constant. Several authors , including 
ourselves (15, 16, 22), found an increase of the VIA ratio 30-60 min after captopril 
administration. One of the reasons might be that a steady state had not been reached in 
these acute studies. Another reason for an increase of the renal VIA renin ratio in the first 
60 minutes is the precipitous fall in blood pressure that occurs in some patients. This may 
cause a reduction in renal plasma flow and thereby an increase in the VI A renin ratio. 
Some investigators used the renal vein renin ratio between the affected and non-affected 
side instead of the VIA renin ratios (15). There is however a steep rise of renin during the 
first 60 minutes after captopril administration (22), and it takes some time to maneuver the 
catheter from one renal vein to the other. Therefore it is extremely important that the renal 
vein and artery plasma samples are drawn at exactly the same time. Instead of the renal 
artery one can use the forearm vein. 
Our study demonstrates that the VI A renin ratio of the contralateral kidney remains 
suppressed during chronic angiotensin-converting enzyme inhibition. The suppression is 
therefore unlikely to be solely caused by feed-back suppression of renin secretion by 
angiotensin II. It is also unlikely that the unaffected kidney produces a renin inhibitor 
because we found the enzymatic activity of renin, expressed as !!U per pg of renin, in the 
renal vein of that kidney not to be different from that of pure kidney renin. 
In our group of patients with renal artery stenosis more than 90% had a renal VI A renin 
ratio on the affected side of 1.50 or more. Thus, renal vein renin measurements are of 
limited use as an adjunct to renal angiography for detecting renal artery stenosis, 'at least in 
patients with unilateral disease. It is however possible that these measurements have some 
predictive value with respect to the response to surgery or percutaneous transluminal 
angioplasty, in the sense that a higher VIA ratio may predict a higher probability of a 
successful outcome. 
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Twenty-four hour blood pressure profiles during 
chronic ACE inhibition. A comparative study of 
twice daily captopril versus once daily enalapril in 
patients with essential hypertension 
P. J. Blankestijn G. J. Wenting M. L. Brouwer 
A. H. van den Meiracker M.A. D. H. Schalekamp 
INTRODUCTION 
The angiotensin convening enzyme (ACE) inhibitors, 
captopril and enalapril, have undoubtedly proved to 
be effective agents for the treatment of essential hyper-
tension. However, the two agents differ in several 
ways: the nature of the molecule's adherence to the 
active site on the converting enzyme, the form in 
which the agent is administered (active compound or 
prodrug), and the kinetics of elimination. The binding 
of captopril to the convening enzyme by means of its 
sulphydryl group is rather loose, its absorption after 
oral administration is fast but influenced by food, and 
its elimination half-life from plasma is short (for 
review, see Williams 1988). Enalapril scores bener on 
all these points but, nevertheless, there is little 
evidence that these differences are of any clinical 
significance. 
Current trends favour twice-daily administration 
of captopril and once-daily dosing of enalapril. The 
results of a European multicentre trial (Garanin 1986) 
even suggested that once-daily captopril was as 
effective as once-daily enalapril. A criticism of this and 
other studies could be the fact that blood pressures 
were only measured 21-27 hours after dosing and that 
increasing doses were used. In the present study, an 
automatic ambulatory blood pressure recording device 
was used to compare, in the same patients, a twice-
daily dosing regimen of cnptopril with a once-daily 
dosing regimen of enalapril. Treatment order· was 
randomised and a fixed dosage ratio of 4:1 was used 
to compare captopril and enalapril. 
PATIENTS AND METHODS 
PATIENTS AND STUDY PROTOCOL 
Ten patients with essential hypertension (aged 39-64 
years, eight men) controlled on captopril (50-200 
88 
mg/day) or enalapril (10-20 mg/day) monotherapy 
participated in this single-blind, crossover study, 
which was conducted in the Hypertension Outpatient 
Clinic. After they had given their informed consent to 
the study protocol, they were randomised (five patients 
in either group) to receive twice-daily captopril 
(morning dose 37.5 mg, evening dose 37.5 mg) or 
once-daily enalapril (morning dose 20 mg, evening 
dose matching placebo). Each patient received his/her 
drug regimen for eight weeks before the first 24-hour 
ambulatory blood pressure monitoring was under-
taken. Following this procedure the patients were 
switched to the other ACE inhibitor, and eight weeks 
after the crossover they were re-studied over a 24-hour 
period to assess blood pressure control. Drug adminis-
tration was standardised to between 07.00-08.00 
hours (morning dose) and 18.00-19.00 hours (evening 
dose). Within these time frames, the patients were 
requested to take the medication with a constant 
relationship to breakfast or evening meal. Tablet 
counts were performed at two-week intervals to verify 
compliance. No other antihypertensive drugs were 
added during the treatment period. 
BLOOD PRESSURE MEASUREMENTS 
After the eight-week treatment periods, blood press-
ure was measured with a London School of Hygiene 
sphygmomanometer. Patients rested supine for 10 
minutes before measurements were made, and an 
average was obtained from three readings. These 
measurements were performed around 08.00 hours, 
12 hours after the last drug dose. After the patients 
had taken their morning dose, the ambulatory blood 
pressure monitoring equipment (Spacelabs 5300 
Monitor, Spacelabs Inc., Hillsboro, Oregon, USA) 
was fixed to the patients. At the start and end of these 
measurements, blood pressure was measured sirnul-
taneously with a standard sphygmomanometer con-
nected to the ambulatory equipment via aT-tube, to 
verify proper function of the equipment and to ensure 
that no gross alteration had occurred in the ability of 
the device to read blood pressure during its use. The 
Spacelabs 5300 Monitor makes use of an occlusion 
cuff and a microphone or oscillometer to detect 
systolic and diastolic blood pressure. The microphone 
was taped over the brachial artery and, whenever the 
microphone failed to identify Korotkoff sounds the 
oscillometer intervened. The cuff is automatically 
inflated by a minipump fastened at the subject's waist, 
and blood pressure data are stored in digit format on 
a RAM package by a built-in computer. The data 
from this memory were fed into a computer which 
produced a printout of all measurements made. The 
data were averaged over periods of one hour. The 
device was programmed to measure blood pressure 
and bean rate every 15 minutes from 06.00 to 24.00 
hours and every 30 minutes from 24.00 to 06.00 
hours. At the time of each measurement, the patients 
were instructed to 'freeze' their activities and keep 
their arm motionless. Each patient was studied twice 
( captopril, enalapril) on the same day of the week 
(eight weeks apan) and the timing of the study was 
always the same. 
STATISTICAL ANALYSIS 
Results are expressed as the mean and standard error 
of the mean. Resting office measurements were 
analysed by a Student t-test. A Wilcoxon matched 
pairs signed rank test was used for comparison of the 
24-hourly means of blood pressure and heart rate. 
A P value of <0.05 was selected as the level of 
statistical significance. 
RESULTS 
The mean of casual office blood pressures and heart 
rates during captopril and enalapril treatment were 
not significantly different (Table 1). 
The 24-hourly means of systolic and diastolic 
pressures are shown in Fig. 1. In the presence of 
captopril or enalapril, diurnal variations in blood 
pressure and heart rate were maintained. However, 
systolic and diastolic pressures were significantly 
lower during enalapril than during captopril treatment 
(systolic pressure: P<0.0015, diastolic pressure: 
P<0.003). Heart rate showed no difference between 
the two treatment g~oups. 
DISCUSSION 
This study compared the effects of captopril and 
enalapril treatment in patients with essential hyperten-
sion using a randomised, crossover, single-blind study 
design. The principal measure of treatment efficacy 
was its effect on 24-hour blood pressure proflles using 
an ambulatory non-invasive blood pressure measuring 
device. Unexpectedly, the results of this study demon-
strated better blood pressure control with once-daily 
enalapril than with twice-daily captopril. Thus, using 
the doses, equipment and regimens studied in this 
small pilot trial, enalapril appeared to be superior to 
captopril. Enalapril caused a more sustained and 
consistent blood pressure reduction than captopril, 
particularly during late afternoon and evening. The 
dose of captopril used and the twice-daily adminis-
tration were, however, sufficient to reduce. blood 
pressure at night and during the (early) morning, 12 
hours after the last dose. Looking at the 24-hour blood 
pressure curves, the given impression is that the 
effects of the evening dose of captopril (around 18.00 
hours) are postponed until the evening. 
How can this 'delay' in efficacy be explained? The 
present study gives no definite answer because no 
measurements were made of plasma drug levels or of 
plasma convening enzyme activity. However, it is 
tempting to relate this temporary lack of blood 
pressure control to an effect of food intake on the 
amount and/or rate of drug absorption (in Holland, 
the principal meal is the evening meal). It has been 
shown by Singhvi eta! (1982) that food can reduce the 
Table 1 Results of measurements of casual office blood pressure (by the London 
School of Hygiene sphygmomanometer) and bean rate (n =I 0, mean ± SEM) 
Systolic arterial pressure (mmHg) 
Diastolic anerial pressure (mmHg) 
Heart rate (beats/min) 
89 
Captopril 
134(5) 
85 (4) 
78 (3) 
Enalapril 
129 (4) 
85 (3) 
78 (3) 
Pvalue 
NS 
NS 
NS 
BLOOD 160 
PRESSURE 
mmHg 
150 
1110 
130 -
60 
HEART 90 
RATE 
bpm 
systolic pressure 
diastolic pressu·re 
TIME houra 
e enalaprll 
o Clllploprll 
• 
FJS. 1 Twenty-four hour blood pressure profiles during captopril and enalapril 
treatment. Data are hourly means ± SEM. 
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absorption of isotope-labelled captopril by 35-40% 
Diminished or delayed absorption could be of critical 
importance, especially when using a low-dose regi 
men, as in the present study. Ohman et al (1985) 
studied the effects of concomitant food intake on 
pharmacokinetics and blood pressure control during 
chronic low-dose captopril administration. Peak cap-
topril plasma concentrations and area under the curve 
of total and non-protein bound captopril were clearly 
reduced with food intake, but this did not n!Tect blood 
pressure control. However, the patients in this study 
were also treated with bendroflumethiazide which 
may have obscured the relationship between plasma 
captopril concentrations and blood pressure reduc-
tion. Salvetti et al (1985) showed that, in patients with 
uncomplicated essential hypertension, the timing of 
captopril administration (one hour before or immedi-
ately after eating) did not modify the haemodynamic 
and humoral effects of chronic captopril (50 mg twice 
daily). However, measurements were only made at a 
single moment in time, 12 hours after the last dose of 
captopril, which could be insufficient. 
How can ()Ur fmdings be related to other 
comparative studies of captopril and enalapril? A 
review of the literarure revealed seven papers. How-
ever, these reports carmot easily be compared with the 
present study because of methodological differences 
(parallel group design, no fixed dosage ratio's of the 
two agents, ambulatory blood pressure monitoring in 
only one small study). Chrysant eta! (1985), Lewis et 
al (1985), and Th.ind et al (1985) followed more or less 
the same parallel group study design in which 
captopril (25 mg thrice daily) or enalapril (5 mg twice 
daily) was added (double-blind) to existing therapy 
with hydrochlorothiazide. Th.ind et al (1985) found 
lower blood pressures during enalapril treatment, but 
this observation was not confirmed by the other two 
groups. Vlasses et al (1986) compared a high ceiling 
dose of captopril (200 mg twice daily) with enalapril 
(20 mg twice daily). They found similar antihyperten-
sive effects. Co-administration of captopril and enal-
april led to no further reduction in blood pressure, 
which is not surprising in view of the high doses used. 
As in the present study, Karlberg et a) (1986) used 
a randomised, crossover design for comparison of 
captopril (twice daily 25 mg, 50 mg) with enalapril 
(once daily 20 mg, 40 mg). Enalapril caused a more 
sustained and consistent blood pressure reduction 
than captopril. Our ambulatory blood pressure daui 
confrrm and extend these casual blood pressure 
measurements. Shionoiri et al (1987) are the only 
authors who recorded ambulatory intra-arterial press-
ures before and during therapy with captopril or 
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enalapril. As could be expected, both drugs lowered 
blood pressure, but the design of the study and the 
small number of patients included do not allow 
comparison between captopril and enalapril. 
In conclusion, 24-hour blood pressure monitoring 
can unmask differences which can not be detected by 
casual readings. In the doses used in this study, 
enalapril clearly resulted in a better 24-hour control of 
blood pressure than did captopril. With captopril, 
vigilance regarding minimal effective dosage intervals 
should be maintained. 
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Treatment of hypertension 
with ketanserin, a new selective 
S-HT2 receptor antagonist 
G J WENTING, A J MAN IN 'T VELD, A J WOITTIEZ, 
F BOOMSMA, M A D H SCHALEKA.l\-iP 
Abstract 
The new selective 5-HT 2 receptor blocking agent ketan-
serin was given in a dose of 10 mg intravenously to 12 
patients with essential hypertension. It caused a distinct 
fall in supine systemic arterial, right atrial, pulmonary 
artery, and pulmonary capillary "wedge" pressures. 
Cardiac output, renal blood flow, and glomerular filtra-
tion rate showed no persistent changes. Thus 5-HT 2 
receptor blockade caused dilatation of both the resistance 
and cal)acitance vessels and of the renal vascular bed. 
Heart rate and plasma concentrations of renin and nor-
adrenaline rose after ketanserin. 
These data suggest that 5-HT may have a role in main-
taining high blood pressure. 
Introduction 
Serotonin (5-hydroxytryptamine, 5-HT) has long been recog-
nised as a potent vasoactive agent.1 It appears to act mainly as an 
amplifier of other vasoconstricting agents such as noradrenaline 
and angiotensin H. 2 5-HT may be implicated in the pathogenesis 
of hypertension, but its role is obscured by its multifaceted 
actions in healthy individuals.1 Furthermore, the lack of specific 
antagonists has hampered the precise delineation of 5-HT's 
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role in blood pressure regulation. Recently Peroutka and Snyder, 
using radio!igand studies, distinguished two distinct 5-HT 
receptors. 3 Binding to the 5-HT 1 receptor has so far not been 
related to any effect of 5-HT, but binding to the 5-HT 2 receptor 
correlates with both in-vitro and in-vivo pharmacological and 
physiological effects of 5-HT. 3 4 A specific 5-HT 2 receptor 
antagonist, ketanserin, is now available which in therapeutic 
doses does not block the effect of amines other than 5-HT. It 
appears to be free of the central side effects associated with less 
specific 5-HT antagonists. 5 This has prompted us to investigate 
the haemodynamic effects of this new compound in patients with 
essential hypertension. 
Patients and m.ethods 
Twelve patients were studied, eight men and four women, aged 
59±(SEM) 4 years (range 40 to 77 years). The diagnosis of essential 
hypertension was established by routine screening, including intra-
venous urography. Antihypertensive treatment, if any, was stopped 
three weeks before the study. The use of a new, intravenous anti-
hypertensive agent was explained to the patients, who all gave their 
informed consent to the study. 
They were admitted to a metabolic ward and received a diet with a 
constant sodium (40-50 mmol/day) and potassium (70-100 mmoljday) 
content. When blood pressure and sodium balance were stable the 
p
1
atients were investigated in the cardiovascular laboratory after an 
overnight fast. A Swan-Ganz catheter was introduced percutaneously 
in an antecubital vein and positioned in the pulmonary artery. A short 
polyethylene catheter was placed in a radial artery. A peripheral vein 
in the opposite arm was cannulated for renal function studies. Baseline 
haemodynamic measurements and blood sampling were started at 
least 90 minutes later. Ketanserin, 10 mg in 20 ml of saline, was in-
fused in the right atrium in three minutes and the effects were followed 
for two hours. Right atrial pressure, pulmonary artery pressure, 
arterial pressure, and heart rate were continuously monitored and 
recorded. Mean pressures were obtained by electronic integration, 
and the mid-axillary line was defined as the zero-pressure reference 
level. The patients remained supine throughout the study. Cardiac out-
put and mean pulmonary capillary "wedge" pressure were measured 
before, five minutes after the end of the ketanserin infusion, and then 
every 30 minutes. Triplicate measurements of cardiac output using the 
thermodilution technique (10 ml 5% dextrose in water at l-2°C) 
were averaged. The following haemodynamic values were derived: 
total peripheral vascular resistance= (mean arterial pressure-right 
atrial pressure)jcardiac output (kPa/s/1); pulmonary vascular 
resistance= (mean pulmonary artery pressure-mean pulmonary 
capillary wedge pressure)jcardiac output (kPa/s/1). Using a con-
tinuous infusion technique6 we estimated the effective renal plasma 
flow and glomerular filtration rate by clearance ofl31l-hippuran and 
1251-thalamate respectively. Renal blood flow was calculated using the 
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venous packed cell volume and assuming 75% renal extraction of 
hippuran. Renal vascular resistance was calculated as the mean arterial 
pressure/renal blood flow (kPa/s/1). Well-established methods 
were used to measure plasma concentrations of active renin 7 and nor-
adrenaline. 8 Statistical analyses were performed using Student's 
t test for paired data. 
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FIG !-Effects ofketanserin on arterial pressure, heart rate, plasma 
, noradrenaline, cardiac output, and total peripheral vascular 
resistance in 12 patients with essential hypertension. 
*p<O·OS; **p<O·Ol; ***p<O·OOl. 
Conversion: SI to traditional units-Vascular resistance: 
1 kPafs/1~ 10 dynfs/cm5• 
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Effects of ketanserin on mean arterial pressure and renal function in 12 patients with essential hypertension 
After ketanserin infusion 
Baseline 1 h p Value 2h p Value 
Mean arterial pressure (mm Hg) 121 ±5 102±7 <0·001 106±7 <0·001 
~I Glomerular filtration rate (ml/min) 90±5 92±5 NS 90±5 NS Effective renal plasma flow (ml/min) 302±18 290±17 NS 296±21 NS 
Renal vascular resistance (kPa/s/1) 1368±102 1202±97 <0·05 1284±110 NS 
Plasma active renin (mU!i)• 9·5±2·0 14·9±3·4 <0·01 15·3±2·8 <0·01 
•Normal range 15-45 mU/1. 
Conversion: SI to traditional uniu-Vascular resistance: 1 kPa/s/1 ~ 10 dyn/s/cm•. 
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Results 
Systolic and diastolic pressures fell from 188 ±6/89 ±5 mm Hg 
to 159 ±9/75 ±6 mm Hg five minutes after the end of the infusion of 
ketanserin (fig 1). Arterial pressure remained significantly below base-
line level during the two-hour observation period. One patient had 
symptomatic hypotension; his arterial pressure fell from 177/85 mm 
Hg to 82/43 mm Hg within five minutes, but by 30 minutes it had risen 
to 105/57 mm Hg. Both the initial and the sustained fall in arterial 
pressure were due to a drop in total peripheral vascular resistance. 
Heart rate and cardiac output rose, ·but in contrast to heart rate, the 
cardiac output increased only transiently (fig 1). The rise in heart rate 
was accompanied by an increase in plasma noradrenaline concentration. 
Ketanserin caused a fall in the filling pressures of both ventricles 
(fig 2). Pulmonary artery pressure also fell, but this was probably not 
due to a direct vasodilating effect of ketanserin on the pulmonary 
vascular bed, as pulmonary vascular resistance did not change. The 
effects of ketanserin on renal function are shown in the table. Renal 
vascular resistance fell significantly, but there were no major changes 
in effective renal plasma flow and glomerular filtration rate. Although 
basal active renin concentration was low it rose significantly. 
Discussion 
5-HT is released by aggregating platelets during clotting and 
it contributes to local vasoconstriction. 2 It is also released by 
enterochromaffin cells, where it increases blood flow to exocrine 
glands of the gut. 9 Apart from such local actions endogenous 
5-HT has not been thought to have systemic haemodynamic 
effects.1 This view, however, is now being challenged by pre-
liminary results with ketanserin, a newly developed specific 
5-HT2 receptor antagonist.10 
Our data show that ketanserin exerted its hypotensive action 
by lowering total peripheral vascular resistance. The fall in right 
atrial pressure suggested that it also had an effect on venous tone. 
The responses of the heart rate and plasma noradrenaline concen-
trations were probably barorefiex-mediated. Reflex sympathetic 
stimulation may also have caused the transient rise in cardiac 
output. This effect might have been overruled by the fall in 
venous return and the reduction of preload. Vasodilatation also 
occurred within the kidneys, and, despite a fall in arterial pres-
sure, the glomerular filtration rate did not diminish. The anti-
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hypertensive action of ketanserin is thus characterised by a 
favourable haemodynamic profile. The observation that ketan-
serin lowered not only systemic arterial pressure but also cardiac 
filling pressures suggests that this balanced vasodilatation may be 
of particular interest for the treatment of congestive heart 
failure. Indeed, a favourable response to ketanserin in this 
condition has been reported recently.U 
5-HT not only acts as a direct vasoconstrictor, but it also 
amplifies the vasoconstrictor responses to agents such as nor-
adrenaline and angiotensin II. 2 5-HT is released by aggregating 
platelets in atherosclerotic arteries, which are abnormally 
responsive to this amine.12 Ketanserin antagonises not only the 
direct vasoconstrictor effect of 5-HT but also its amplifying 
effects on other vasoactive substances. 5 These mechanisms may 
all be implicated in the haemodynamic effects of 5-HT2 receptor 
99 
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blockade by ketanserin. This compound is thus a new therapeutic 
tool for investigating the role of 5-HT in the pathogenesis of 
various forms of hypertension. Experience so far warrants further 
assessment of its place in the management of hypertension. 
We thank Dr J Symoens of Janssen Pharmaceutica for generous 
supplies of ketanserin. 
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Chronic Effect of Ketanserin in 
Mild to Moderate Essential Hypertension 
AREND J.J. WonTIEZ, GERT J. WENTING, ANTON H. VAN DEN MEIRACKER, 
HENK J. RITSEMA VANEcK, ARIE J. MAN IN 'T VELD, FRANS A. ZANTVOORT, 
AND MAARTEN A.D.H. SCHALEKAMP 
SUMMARY Ketanserin, an antagonist highly selective for 5-hydroxytryptamine (serotonin) type 2 
(S2) receptors, was given as monotherapy in a dose of 40 mg b.i.d. to 24 subjects with mild to moderate 
essential hypertension. Its effects were evaluated in a placebo-controlled double-blind crossover 
study. The effect on blood pressure in 18 subjects was monitored by 24-hour ambulatory intra-arterial 
measurements. Systolic and diastolic intra-arterial pressures were significantly lowered by ketanserin 
both during the day and at night, whereas heart rate was unchanged. Cuff pressure readings (tripli-
cate measurements) with the London School of Hygiene sphygmomanometer and an automatic device 
(12 measurements in 1 hour) in the outpatient clinic also showed a significant effect on both supine and 
standing pressures. No postural hypotension was noted. Ketanserin had no effect on endogenous 
creatinine clearance, serum cholesterol levels, and the plasma levels of norepinephrine, renin, and 
aldosterone. The only side effect that was significantly more common with ketanserin than with 
placebo treatment was an increase in body weight. Ketanserin may have a place in the treatment of 
mild to moderate essential hypertension. (Hypertension 8: 167-173, 1986) 
KEY WoRDS • serotonin • blood pressure • ketanserin • ambulatory monitoring 
SEROTONIN has been implicated in the regula-tion of blood pressure and pathogenesis of hy-pertension for more than 2 decades, but its role 
is still controversial. 1.2 Although central serotoniner-
gic neurons are likely to be involved in blood pressure 
control, surgical and pharmacological manipulations 
of these central serotoninergic pathways have pro-
duced conflicting results.' The effect of intravenously 
administered serotonin on blood pressure is also noto-
riously variable because activation of vascular seroto-
ninergic receptors can elicit constriction, dilatation, or 
a biphasic response, depending on the type of blood 
vessel, its anatomical location, the animal species, and 
the concentration of the monoamine. The vascular re-
sponse is also dependent on sympathetic tone. 4 
Radioligand binding studies on brain tissue have led 
to a subdivision of S 1- and S2-serotoninergic recep.-
tors.5 A vascular S2-receptor has been shown to medi-
ate serotonin-induced constriction. This receptor also 
appears to be involved in the so-called amplifying ef-
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feet of serotonin on the pressor responses to norepi-
nephrine and angiotensin IJ.6-8 Ketanserin, a serotonin 
antagonist that is highly selective for S2-receptors. is 
now available for clinical research. Herein, we report 
on a double-blind placebo-controlled crossover study 
of the blood pressure lowering effect of ketanserin in 
24 subjects with mild to moderate essential hyperten-
sion. In 18 of these subjects, the effect was evaluated 
by 24-hour ambulatory intra-arterial monitoring of 
blood pressure. 
Subjects and Methods 
Trial Design 
The study comprised 17 men and 7 women, aged 
50 ::': 3 years (mean ::': SEM; range, 24-69 years). 
A diagnosis of essential hypertension was made 
after routine screening, which included isotope reno-
graphy. Antihypertensive treatment, if any, was ta-
pered off 3 weeks before the study began and was 
replaced by placebo. Hypertension was defined as a 
cuff measurement of blood pressure in excess of 95'-
mm Hg diastolic on two or more consecutive visits to 
the outpatient clinic. After a single-blind placebo run-
in period of 4 weeks, the subjects were randomly allo-
cated to receive either placebo or 40 mg of ketanserin 
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at 0800 and I800 for 8 weeks, followed by an identical 
crossover period. The randomization schedule was 
kept in the hospital pharmacy, and unmarked formu-
lations were provided by Janssen Pharmaceutica 
(Beerse, Belgium). Neither the investigator nor the 
subjects were aware of who was receiving the assigned 
drug. 
Throughout the study the subjects were seen in the 
outpatient clinic at 2-week intervals between 0900 and 
1100. Side effects, both volunteered and elicited by 
direct questioning, were recorded, and compliance 
was checked by tablet counting. In the last week of the 
two treatment periods ambulatory blood pressure was 
monitored by 24-hour continuous intra-arterial mea-
surement. The recordings were taken while the sub-
jects were hospitalized, which allowed their environ-
mental and living conditions to be relatively well 
standardized, particularly witb regard to physical ac-
tivity, timing of meals, afternoon nap. and night rest. 
Apart from these periods, the subjects were free to 
move around. During the hospital stay, blood was tak-
en, with the subjects in the supine position, I to 2 hours 
after the morning dose of placebo or ketanserin for 
biochemical determinations, including plasma levels 
of ketanserin and hormones. 
The protocol was approved by the Hospital Ethical 
Review Committee. Informed consent was obtained 
from all subjects. 
Blood Pressure Measurements 
Office readings were made at each visit to the outpa-
tient clinic, witb the London School of Hygiene sphyg-
momanometer.9 Blood pressure was also recorded for 
I hour in each subject with an automatic device (Accu-
torrTMI, Datascope, Paramus, NJ, USA). Direct 24-
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hour intra-arterial ambulatory recordings, using the 
Oxford system, 10 were made in 18 of the 24 subjects. 
Measurements with the London School of Hygiene 
sphygmomanometer were made after 5 minutes of su-
pine rest. Korotkoff phase V was taken as diastolic 
pressure. Readings were taken at !-minute intervals, 
and the arithmetic mean of three measurements was 
recorded. Measurements were repeated with the sub-
ject in the upright position. Pulse rate was counted for 
30 seconds in both positions. Mean arterial pressure 
was calculated as diastolic pressure plus one third of 
the pulse pressure. 
The Accutorr noninvasive blood pressure monitor 
has been designed for measuring systolic, mean, and 
diastolic pressure according to the oscillometric meth-
od. The microprocessor computes the displayed varia-
bles as follows. The systolic pressure is the preset cuff 
pressure at which the pressure oscillations begin to 
increase in amplitude during deflation. The mean pres-
sure is the lowest preset cuff pressure at which the 
oscillations are maximal. The diastolic pressure is the 
preset cuff pressure at which the oscillations stop de-
creasing in amplitude. Twelve consecutive measure-
ments were made at 5-minute intervals with the subject 
in the supine position. The accuracy of the Accutorr 
was assessed by comparison with direct intra-arterial 
measurement. Results are shown in Figure I. In the 
pressure range tested, the Accutorr slightly underesti-
mated intra-arterial systolic pressure; the mean differ-
ence was 7.5 mm Hg (SD = 7.1). The Accutorr-
measured diastolic pressure was consistently higher 
than the intra-arterial value; the mean difference was 
11.7 mm Hg (SD = 6.6). These results are compara-
ble with data obtained with the Dinamap oscillometric 
device." 
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FIGURE I. Comparison betv.'een blood pressures simultaneously determined by Accutorr and intra-arterial 
measurement in 24 subjects. Data were analyzed by linear regression;for systolic pressure: y = 0.98x- 4.77, 
r = 0.95, p < 0.0/;for diastolic pressure: y = 1.04x + 9.14, r = 0.92. p < 0.01. 
102 
KETANSERIN AND 24-HOUR BLOOD PRESSURE/Woittiez eta/. 169 
Reproducibilit:v of blood pressure readings obtained 
with the Accutorr at weekly intervals was assessed by 
comparing pressures obtained during Weeks 7 and 8 of 
placebo treatment. The correlation coefficient (linear 
regression) for 12 consecutive measurements of sys-
tolic pressure in individual subjects ranged from an r 
value of0.78 to 0.92 (mean, 0.84; SEM = 0.02; n = 
24; p < 0.01). The correlation coefficient for 12 con-
secutive measurements of diastolic pressure ranged 
from an r value of 0.64 to 0. 78 (mean, 0. 72; SEM = 
0.03; n = 24; p < 0.01). 
The Oxford system was used for continuous intra-
arterial ambulatory blood pressure monitoring. Its ac-
curacy and the reproducibility of 24-hour blood pres-
sure profiles have been reported by others. 10 Briefly, a 
small (1-mm diameter) catheter (Seldicath, Plastimed, 
Saint-Leu-La Foret, France) was inserted into the non-
dominant brachial artery after local anesthesia with 2% 
lidocaine solution and connected to a transducer-perfu-
sion unit suspended in front of the subject's chest. 
Signals from the transducer and from two thoracic 
electrocardiographic electrodes were registered on a 
portable minicassette tape recorder (Medilog 2, Ox-
ford Instruments, Oxford, UK). Calibration was per-
formed before and after registration. The analogue 
pressure signal was digitized with a sample frequency 
of 33V3 samples per second of real time and fed into a 
Hewlett-Packard 2113-E computer (Palo Alto, CA. 
USA). A computer-based program was used to prepro-
cess the signal, which was scrutinized for beat loss, 
damping, clipping, and movement artifacts, but the 
final editing of distorted tracings was done after visual 
inspection. For each 24-hour tracing, the number of 
beats that had to be excluded from the final analysis 
was less than 10% of the total. The computer deter-
mined systolic, 1mean, and diastolic pressure and pulse 
interval and stored this information for each beat. 
Blood pressure and heart rate obtained during placebo 
and with ketanserin treatment were examined in two 
ways: as hourly means and as 6-hour means. 
Blood Chemistry 
The plasma levels of active renin (normal range. 
6-52 ~-tU/ml, unrestricted sodium intake) and aldoster-
one (normal range, 40-180 pg/ml) were measured by 
radioimmunoassay. 12• 13 Plasma norepinephrine (nor-
mal range, 150-400 pg/ml) was measured by a ra-
dioenzymatic technique. 14 The plasma level of ke-
tanserin was measured by high-performance liquid 
chromatography. 15 
Statistical Analysis 
Data are given as means ± SEM. Mean values of 
renin were calculated after logarithmic transformation. 
Treatment-order interactions were tested by analysis of 
variance. The differences between placebo and ketan-
serin therapy were assessed by the two-tailed paired 
Student's t test. Chi-square test was used for calculat-
ing differences in the number of subjects having side 
effects and in the number of subjects who responded to 
treatment. Subjects, in whom supine diastolic pres-
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TABLE 1. Clinical Characteristics of Subjects at the Time of Ran-
domization 
Ketanserin Placebo to 
Variable to placebo Ketanserin 
Number of subjects II 13 
Men/women 6/5 10/3* 
Age(yr) 48 (33-63) 51 (24-69) 
Blood pressure 
(mm Hg)t 161 ± 101!04±5 174±61109±4 
Duration of 
hypertension (mo) 61 (20-200) 74 (15-200) 
Weight (kg)t 72.4±3.1 75.3 ± 2.8 
Serum creatinine 
(mg/dl)t 0.94±0.04 1.08±0.07 
Range is given in parentheses. 
*p < 0.05. compared with ketanserin-to-placebo value. 
tValues are means ± SEM. 
sure, as measured by the London School of Hygiene 
sphygmomanometer, fell by more than 10% after 
8 weeks of treatment from the last measurement in 
the placebo run-in period were considered to be 
responders. 
Results 
The study began with 29 subjects. During the run-in 
phase, three subjects appeared to be normotensive and 
one had to be withdrawn because of concomitant dis-
ease (sarcoidosis). Six weeks after randomization one 
patient withdrew because she moved to another city. 
Of the remaining 24 subjects, II were first treated with 
ketanserin and 13 were first treated with placebo. Both 
groups were reasonably matched for blood pressure 
and age (Table 1). 
Blood Pressure 
As shown in Figure 2, supine systolic and diastolic 
cuff pressures, as measured with the London School of 
Hygiene sphygmomanometer. were significantly re-
duced by ketanserin treatment in both groups. Similar 
results were obtained for standing blood pressures 
measured with the London School of Hygiene sphyg-
momanometer and for supine !-hour blood pressure 
measurements obtained with the automatic device, Ac-
cutorr. Since a significant carryover effect of ketan-
serin was observed in the first 2 weeks after switching 
to placebo, the data obtained from the two groups after 
more than 2 weeks are combined in Table 2. Based on 
the criterion described in Methods, II subjects (46%) 
were considered to be responders to ketanserin. where-
as three subjects (12%) responded to placebo (p < 
0.05). Ketanserin had no effect on heart·rate. None of 
the subjects showed a more than I 0 mm Hg drop in 
systolic or diastolic pressure on standing. 
Eighteen subjects (3 women), aged 49 ± 3 years, 
were studied by using continuous 24-hour intra-arterial 
measurement of pressure. Ketanserin lowered systolic 
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FIGURE 2. Effect of ketanserin on supine blood pressure in 24 
subjects, as measured with the London School of Hygiene 
sphygmomanometer. *p < 0.05, **p < 0.01, for difference 
from the last week of the placebo run-in period (Week zero). 
and diastolic pressure both at night and during the day 
(Figure 3, opposite). The effect on intra-arterial pres-
sure in the late morning was comparable to the effect 
on cuff pressure measured at about the same time of 
day in the outpatient clinic (Tables 2 and 3). The blood 
pressure patterns in our subjects showed a dip between 
1300 and 1500 that corresponded with the time of the 
afternoon nap. 
Humoral a~td Biochemical Parameters 
Ketanserin had no effect on the serum levels of urea, 
uric acid, and cholesterol. Endogenous creatinine 
clearance and the plasma levels of norepinephrine, 
renin, and aldosterone were unchanged (Table 4). So-
dium excretion on the day that blood samples for hor-
mone measurements were taken was 133 ± 13 
mEq/24 hr during placebo treatment and 144 ± 15 
mEq/24 hr during ketanserin treatment; the difference 
was not statistically significant. The values for serum 
electrolytes, bilirubin, alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase, glutam-
ic-oxaloacetic transaminase and lactate dehydrogen-
ase, and white blood cell and platelet counts were also 
unchanged. 
TABLE 3. Effect of Ketanserin on Ambulatory Intra-arterial 
Pressure in 18 Subjects 
Blood 
pressure 
(mm Hg) 
Systolic 
Diastolic 
Time of day 
0600-1200 
1200-1800 
1800-2400 
0000-0600 
0600-1200 
1200-1800 
1800-2400 
0000-0600 
Values are means ± SEM. 
Placebo Ketanserin 
149±2 145 ± 3* 
153±3 150±2 
155±3 145 ± 3t 
132± 1 123±2t 
98±2 91 ±2t 
99±2 94± l:j: 
99±3 90±2t 
81 ± 1 75± It 
*p < 0.05. tp < 0.001, :l:p < 0.01. compared with placebo 
value. 
TABLE 2. Effect of Ketanserin on Cuff Blood Pressure in 24 Subjects 
Run in Place be Ketanserin 
Variable (4 wk) 4 wk 6 wk 8 wk 4 wk 6 wk 8 wk 
LSH 
Supine 
Systolic BP (mm Hg) 168±5 164±6 162±5 164±6 158±5 158±5 158±5* 
Diastolic BP (mm Hg) 107±3 104±3 101 ±2 104±3 99±3* 99±2 98±2t 
Heart rate (beats/min) 72±2 74±2 71 ±2 73±2 72±2 70±2 70±2 
Standing 
Systolic BP (mm Hg) 160±5 160±5 156±5 158±5 157±5 154±5 154±4 
Diastolic BP (mm Hg) 109±3 107±4 104±3 112±3 104±3 102±2 104± 2+ 
Heart rate (beats/min) 82±2 81 ±2 '81 ±2 84±2 82±3 80±2 80±2 
Accutorr ( 1-hr measurement) 
Systolic BP (mm Hg) 149±4 152±4 152±4 152±5 148±5 144±4:j: 149±4 
Diastolic BP (mm Hg) 101 ±3 102±3 100±2 101 ±3 96±2t 95±2:1= 95±2:j: 
Heart r~te (beats/min) 74±2 74±2 73±2 7'2±2 71 ±2 71 ±2 71 ±2 
Values are means ± SEM. LSH = London School of Hygiene sphygmomanometer; BP = blood pressure. 
*p < 0.05, tp < 0.01, j:p < 0.001, as compared with 8-week placebo value. 
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FIGURE 3. Effect of ketanserin on ambulatory 24-hour sys-
tolic and diastofic intra-arterial pressure and heart rate in 18 
subjects. Each circle represents the mean value of ]-hour con-
tinuous measurement. Ketanserin. 40 mg, was given at 0800 
and 1800. Note the dip in pressure during the afternoon nap and 
during the night. *p < 0.05, **p < 0.01, for difference from 
placebo; bpm = beats per minute. 
Subject Compliance and Side Effects 
Subject compliance was excellent. Less than 5% of 
the tablets to be taken were returned. Also, the plasma 
level of ketanserin was 71.9 ± 7 .I ng/ml, which is in 
the upper therapeutic range. 15• 16 Ketanserin caused an 
increase in body weight, and this effect was sustained 
for the fullS weeks of treatment (see Table 4). Drowsi-
ness was reported by 50% of the subjects at some time 
during the active treatment period and by 25% of the 
subjects receiving placebo (Figure 4). The difference 
was not statistically significant. Other side effects also 
were not significantly more common with ketans.erin 
than with placebo treatment. 
Discussion 
Long-term oral treatment with ketanserin, 40 mg 
b.i.d., significantly reduced blood pressure. Intra-arte-
rial 24-hour measurements showed a 5% fall in mean 
arterial pressure as compared with results of placebo 
treatment. Since these measurements were made in the 
hospitaL they might not have been representative for 
daily practice; however, the effect on intra-arterial 
pressure in the hospital was comparable to the effect on 
the office cuff pressure readings (see Tables 2 and 3). 
A reduction of approximately 10% in cuff pressure 
has been reported in a double-blind placebo-controlled 
study of 10 patients using ketanserin, 20 mg t.i.d., 16 in 
a similar study of 8 patients using ketanserin, 40 mg 
b.i.d., 17 in a dose-finding study of 16 patients using 
ketanserin in an average daily dosage of 91 mg, 18 and 
in a single-blind study of 13 patients receiving 40 mg 
once daily and 12 patients receiving 40 mg b.i.d." A 
somewhat lower pressure reduction has been observed 
in a double-blind placebo-controlled crossover study 
of 14 patients receiving ketanserin, 40 mg t.i.d.; sys-
tolic and diastolic pressures fell by 6%,20 which agrees 
with our findings. We chose a dosage of 40 mg b.i.d. 
because the terminal plasma half-life of ketanserin has 
been reported to be approximately I 0 hours." Al-
though this fixed dose may not have been optimal in all 
subjects, the continuous blood pressure measurements 
showed an effect that lasted for a large proportion of 
the 24-hour period, if not for the full period. 
About half of the subjects receiving ketanserin 
showed a more than I 0% decrease in diastolic pressure 
TABLE 4. Effect of Ketanserin on Body Weight, Biochemical Variables, and Renal Function in 24 Subjects 
Run in Placebo Ketanserin 
Variable (4 wk) (8 wk) (8 wk) 
Weight (kg) 76.8 :':2.3 
Plasma 
Norepinephrine (pg/ml) 340:':34 
Renin (jLU/ml) 10.5 (8.9-12.4) 
Aldosterone (pg/ml) 115:': II 
Ketanserin (ng/ml) 0 
Serum 
Urea (mg/dl) 31.8 :': 1.8 
Uric acid (mg/dl) 6.0:':0.3 
Cholesterol (mg/dl) 205:':8 
Endogenous creatinine clearance (mUmin) 136+ 14 
Values are means ± SEM. Range is given in parentheses. 
*p < 0.01, compared with placebo value. 
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76.7:':2.4 78.0:':2.4* 
284:':25 314:':23 
9.8 (8.2-11.6) 9.2 (7.8-10.8) 
110:': 16 103:': 13 
0 71.9:': 13 
33.0:':2.4 32.4:':1.8 
6.0:':0.3 5.9:':0.3 
213:':8 205 :': 12 
112+ 13 118+ 17 
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KETANSERIN PLACEBO FIGURE 4. Incidence of side effects during 8 
weeks of treatment with ketanserin, 40 mg 
b.i.d .. in 24 subjects. None of the side effects 
was significantly more frequent with ketan-
serin than with placebo treatment. 
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as compared with the pressure at the end of the placebo 
run-in period. A similar response rate has been ob-
served with thiazide diuretic or !3-adrenergic receptor 
antagonist treatment."'· 11 In our series, the responders 
could not be distinguished from the nonresponders 
with respect to age or initial blood pressure. 
Ketanserin did not modify the circadian blood pres-
sure pattern, since the blood pressure lowering action 
of the drug was at least as strong during the night as 
during the day. It is difficult to draw conclusions from 
these observations as to ketanserin's mechanism of 
action. Various drugs, such as diuretics, !3-adrenergic 
antagonists, a 1-adrenergic receptor antagonists, and 
calcium entry blockers, have also been found to exert 
little influence on the circadian blood pressure vari-
ations. zz-26 
Heart rate and plasma norepinephrine levels were 
not altered by ketanserin, and these findings certainly 
contrast with the reduction in these parameters that 
occurs during treatment with a centrally acting drug, 
such as clonidine.17 Animal experiments, in which ke-
tanserin was injected into the cerebral ventricles, have 
provided evidence that the drug does not lower blood 
pressure by a central action. 28 
Previous studies have shown that the fall in blood 
pressure after an intravenous injection of 10 mg of 
ketanserin is associated with a small and transient rise 
in heart rate and plasma norepinephrine levels. 29 No 
such changes were observed in the present study, pos-
sibly because the effect on blood pressure was more 
gradual, thereby allowing the baroreflex to be reset. 
The pharmacological evidence now available indi-
cates that ketanserin selectively antagonizes the S2-
mediated peripheral pressor action of serotonin but is 
not fully specific for S2-receptors. It also has some 
affinity for a 1-adrenergic receptors. Intravenous ketan-
serin, however, appears to be capable of lowering 
blood pressure in hypertensive subjects independently 
of a,-adrenergic receptor blockade. 30• 31 Steady state 
plasma levels of ketanserin in these intravenous stud-
ies19· 31 • 32 were about 80 ng/ml, which is comparable to 
the peak levels measured after oral intake in the present 
study. 
Ketanserin did not cause postural hypotension in our 
subjects. Body weight had increased by 1.3 kg after 
both 4 and 8 weeks of ketanserin treatment. This in-
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crease may have been caused by renal sodium and 
water retention, as is often seen during treatment with 
vasodilator drugs, but we did not perform balance 
studies to prove this possibility. Among other minor 
side effects. none were significantly more frequent 
with ketanserin than with placebo treatment. 
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5-HT, Alpha-Adrenoceptors, and Blood Pressure 
Effects of Ketanserin in Essential Hypertension and Autonomic 
Insufficiency 
GERT J. WENTING, M.D., AREND J.J. WOITTIEZ, M.D., ARIE J. MAN IN 'T VELD, M.D., 
AND MAARTEN A.D.H. SCHALEKAMP, M.D. 
SUMMARY The serotonin (5-hydroxytryptamine, 5-HT) antagonist, ketanserin, has a high affinity 
for 5-HT,-receptors but it also binds to a 1-adrenoceptors. The compound (10 mg i.v.) lowered mean 
arterial pressure by 22% ± 2% (mean ± SEM, p < 0.001) in 30 patients witb essential hypertension. 
Measurements of heart rate, cardiac output, cardiac filling pressures, forearm blood How, renal 
blood How, and glomerular filtration rate revealed a hemodynamic pattern compatible with vasodila-
tion of both resistance and capacitance vessels. This was accompanied by moderate reflex cardiostim-
ulation. Ketanserin did not alter the pressor effect of bolus injections of (-)-phenylephrine hydrochlo-
ride (25, 50, 100, and 200 jLg i. v.). Ketanserin also had a distinct hypotensive effect in four 
normotensive patients with autonomic insufficiency due to an efferent sympathetic lesion, who were 
unresponsive to phentolamine (20 mg i. v.). Thus, ketanserin in the dose we have used appears to lower 
blood pressure independently of a 1-adrenoceptor blockade. On the other hand, in patients with 
essential hypertension the antihypertensive effect of ketanserin was blunted by pretreatment with 
prazosin (12 mg/day). Therefore, a certain degree of a 1-adrenergic tone seems to be required for the 
compound to exert its full antihypertensive action. The findings are indirect evidence for a role of 5-
HT in the maintenance of increased vascular resistance in essential hypertension. This may be related, 
at least in part, to the alleged amplifying effect of 5-HT on a 1-adrenoceptor-mediated vasoconstric-
tion. (Hypertension 6: 100-109, 1984) 
KEY WoRDS • a-adrenoceptors • blood pressure • 5-hydroxytryptamine • ketanserin • 
prazosin 
LTHOUGH 5-hydroxytryptamine (5-HT, sero-
tonin) was among the first vasoactive amines 
to be discovered and synthesized, its func-
tion in blood pressure regulation is still unclear. 
Recently, a differentiation between two subtypes of 
5-HT-receptors has been made on the basis of radioli-
gand-binding studies using membranes prepared from 
rat frontal cortex. 1 Although specific functions associ-
ated with these brain receptors have not been identi-
fied, it has been shown that the 5-HT -receptors sub-
serving contraction of vascular smooth muscle cells 
are of the 5-HT,-subtype.'·' 
A 5-HT,-receptor antagonist, ketanserin (3-2-
[4- (- fluorobenzoyl) -1-piperidinyl] ethyl-2.4-[ 1H.3H] 
quinazolinedione, Janssen Pharmaceutica, Beerse, 
Belgium), devoid of agonist activity, is now available 
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for clinical investigation.4-6 Ketanserin. however, is 
not fully specific for 5-HT,-receptors, since it also 
binds to a 1-adrenoceptors·. High concentrations of ke-
tanserin have an antagonistic effect on a 1-adrenocep-
tor-mediated contractions of isolated arteries and 
veins. 4 
Experiments in animals4 and preliminary data in hu-
mans'· 9 have shown that ketanserin has antihyperten-
sive properties. This may, at least in part, depend on 
blockade of a 1-adrenoceptors. Indeed, it has been re-
ported that hypotensive doses of ketanserin abolished 
the pressor response to a 1-agonists in the pithed rat, the 
anesthetized normotensive rat, and the conscious 
spontaneously hypertensive rat. 10• 11 
This paper describes the hemodynamic profile of 
ketanserin's antihypertensive action in patients with 
essential hypertension. The possibility that the antihy-
pertensive effect of ketanserin depends on interference 
with a 1-adrenoceptor-mediated vasoconstriction was 
tested by comparison of the pressor effects of the a 1-
adrenoceptor agonist, phenylephrine, before and after 
ketanserin and by assessment of the antihypertensive 
effect of ketanserin after administration of the a 1 -adre-
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noceptor antagonist. prazosin. The cardiovascular ef-
fects ofketanserin were also studied in a small group of 
patients with autonomic insufficiency, who were unre-
sponsive to the hypotensive action of the nonselective 
a-adrenoceptor antagonist, phentolamine. 
Methods 
Patients 
Thirty hypertensive subjects were studied, 21 men 
and nine women, aged 55 ± 2 years (mean ± SEM; 
range, 38 to 77 years). The diagnosis of essential hy-
pertension was made by routine screening including 
intravenous urography. Antihypertensive treatment. if 
any, was stopped 3 weeks before the study. The pa-
tients were admitted to a metabolic ward and received 
a diet with a fixed sodium and potassium content (50-
70 mEg/day and 70-100 mEg/day, respectively). 
When blood pressure and sodium balance were stable, 
the patients were investigated in the cardiovascular 
laboratory after an overnight fast. The use of a new 
antihypertensive agent was explained to the patients. 
They all gave their consent to participate in the study. 
The study protocol was approved by the local hospital 
ethical committee. 
Four patients aged 40-76 years, three women and 
one man, with chronic autonomic failure of the periph-
eral type, were also studied. Two patients had idio-
pathic autonomic neuropathy, one patient had primary 
amyloidosis, and the remaining patient had amyloido-
sis of the hereditary type. Clinical signs of involve-
ment of the central nervous system were absent in all. 
Diagnostic aspects of these patients have been de-
scribed in detail elsewhere. 12• 13 Incapacitating ortho-
static hypotension was the presenting symptom. The 
systolic pressure overshoot in the Valsalva maneuver 
was absent, and heart rate did not increase after atro-
pine (2 mgj.v.). Plasma norepinephrine was below the 
detection limit of20 pg/ml in two patients and it was 40 
and 135 pg/ml in the remainder. It was unresponsive to 
head-up tilting in all. Thus, the patients had combined 
efferent sympathetic and parasympathetic lesions. At 
the time of the study, they had not been on any drug for 
at least 3 weeks. 
Hemodynamic Measurements 
Arterial pressure was measured directly in a radial 
artery with a P 23 D Statham transducer and recorded 
on a direct-writing Hewlett-Packard multigraph. Heart 
rate was determined from the simultaneously recorded 
ECG signal. Ketanserin, I 0 mg in 20 ml of saline, was 
infused intravenously in 2 to 3 minutes, and the effects 
were followed for 2 hours. In the patients with auto-
nomic insufficiency, the effects of ketanserin were 
compared with those of phentolamine, 20 mg i.v. Ke-
tanserin and phentolamine were given on different oc-
casions at least 2 weeks apart. 
More detailed data on central and renal hemody-
namics were obtained in 12 hypertensive patients. A 
Swan-Ganz thermodilution catheter was introduced 
percutaneously in an antecubital vein and positioned in 
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the pulmonary artery. Triplicate cardiac output (CO) 
measurements were performed at frequent intervals 
and integrated mean values for systemic arterial pres-
sure (MAP), right atrial pressure (RAP), pulmonary 
arterial pressure (PAP), and pulmonary capillary 
wedge pressure (PCWP) were determined. Pressures 
and cardiac output were measured with the patients in a 
supine position, and the transducers were zeroed at 
midthoracic level. Cardiac output was corrected for 
body surface area and is expressed per 1. 73 m2 • The 
following variables were derived: total peripheral re-
sistance is TPR = (MAP - RAP)/CO and pulmonary 
vascular resistance is PVR = (PAP - PCWP)/CO. 
A peripheral vein was cannulated for renal function 
studies using a constant infusion technique. Effective 
renal plasma flow and glomerular filtration were esti-
mated by the clearances of 1311-hippuran and 1251-thala-
mate, respectively. Hemodynamic measurements 
were made after a 90-minute equilibration period. 
Renal blood flow (RBF) corrected for 1.73 m' body 
surface area was calculated using central venous 
packed cell volume and assuming 75% renal extraction 
of hippuran. 14 Renal vascular resistance was derived as 
RVR = MAP/RBF. 
The effects of ketanserin on peripheral hemodynam-
ics were studied in a subgroup of eight hypertensive 
patients. Measurements were taken with the patients 
supine after resting for at least 30 minutes at a room 
temperature of 23°-25°C and in an air humidity of 
approximately 50%. Forearm blood flow including 
hand flow was measured semicontinuously by means 
of an ECG-triggered venous occlusion plethysmo-
graph (Janssen Scientific Instruments). A mercury-in-
Silastic strain gauge was placed around the midfore-
arm, and the arm was elevated so that venous pressure 
approached zero. Venous occlusion was achieved 
within 50 msec by inflation of a sphygmomanometer 
cuff wrapped around the upper arm and attached to a 
container of compressed air with a pressure valve pre-
set at 50 mm Hg. This occlusion pressure was intermit-
tently applied for a period of three heart beats. with a 
recovery period of two heart beats. To obtain synchro-
nization between cuff pressure and flow pulse, the 
occlusion pressure was regulated by means of electro-
magnetic valves that were triggered by properly de-
layed impulses derived from the R-top of the electro-
cardiogram. Forearm blood flow was calculated from 
the change in forearm circumference during occlusion 
and was expressed as ml per I 00 ml of tissue per 
minute. Rectal temperature and skin temperature of the 
forehead and distal, volar surface of digits no. 2, 3. 
and 5 of the nonoccluded arm were recorded by means 
of telethermometers (Yellow Springs Instruments, 
Cleveland, Ohio). 
Phenylephrine Injections 
In seven patients with hypertension, bolus injections 
of (-)-phenylephrine hydrochloride (25, 50. 100, and 
200 p..g), in random order, were flushed into the circu-
lation through a cannula in an antecubital vein, before 
and during ketanserin infusion. Intraarterial pressure 
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and the electrocardiogram were simultaneously re-
corded on a multichannel ink-jet writer (Mingograph 
Siemens, Elema, Solna, Sweden) at a paper speed of 
100 mrnlsec. The interval between the injections was 
I 0 minutes. After the first series of injections had been 
finished, a loading dose of 10 mg ketanserin was in-
fused intravenously in 2 or 3 minutes followed by a 
sustaining infusion of 2 mg/hour. According to the 
manufacturer, in this way a stable plasma level of 
about 80 ng/ml is reached within 15 minutes. A second 
series of phenylephrine bolus injections was then giv-
en. The 200 JLg dose of phenylephrine was used for 
determination of baroreflex sensitivity. Measurements 
covered the period from the onset of the rise in arterial 
pressure until pressure had reached its peak level. Bar-
oreflex sensitivity was expressed as the slope of the 
regression line relating RR-interval to the systolic 
pressure of the preceding heart beat." The result was 
accepted only when the correlation coefficient was 
greater than 0.75, with ap value of less than 0.05. In 
one patient these conditions were not met. 
A third series of phenylephrine injections was given 
to five patients after they had been treated with prazo-
sin, 4 mg orally three times a day for 2 days. Phenyl-
ephrine was injected 6~90 minutes after the morning 
dose of prazosin. 
FIGURE I. Responses of systemic arterial pres-
sure, heart rate, and plasma norepinephrine to a 
single dose of ketanserin (I 0 mg i. v.) in 20 patients 
with essential hypertension. Changes in arterial 
pressure and norepinephrine were significant (p 
< 0.01) throughout the observation period. Heart 
rate had returned to baseline after 45 minutes. 
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Pretreatment with Prazosin and Furosemide 
Fourteen patients with essential hypertension, in 
whom the effects of a first dose of ketanserin (I 0 mg 
i.v.) had been followed for 2 hours, were randomly 
assigned to two treatment modalities. Eight patients 
were treated with prazosin (4 mg three times a day) for 
I week, and the effects of a second dose of ketanserin 
(10 mg i.v.) were studied 6~90 minutes after the 
"morning dose of prazosin. Six patients were treated 
with furosemide (40 mg daily) and after 1 week a sec-
ond dose ofketanserin (10 mg i.v.) was administered. 
Analytical Procedures 
For determinations of plasma renin and aldosterone, 
arterial blood was collected in chilled tubes containing 
disodium ethylenediaminetetraacetate (EDT A) in a fi-
nal concentration of 2 mg/ml of blood, and stored on 
ice for no longer than 60 minutes until centrifugation at 
5,000 rpm for 15 minutes at 4°C to separate the plas-
ma. Plasma was stored at - 20°C. Active renin was 
measured by radioimmunoassay as described pre-
viously. 16 Semi purified human kidney renin (MRC 
standard no. 68/356, WHO International Laboratory. 
for Biological Standards and Control, London, Eng-
land) was used as a standard, and results are expressed 
as microunits of this standard per milliliter of plasma. 
-30 
112 
ARTERIAL PRESSURE mmHg 
HEART RATE beats/min 
PLASMA NOREPINEPHRINE pg/ml 
~KETANSERIN 
30 60 
TtME (min) 
90 
j 
120 
5-HYDROXYTRYPTAMINE AND BLOOD PRESSURE!Wenting eta/. 103 
The normal range in our laboratory is 15-40 jLU/ml. 
Plasma aldosterone was also measured by radioim-
munoassay. 17 The normal range is 40--180 pg/ml. For 
determination of plasma norepinephrine, I 0 ml of arte-
rial blood was collected into a chilled tube containing 
143 USP units lithium heparin and 15 mg glutathione 
in 200 ILl distilled water. After centrifugation, the plas-
ma was deproteinized with trichloroacetic acid. The 
precipitate was removed by centrifugation at 8000 rpm 
for 15 minutes and the supernatant was stored at 
-20°C. Norepinephrine was measured by a radioen-
zymatic method, in which norepinephrine is quantita-
tively converted to 3H -epinephrine in the presence of 
phenylethanolamine-N-mettyltransferase using 3H-S-
adenosyl-L-methionine as a 3H-methylgroup donor. 18 
All samples were assayed in duplicate, both with and 
without the addition of norepinephrine as the internal 
standard. The normal range is 150-450 pg/ml. 
Statistical Analysis 
Data are given as means ± SEM. Plasma levels of 
renin were not distributed normally. Mean values and 
standard errors were calculated after logarithmic trans-
formation. Student's t tests for paired and unpaired 
data were used. Statistical significance was taken to be 
p < 0.05. 
Results 
Studies in Essential Hypertension 
Systemic, Central, and Peripheral Hemodynamics and 
Plasma Norepinephrine 
In 30 patients, arterial pressure fell from 177 ± 5/86 
± 3 mm Hg before ketanserin to 139 ± 6/68 ± 3 mm 
Hg (p < 0.001) after ketanserin injection. Heart rate 
rose from 68 ± 2 to 78 ± 3 bpm (p < 0.01). Fifteen 
minutes after ketanserin. arterial pressure was still 
low, 147 ± 6/72 ± 3 mm Hg (p < 0.001 for differ-
ence from baseline), but heart rate had returned to 73 
± 3 bpm. The effects on arterial pressure, heart rate, 
and plasma norepinephrine, which were followed for 2 
hours in 20 patients, are shown in Figure I. After 2 
hours, mean arterial pressure was still significantly 
below baseline (p < 0.05) and norepinephrine was still 
elevated (p < 0.05), whereas heart rate had already 
returned to baseline. 
The fall in arterial pressure after ketanserin was 
caused by a fall in total peripheral resistance (Figure 
2). Cardiac output rose from 4.35 ± 0.26 liter/min 
before ketanserin to 4.68 ± 0.26liter/min (p < 0.01) 
5 minutes after the ketanserin injection. Thereafter, 
cardiac output fell, and after 90 minutes it was 4.08 ± 
0.23 liter/min, which was even below baseline (p < 
0.05). Stroke volume was 68 ± 4 ml before ketan-
serin. It was not altered 5 minutes after ketanserin but 
it fell to 61 ± 3 ml after 90 minutes (p < 0.01 for 
difference from baseline). Right atrial pressure, pul-
monary arterial pressure, and pulmonary capillary 
wedge pressure were also lowered (Figure 3). Pulmo-
nary vascular resistance was not altered. Forearm 
blood flow and digital skin temperature increased mar-
113 
kedly after ketanserin (Table I). Rectal temperature 
and skin temperature of the forehead remained con-
stant. 
Renal Hemodynamics. Plasma Renin. and Aldosterone 
The pattern of flow and resistance changes induced 
by ketanserin in the renal vascular bed resembled the 
changes in the systemic circulation (Figure 4 )'. Renal 
blood flow was 736 ± 44 ml!min before ketanserin 
and rose to 767 ± 51 ml!min (p < 0.05) 15 minutes 
after the drug. Glomerular filtration rate was 90 ± 5 
ml/min before ketanserin and remained unchanged de-
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FIGURE 2. Effects of ketanserin ( 10 mg i. v.) on systemic he-
modynamics in 12 patients with essential hypertension. The 
decrease in arterial pressure was due to a decrease in total 
peripheral resistance. After 120 minutes ,_arterial pressure and 
total peripheral resistance were still below baseline (p < 0.05 ). 
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FIGURE 3. Effects of ketanserin (10 mg i.v.) on central hemodynamics in 12 
patients witfr essential hypertension. After 120 minutes. all changes were still 
significant at p < 0.05. 
spite the decrease in arterial pressure. Plasma renin 
rose from 9.4 JLU!ml (antilog of arithmetic mean after 
logarithmic transformation of data) before ketanserin 
to 17 JLU/ml (p <. 0.01) 30 minutes after the drug. 
Plasma aldosterone did not change; it was I 02 ± 15 
pg/ml before ketanserin and 92 ± 14 pg/ml after 30 
minutes. 
Responses to Bolus Injections of Phenylephrine 
From the start of the injection until changes had 
returned to baseline pulsatile and mean arterial pres-
sures and the RR-interval of the ECG were analyzed 
beat to beat. Figure 5 shows an example. Mean arterial 
pressure and the subsequent RR-interval (pulse inter-
val) were used for constructing log dose-response 
curves. As shown in Figure 6, the changes in mean 
arterial pressure and pulse interval were not modified 
by ketanserin. However, treatment with prazosin com-
petitively antagonized the responses. as indicated by a 
parallel shift of the dose-response curve to the right 
(Figure 7). Baroreflex sensitivity was not modified by 
ketanserin. It was 8.82 ± 1.71 msec/mm Hg before 
ketanserin and 9.03 ± 1.52 msec/mm Hg after the 
drug. 
Effects of Pretreatment with Prazosin or Furosemide 
Mean arterial pressure was 114 ± 8 mm Hg in the 
patients who were to be treated with prazosin and 116 
± 6 mm Hg in the patients to be treated with furose-
mide. After 1 week of treatment, mean arterial pres-
;;ure was 103 ± 6 mm Hg in the prazosin group (p < 
0.05 for difference from the value before treatment) 
and 102 ± 4 mm Hg in the furosemide group (p < 
0.05). Body weight did not change with prazosin and 
fell by 2.1 ± 0.3 kg with furosemide (p < 0.01 ). The 
blood pressure r.osponse to ketanserin was blunted by 
pretreatment with prazosin and was not affected by 
pretreatment with furosemide (Figure 8). 
Studies in Aut<>nomic Insufficiency 
Arterial pressure fel.l from 128 ± 8/66 ± 3 mm Hg 
before ketanserin to 95 ± 4156 ± 3 mm Hg (p < 
114 
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FIGURE 4. Effects of ketanserin ( 10 mg i. v.) on renal hemo-
dynamics in 12 patients with essential hypertension. Note the 
decrease in renal vascular resistance (p < 0.01 after 15, 30, 
and 45 minutes). 
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TABLE I. Effects o/Ketanserin ( 10 mg i. v.) on Systemic and Regional Hemodynamics (mean :± SEM) in Eight Patients 
with Essential Hypertension 
Time {min) before and after ketanserin administration 
Mean arterial 
pressure {mm Hg) 
Heart rate (bpm) 
Forearm blood 
flow (ml!min/100 ml) 
Digital skin 
temperature (°C) 
*p < 0.05. 
tp < 0.01. 
-5 
Ill ±6 115±5 
65±4 65±4 
3.6 ±0.2 3.7±0.2 
31.3±0.8 31.2±0.8 
0.001) after the ketanserin injection (Table 2). In con-
trast. 20 mg phentolamine i. v. had no effect on arterial 
pressure in these patients. With both drugs. heart rate 
did not change. 
Discussion 
Cardiovascular and Hormonal Effects of Ketanserin 
The profile of ketanserin's hemodynamic effects is 
compatible with combined arteriolar and venous dila-
tation. Systemic arterial pressure. total peripheral re-
sistance, and cardiac filling pressures were lowered. 
Part of the decrease in total peripheral resistance was 
mmHg 
200 
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140 
120 
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80 
60 
saline 25 ~g 50 ~9 
2.5 10 15 
99±6t 101 ±6t 105 ±6* 106±6* 
72±3t 70±3* 67±4 65±4 
6.5 ±0.5t 6.3 ±0.6t 5.4±0.5* 4.4±0.6* 
31.8±0.9 33.2±0.6* 33.3±0.6* 33.6±0.8* 
caused by renal vasodilatation. Forearm resistance was 
also reduced. and this reduction appeared out. of pro-
portion as compared to the overall reduction in vascu-
lar resistance. The hand was included in our semicon-
tinuous measurements of forearm flow so that changes 
in hand skin flow have influenced the results. Indeed. 
our thermographic studies showed that digital skin 
flow was increased by ketanserin, presumably by 
opening of arteriovenous shunts, which are densely 
innervated by sympathetic nerves" and possibly also 
by serotonergic fibers. 20 It is worth mentioning that 
forehead skin flow. as estimated by skin temperature 
PHENYLEPHRINE 
100 ~9 200 ~g 400 ~g 
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IOOOf 
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600 
~-::::0P"~JP 
10 20 0 10 20 0 10 20 0 10 20 0 10 20 0 10 20 
SUCCESSIVE HEART BEATS 
FtGURE 5. Effects of bolus injections of phenylephrine in a 38-year-old mildly hypertensive patient before (black circles) and during 
(open circles) ketanserin infusion. 
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measurements, was not increased by ketanserin. This 
contrasts with the rise of forehead temperature after 
hydralazine." 
The fall in arterial pressure was associated with in-
crements in heart rate and cardiac output, probably by 
baroreftex-mediated withdrawal of vagal tone and in-
crease in sympathetic activity. 22 The increased sympa-
thetic activity was reflected by a rise in plasma norepi-
nephrine. Despite continued sympathetic stimulation, 
cardiac output returned to its initial level. This may 
have been due to the gradual decrease in cardiac filling 
pressures. For a given effect on arterial pressure, the 
increase in heart rate after ketanserin was less than 
with drugs like hydralazine and diazoxide, "· 12 which 
have their predominant effect on the resistance vessels. 
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FIGURE 6. Peak responses to bolus injections of phenyleph-
rine in seven patients with essential hypertension before (black 
circles) and during (ope it circles) ketanserin infusion. 
Sympathetic stimulation may have contributed to 
the observed rise in plasma renin. It may be of interest 
that plasma aldosterone did not change after ketan-
serin. From studies with isolated rat glomerulosa cells 
it is known that 5-HT has direct aldosterone-stimulat-
ing properties. 23 Suppression of aldosterone was found 
in patients with idiopathic aldosteronism after admin-
istration of the antiserotonergic agent cyprohepta-
dine. 24 The divergent responses of plasma renin and 
aldosterone after ketanserin in our patients suggest a 
suppressive effect of 5-HT blockade on aldosterone 
secretion but further studies are needed to clarify this 
point. 
Mechanism of Antihypertensive Action of Ketanserin 
Ketanserin has been characterized as a selective 'H-
ligand for 5-HT,-binding sites in brain.' These binding 
sites probably differ' from the D- and M-types of 5-
HT-receptors postulated by Gaddum and Picarelli. 25 
The close connections between the central serotoner-
gic neuronal system and the pathways of catechola-
minergic neurons suggest a role for 5-HT in cardiovas-
cular control, but both pharmacological and surgical 
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PHENYLEPHRINE (pg) 
FIGURE 7. Dose-response curves for phenylephrine in seven 
patients with essential hypertension before (black circles) and 
during (open circles) ketanserin infusion. In five patients, phen-
ylephrine injections were also given after treatment with prazo-
sin (open triangles). Baseline values for mean arterial pressure 
were I 06 ± 5 mm H g before ketanserin. 96 ± 3 mm H g during 
ketanserin, and 97 ± 6 mm Hg after pra:osin. 
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FIGURE 8. Effects of pretreatment with furosemide or pra::.osin on the antihy-
pertensive action of keranserin ( 10 mg i. \'.) in, respectively, six and eight patients 
with essential hypertension. The decrements in arterial pressure after ketanserin 
were smaller (p < 0.01) throughout the observation period in the pra:::osin-
treated patients. 
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TABLE 2. Effects of Ketanserin ( 10 mg i. v.) and Phentolamine (20 mg i. v.) on Systemic Arterial Pressure and Heart Rate in Four Patients 
with Autonomic Insufficiency 
Ketanserin Phentolamine 
Case time (min) time (min) 
no. -5 2.5 lO 15 -5 2.5 lO 15 
Systolic arterial 
pressure (rnm Hg) 117 115 90 91 89 90 121 123 125 125 123 121 
Ill 112 94 92 90 90 119 119 121 123 120 120 
147 143 107 113 108 109 165 163 167 169 161 162 
4 139 142 90 88 86 89 137 135 135 142 140 140 
129 128 95* 96* 93* 95* 136 135 137 140 136 136 
mean± SEM 9 8 4 6 5 5 II 10 lO II 9 lO 
Diastolic arterial 
pressure (mm Hg) 60 60 53 51 49 50 61 60 63 63 61 60 
68 66 51 52 51 53 61 63 61 65 65 64 
60 61 60 60 50 52 75 75 79 81 79 78 
4 73 75 61 59 58 61 73 73 73 75 73 71 
65 66 56* 56* 52* 54* 68 68 69 71 70 68 
mean± SEM 3 3 3 4 4 4 4 4 4 
Heart rate (bpm) 73 74 72 71 70 71 69 69 70 69 69 70 
93 95 90 92 90 91 98 95 95 95 96 95 
69 68 65 65 66 66 70 70 71 71 73 71 
4 56 55 54 52 50 52 52 54 52 50 55 55 
72 73 70 70 69 70 72 72 72 71 73 73 
mean± SEM 8 8 8 8 8 8 10 9 9 9 9 8 
*p < 0.01. 
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manipulations of this central serotonergic system have 
yielded conflicting results. 26 From animal studies, ke-
tanserin appears to be more potent as a serotonin an-
tagonist in the periphery than in the central nervous 
system.' 
The peripheral effects of 5-HT are notoriously vari-
able. 27- 29 5-HT can cause either contraction or relax-
ation of vascular smooth muscle cells depending on the 
anatomical origin of the blood vessel studied. the spe-
cies. experimental conditions, and concentration of the 
monoamine. Apart from its direct vasoconstrictor ef-
fect, 5-HT also amplifies the responses to endogenous 
vasopressor substances such as norepinephrine and an-
giotensin II. 30 This could be a conceptual framework 
for visualizing how 5-HT may contribute to the elevat-
ed vascular resistance in essential hypertension. The 
available pharmacological evidence. which includes 
experiments using ketanserin as a 5-HT-antagonist. 
indicates that the 5-HT-receptors subserving vascular 
smooth muscle contraction are of the 5-HT2-receptor 
subtype. 3-7 This is not only true for the direct vasocon-
strictor effect of 5-HT but probably also for its indirect 
effect through amplification of the responses to norepi-
nephrine.4 
In anesthetized normotensive rats and in conscious 
spontaneously hypertensive rats. doses of ketanserin 
required to lower blood pressure were 25-100 times 
higher than those required to inhibit the blood pressure 
response to 5-HT. 10• 11 At such high doses, however. 
the pressure responses to a,-adrenoceptor agonists 
were also blocked. It is unlikely that ketanserin (I 0 mg 
i.v.) caused a 1-adrenoceptor blockade in our patients. 
since the pressor responses to bolus injections of phen-
ylephrine were not altered. This contrasted with the 
shift of the dose-response curve to the right that was 
observed after treatment with the a 1-adrenoceptor an-
tagonist. prazosin. Heart rate was reduced by bolus 
injections of phenylephrine due to a baroref!ex-medi-
ated increase in vagal tone. 31 • 32 The relationship be-
tween the responses of pressure and heart rate to phen-
ylephrine was not altered by previous administration of 
ketanserin. which suggests that the sensitivity of the 
baroreflex was not affected by this drug. 
That ketanserin can lower blood pressure indepen-
dently of a-adrenoceptor blockade was substantiated 
in our patients with autonomic insufficiency. The non-
selective a-adrenoceptor antagonist phentolamine (20 
mg i.v.) had no effect on blood pressure and heart rate 
in these patients, whereas this dose is known to cause 
hypotension and tachycardia in normal individuals. 
This confirmed the presence of an efferent sympathetic 
lesion in our patients resulting iri a low occupancy of 
the a,- and a 2-adrenoceptors. Still, ketanserin had a 
distinct hypotensive effect in these patients. 
Pretreatment with prazosin attenuated the antihyper-
tensive effect of ketanserin in our hypertensive pa-
tients. Pretreatment with furosemide, which had an 
effect on blood pressure comparable to that of prazo-
sin, did not affect the response to ketanserin. Perhaps a 
certain degree of endogenous tone on vascular a 1-
adrenoceptors is required for ketanserin to exert its full 
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antihypertensive action. This is in accord with the con-
tention that 5-HT-2-receptor stimulation is capable of 
amplifying the pressor response to norepinephrine.4 
We conclude that the antihypertensive action of ke-
tanserin that we have observed is not caused by block-
ade of a,-adrenoceptors. The pharmacological evi-
dence obtained so far supports that this effect depends 
on blockade of vascular 5-HT 2-receptors. Our findings 
are therefore indirect evidence for a role of 5-HT in the 
maintenance of an increased vascular resistance in es-
sential hypertension. 
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Role of a-Adrenergic Blockade in the Cardiovascular Actions of 
Ketanserin: Studies in Patients with Essential Hypertension, 
Autonomic Insufficiency, and Raynaud' s Phenomenon 
R. M. L. Brouwer, G. J. Wenting, A. J. Man in't Veld, and M. A. D. H. Schalekamp 
Department of Internal Medicine/, University Hospital ''Dykzigt"' Rotterdam. Rotterdam. The Netherlands 
Summary: It remains to be established whether· ketanserin • s 
antihypertensive effect is caused by S2-serotonergic blockade. 
by o: 1-adrenergic blockade, or by a combination of both. Ke-
tanserin, I 0 mg i. v. or 40 mg t.i.d. orally, blocked the serotonin-
induced contractions of hand veins in patients with essential 
hypertension. Intravenous ketanserin had no effect on the vena-
constrictor action of noradrenaline. The increase-in digital blood 
flow after i.v. ketanserin, as measured by the change in digital 
skin temperature in patients with Raynaud's phenomenon, was 
The mechanism by which the S2-serotonergic antago-
nist ketanserin Jowers blood pressure in humans is not 
fully understood. Ketanserin, in higher concentrations 
than required to inhibit Sz-serotonergic receptors, also 
binds to ex 1-adrenergic sites and antagonizes ex 1-adreno-
ceptor-mediated contractions of isolated arteries and 
veins (1). It remains to be established whether ketanse-
rin' s antihypertensive effect is caused by serotonergic 
blockade, by ex-adrenergic blockade, by a combination 
of both, or by some other action (2). Here we report 
some studies in patients with hypertension, indicating 
blockade of serotonin-induced constriction of hand veins 
by ketanserin; we also report studies on patients with 
Raynaud's syndrome and those with autonomic insuffici-
ency, indicating that ketanserin is capable of causing 
vasodilation independently of ex-adrenergic blockade. 
PATIENTS 
Ketanserin, 10 mg i. v., was given to 30 patients (21 men, 
9 women, aged 55 ± 2 years, mean ± SEM, range 38--77 
years) with essential hypertension, to four patients (three 
women, one man, aged 40-76 years) with chronic autonomic 
failure of the peripheral type. and to II patients (nine women 
and two men, aged 37 ± 4 years) with primary Raynaud's 
phenomenon. 
The diagnosis of essential hypertension was made after rou-
tine screening, which included i. v. urography. These patients 
not blocked by phentolamine or pretreatment with prazosin. 
Intravenous ketanserin also lowered arterial pressure in patients 
with autonomic insufficiency who were unresponsive to phento-
lamine. These observations suggest that a-adrenergic blockade 
is not the sole mechanism of ketanserin's cardiovascular ac-
tions in humans. 'Key Words: a-Adrenoceptors-Autonomic 
Failure-Hypertension-5-HT2 receptors-Ketanserin-Ray-
naud's phenomenon. 
were admitted to the hospital and received a diet with fixed 
sodium content. Antihypertensive treatment had been stopped 
3 weeks before the study. Patients were studied when blood 
pressure and sodium balance were stable. 
Patients with chronic autonomic insufficiency suffered from 
incapacitating orthostatic hypotension. All patients had com-
bined efferent sympathetic and parasympathetic lesions of the 
baroreflex arc. Plasma noradrenaline was abnormally low in 
all patients and was unresponsive to head-up tilting. A detailed 
description of these patients has been given elsewhere (3). 
At the time of the study, they had not used any drug for at 
least 3 weeks. 
The diagnosis of Raynaud' s phenomenon was made accord-
ing to the criteria proposed by Allen and Brown (4). Secondary 
Raynaud's phenomenon was excluded by history. physical ex-
amination, and laboratory screening. All drugs were discontin-
ued 2 weeks prior to the study. 
The use of a new drug was explained to the patients. and 
all gave their consent to participate in the study. The study 
protocols were approved by the Hospital Ethical Review Com-
mittee. 
MEASUREMENT OF BLOOD PRESSURE 
Blood pressure was measured directly from a radial artery 
with a P23 lD Statham transducer and recorded on a direct-
writing Hewlett-Packard multi graph. Heart rate was determined 
from the simultaneously recorded ECG signal. Ketanserin, I 0 
mg in 20 ml of saline. was infused intravenously in 3 min. 
In 20 patients with essential hypertension. the effects of 
Address correspondence and reprint requests to Dr. M. A. D. H. Schalekamp at University Hospital "Dykzigt" Rotterdam, Dr. Molewaterplein 
40, 3015 GD Rotterdam, The Netherlands. 
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ketanserin on blood pressure and heart rate were followed 
for 2 h .. After this investigation. 14 patients were randomly 
assigned to two treatment modalities. Eight patients were treated 
with prazosin (4 mg t.i.d) and six patients were treated with 
furosemide (40 mg daily). In both groups, after I week of 
treatment. a second doscofkctanscrin ( 10 mg i.v.) was adminis-
tered. 
In patients with autonomic insufficiency, the effects of ke-
tanserin (I 0 mg i. v.) were compared with those of phentola-
mine (20 mg i.v.). Ketanserin and phentolamine were given 
on different occasions at least 2 weeks apart. 
HAND VEIN SENSITIVITY TEST 
In six men with essential hypertension, the effect of ketanse-
rin on serotonin-induced venoconstriction was studied. The 
hand vein sensitivity test was performed during saline infusion, 
during infusion of ketanscrin (I 0-mg bolus injection dissolved 
in 20 ml of saline in 3 min. followed by constant infusion of 
2 mg/h). and after 3 days of oral treatment with ketanserin 
(40 rng t.i.d.). 
An antecubital vein of the right arm was cannulated for 
infusion of ketanserin or matching placebo (saline) infusion. 
The left hand was supported on an arm rest at midchcst position. 
with the patient supine. A 22-gauge needle (Quick-Cath. Tra-
venol Laboratories. Castlcbar. lrdam.l) with extension with 
"T' (Abott, Sligo, Ireland) and short polyethylene tubing 
was inserted into a dorsal hand vein of the left hand. The 
needle in the hand vein was connected to a Gould Statt,Iam 
P23 ID pressure transducer with a sterile diaphragm dome 
and an infusion pump (Pcrfusor, Braun, Melsungen, West Ger-
many) delivering saline at a constant infusion rate of 55 
ml/h. Venoconstriction. locally induced in the hand vein. will 
increase resistance to flow and thereby cause a rise in pressure. 
The pressure signal was recorded on a direct-writing Hewlett-
Packard multigraph. Serial dilutions of serotonin (100--10,000 
ng/ml) and noradrenaline (I 00--5000 ng/ml) were prepared. 
Incremental doses of serotonin and noradrenaline (volume: I 
ml) were injected in the hand vein at regular intervals. Contrac-
tions induced in the vein produced elevations of pressure. which 
returned to baseline in I 0-- I 5 min. The area under the curve 
was taken as a measure of the venous response. Recordings 
of a hand vein sensitivity test are shown in Fig. I. 
For studying the effect of ketanserin on the venoconstrictor 
action of serotonin and noradrenaline. identical doses of each 
amine were given during infusion of saline, during infusion 
of kctanserin, and after oral treatment with ketanserin. Veno-
constfiction pressure curves are influenced by the diameter 
and filling of the vein and by the position of the hand. As a 
consequence, the potency of serotonin and noradrenaline to 
produce venoconstriction showed considerable variance when 
studied at different occasions. For studying the effect of oral 
treatment with ketanserin. the results were standardized by 
taking the ratio between the responses to serotonin and nor-
adrenaline. 
MEASUREMENT OF DIGITIAL BLOOD FLOW 
In II patients with primary Raynaud's phenomenon, the 
effect of ketanserin (I 0 mg i. v.) on digital blood flow was 
followed. The skin temperature of the volar portions of digits 
I. Ill. and V of the right hand was measured with thermistors 
(Yellow Springs Instruments, Cleveland, Ohio, U.S.A.) and 
recorded semicontinuously. Seven measurements per finger 
per minute were taken. After I h of supine rest in a climatized 
room (temperature: 22-24°C), ketanserin ( 10 mg dissolved in 
20 ml of saline) was injected in an antecubital vein of the 
left arm. The effect of ketanserin on digital skin temperature 
was followed for 30 min. In a subgroup of patients, a second 
injection ofkctanserin ( 10 mg i.v.) was given after pretreatment 
with the nonselective a-antagonist phentolamine (20 mg i. v.) 
and after 2 weeks of oral treatment with prazosin (2 mg t.i.d 
for the first week, followed by 4 mg t.i.d. for the second 
week). 
I 
+ 250 ng serotonin + 500 ng serotonin + t 000 ng serotonin 
FIG. 1. Serotonin-induced venoconstriction. A: Response of hand veins without pretreatment. B: Attenuated response to serotonin 
during infusion with ketanserin. 
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RESULTS 
Effect on blood pressure 
In 30 patients with essential hypertension. arterial pres-
sure fell from 177 ± 5/86 ± 3 mm Hg before ketanserin 
to !39 ± 6/68 ± 3 mm Hg (p < 0.001 I after ketanserin 
injection. Heart rate rose from 68 ± 2 to 78 ± 3 beats/ 
min (p < 0.0 I). After 2 h. mean arterial blood pressure 
was still below baseline. After pretreatment with prazo-
sin, the blood pressure response to ketanserin was blunted 
(Fig. 2). whereas pretreatment with furosemide did not 
affect the response to ketanserin. 
ln. patients with autonomic insufficiency. arterial pres-
sure fell from 128 ± 8/66 ± 3 mm Hg before ketanserin 
to 95 ± 5/54 ± 2 mm Hg (p < 0.001) after ketanserin 
injection (Fig. 3). In contrast. phentolamine (20 mg i.v.) 
had no effect on blood pressure in these patients. Neither 
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FIG. 2. Effects of pretreatment with furosemide or prazosin 
on the hypertensive action of ketanserin (1 0 mg i.v.) in patients 
with essential hypertension. Mean arterial pressure was 114 
± 8 mm Hg in the patients who were to be treated with 
prazosin and 116 ± 6 mm Hg in patients to be treated with 
furosemide. After 1 week of treatment, mean arterial pressure 
was 1 03 ± 6 mm Hg in the prazosin group and 1 02 ± 4 
mm Hg in the furosemide group. (From ref. 3, with permission 
of the American Heart Association.) 
ketanserin nor phentolamine had an effect on heart rate 
in these patients. 
Hand vein sensitivity test 
Intravenous infusion of ketanserin significantly re-
duced the serotonin-induced contraction of the hand veins 
of patients with essential hypertension. whereas it had 
no effect on noradrenaline-induced venoconstriction 
(Figs. I and 4). In four patients the constrictor effect 
of serotonin on hand veins was also studied after oral 
treatment with ketanserin (40 mg t.i.d. for 3 days). Oral 
treatment with ketanserin caused an attenuation of the 
response to serotonin in these patients (Table I). 
Effect on digital blood flow 
After acclimatization for I hat an ambient temperature 
of 22-24°C, the mean temperature of the fingers of II 
FIG. 3. Effects of ketanserin (10 mg i.v.) and phen-
tolamine (20 mg i.v.) on arterial pressure and heart 
rate in four patients with autonomic insufficiency. 
(From ref. 5, with permission of Raven Press.) 
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FIG. 4. Constrictor responses of hand vein to sero-
tonin (left) and noradrenaline (right) in six patient& 
with essential hypertension. 
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patients with Raynaud's phenomenon was 24.2 ± 0.8°C. 
Ten minutes after injection of ketanserin (10 mg i.v.). 
this pathologically low skin temperature rose to 31 .5 
± 0.7°C (Jl < 0.001). The nonselective cr-antagonist 
phentolamine (20 mg i.v.) induced a small increase in 
digital skin temperature. after which ketanserin (I 0 mg 
i.v.) caused an additional rise in digital temperature. 
Chronic oral pretreatment with prazosin did not affect 
basal digital skin temperature. The rise in digital skin 
temperature after injection of ketanserin was comparable 
TABLE I. E.fj'ect l~j' ketanserin on serotonin-induced contractions l~l the dorsal hand vein 
No treatment Kctan:-;crin intravenously Kctanscrin orally 
Patient 
no. SI:I/2N S2: I/2N SJ: I/2N S2: I/2N S3: I/2N S4: I/2N Sl: I/2N S2: I/2N 
0.7 8.7 0 0 2.X 26.7 0.7 1.2 
I.R 3.3 0 0 0 3.6 0.3 0.5 
3 2.3 5.7 0 0 0.2 2.8 0.6 7.R 
4 1.4 5.2 0 0.5 1.8 0.1 1.2 
The response to diifcrcnt dos~:-. of serotonin (S I, S2. S3. and S4) was Jividcd by the mc;.~n rc~pon:-.c ( I/2N) to two do:-.c:-. of noradn:nalinc 
(NI and N2) (sec Fig. 4). The response of the hand vein to serotonin was reduced both after intravcnou:-. and oral admini:-.tr..ttion of 
kctanscrin. 
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FIG. 5. Effect of ketanserin on digital flow in 
a patient with Raynaud's phenomenon without 
pretreatment (left), after phentolamine (20 mg 
i.v., middle), and after chronic oral treatment 
with prazosin (4 mg t.i.d., right). 
to the rise in temperature without pretreatment with prazo-
sin. An example of the effect of ketanserin on digital 
flow is shown in Fig. 5. More detailed results of this 
study have been submitted for publication. 
in digital skin temperature after administration of ketanse-
rin was more pronounced and of longer duration in the 
hand devoid of sympathetic tone (Fig. 6). 
Additional evidence that ketanserin may increase digi-
tal blood flow independently of an a-adrenoceptor-medi-
ated effect was obtained in a patient who underwent a 
complete unilateral· (left -sided) sympathectomy. Increase 
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DISCUSSION 
In the present study, i.v. ketanserin blocked there-
sponse of hand veins to serotonin. Serotonin-induced 
RIGHT HAND 
(no sympathectomy) 
t TIME (min) t 
KETANSERIN 10mg i.v. KETANSERIN 10mg i.v. 
FIG. 6. Effect of ketanserin (10 mg i.v.) on digital skin temperature in a 24-year-old man who underwent a left-sided cervical sympathec-
tomy. The increase in digital flow was more pronounced and of longer duration in the hand without sympathetic tone. 
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venoconstriction was also attenuated during oral treat-
ment with ketanserin. This effect of ketanserin seems 
to be independent of a-adrenoceptors. since i. v. ketanse-
rin did not affect the venoconstrictor response to nor-
adrenaline. 
Also. the increase of digital flow (at least part of it) 
after administration of ketanserin does not seem to be 
mediated by a-actfenoceptors. since the response to ke-
tanserin was not blocked by pretreatment with phentola-
mine or prazosin. Furthermore. o~r observation that ke-
tanserin had a hypotensive eff4ct in patients with 
autonomic insufficiency. who were unresponsive to phen-
tolamine. is an indication that ketaaserin is capable of 
lowering arterial blood pressure independently of a-ad-
renergic blockade. 
The above findings do not exclude that a-adrenoceptor 
antagonism is involved in the blood pressure lowering 
effect of ketanserin in normal and hypertensive subjects. 
In fact. our previous observations that the antihyperten-
sive effect of ketanserin was blunted by pretreatment 
with prazosin may suggest an a-adrenoceptor-mediated 
component (3). However, the findings we report here 
suggest that a-adrenergic blockade is not the sole mecha-
nism of ketanserin's cardiovascular actions. 
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ACUTE EFFECTS AND MECHANISM OF 
ACTION 
OF KETANSERIN 
IN PATIENTS WITH PRIMARY 
RAYNAUD'S PHENOMENON 
SUMMARY 
This study evaluates the vasoactive effects and mode of action of ketanserin, a selective 
5HTz receptor antagonist, on digital circulation in 11 patients with primary Raynaud's 
phenomenon. Reflex digital vasoconstriction was induced by moderate body cooling. We 
found that ketanserin, 10 mg i. v., normalized digital skin temperature and digital blood 
flow estimated by venous occlusion plethysmography and laser-Doppler flowmetry. These 
effects were much more pronounced than with administration of a high dose of the non-
selective alpha- adrenoceptor antagonist phentolamine. In order to differentiate between 
effects of ketanserin on capillary nutritional flow and on arteriovenous (AV) shunt flow, 
digital blood flow was also assessed by transcutaneously measured oxygen pressure 
(TcPOz). Effects ofketanserin on TcPOz were modest. This could imply a preferential 
effect of ketanserin on AV shunt flow. Pretreatment with high doses of the alpha1-selective 
antagonist prazosin and with phentolamine did not diminish the effects of ketanserin on 
digital blood flow. Ketanserin caused a small drop in systemic blood pressure in these 
normotensive subjects. This effect was blunted by pretreatment with the alpha-
adrenoceptor antagonists. We conclude that 5HTz receptors are present in digital blood 
vessels and that the principle mechanism of digital vasodilatation after ketanserin is 
blockade of these receptors. In primary Raynaud's phenomenon activation of these 
receptors plays an important role in cold induced digital vasoconstriction. 
INTRODUCTION 
Primary Raynaud's phenomenon is characterized by episodic reversible vasospasms of 
blood supply to fingers and toes, triggered by cold exposure or emotional stress.(l-4) The 
often severe vasoconstriction has been suggested to be a consequence of overactivity of the 
sympathetic nervous system,(5) but therapy with alpha-adrenoceptor blocking agents has 
been disappointing.(6) 
The circulation of the human digit is complex in that two vascular beds exist in parallel. 
There are large numbers of arteriovenous anastomoses (AVA), on the finger tip in 
particular.(7 ,8) These AVA's play an important role in the temperature regulation of the 
fingers; in a warm environment, they are the major pathway of digital blood flow while 
they are almost closed during cold exposure. The capillary vascular bed supplies the 
nutritional digital blood flow, which must be maintained even during extreme cold 
exposure. If the temperature drop is sufficiently drastic and prolonged, mechanisms 
promoting a decrease in flow through vasoconstriction can be overcome by factors tending 
to cause "cold" vasodilatation.(9,10) 
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Unfortunately our knowledge about this system of multiple interacting and opposing 
forces is very limited. It has been shown that an AVA receives a substantial amount of 
innervation by adrenergic sympathetic nerves (ll) but relatively little information is 
available concerning the contribution of other vasoconstrictor and vasodilator 
mechanisms.(12-15) Moreover much of our thinking about arteriovenous shunt flow in the 
digital vascular bed is based on the difference between total digital blood flow as measured 
by capacitance plethysmography and the clearance rate of subcutaneous deposits of Na131I· 
or 22Na+.(l6,17) The fairly constant clearances ofNami- or 22Na+, in the face of a wide 
range of plethysmographically determined digital flows, have led to the assumption that 
these substances measure capillary blood flow but the evidence for this is rather 
circumstantial. Both substances are electrically charged and chemically active and,'ai high 
flow rates, their clearance is diffusion limited, which makes it hazardous to assume that 
they really measure skin capillary blood flow.(l8) 
In vitro isolated arteries and veins from the hand of healthy humans are contracted by 
serotonin with an intrinsic activity approximately equal to that of noradrenaline and 
adrenaline.(l9) Direct infusion of serotonin into the brachial artery of humans caused a 
drop in the digital temperature and induced the characteristic sequential skin discoloration 
ofRaynaud's phenomenon.(20,21) To date it is unknown whether these effects are 
mediated by changes of arteriovenous shunt flow or capillary blood flow. 
Recently three major subclasses of serotonin receptors haven been identified.(22) 
Contraction of vascular smooth muscle is induced by activation of 5HTz receptors.(23) 
Ketanserin is a selective 5HTz receptor antagonist.(24) Unlike most other serotonergic 
antagonists, it has no partial agonist activity. During its initial clinical evaluation as an 
antihypertensive agent, ketanserin appeared to improve symptoms in patients with 
Raynaud's phenomenon(25-27), raising the possibility of a role for serotonin in this 
condition. However, in addition to its serotonergic antagonist properties, ketanserin inhibits 
alpha-adrenergic receptors.(28) Although it has been shown that ketanserin is capable of 
lowering systemic blood pressure independently of alpha-adrenoceptor blockade, blockade 
of these receptors is likely to contribute to its hypotensive effect. Thus it is possible that the 
beneficial effect of ketanserin on digital blood flow is also related to blockade of alpha-
receptors rather than 5HTz receptors. 
The purpose of the present study was to explore the mode of action of ketanserin in 
patients with primary Raynaud's phenomenon. Changes of digital blood flow after 
ketanserin administration were studied in the presence and absence of alpha1- and 
alphal+z-adrenoceptor blockade. In addition, and maybe more importantly, we have tried to 
determine whether ketanserin's actions concerned arteriovenous shunt flow or capillary 
nutritional blood flow (Fig.l). For this purpose the effects ofketanserin on total finger 
blood flow (digital skin temperature, venous occlusion plethysmography) were compared 
with skin blood flow measurements (laser-Doppler flow, transcutaneous measured oxygen 
pressure). 
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Figure I. 
schematic drawing 
of digital glomus 
(arterio-venous 
anastomosis) 
It tcan,outaneou" p02 laser-Doppler flowmetry 
venous occlusion 
plethysmography 
Schematic drawing of digital cutis with different layers and a glomus, the arteriovenous 
anastomosis that connects subpapillary arterioles and venules. This specialized vascular 
structure is supplied from the subpapillary plexus, which runs in parallel with the skin 
surface. Venous occlusion plethysmography obviously measures total digital blood flow. 
Laser light, after penetrating the layer of keratin, problably will reach the arteriovenous 
anastomes. The papillary layer of the dermis is scanned by the transcutaneous oxygen 
monitor. 
PATIENTS AND METHODS 
PATIENT SELECTION 
Eleven patients with primary Raynaud's phenomenon, nine women and two men, aged 
37± 4 years (mean±SEM), consented to participate in the study which was approved by the 
local Hospital Ethical Review Committee. They were selected from the outpatient clinics 
of the departments of internal medicine and dermatology at the university hospital 
"Dijkzigt". They all had reversible vasospastic attacks in response to cold. History revealed 
that symptoms existed for more than 3 years. After cold provocation all subjects had a 
lower digital skin temperature and longer temperature recovery time than healthy 
volunteers. They fulfilled the clinical criteria of Allen and Brown (29) for classification as 
primary Raynaud's phenomenon. In addition, they had normal physical examinations and 
normal results were obtained by laboratory screening including the absence of serum 
antinuclear antibodies and serum cryoglobulin. Medical treatment, if any, was stopped 
three weeks before the study. The use of a new vasoactivedrug was explained to the 
parients, who all gave their informed consent to the study. 
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STUDY DESIGN 
Patients were seen at three separate sessions, 7-9 days apart, during the period from 
december to march. All investigations were carried out in the morning. Patients came to 
the cardiovascular laboratory after a light breakfast. They had refrained from smoking and 
drinking coffee since the preceding evening. An antecubital vein of the left arm was 
cannulated. Telethermometers and the equipment (see methods) for measurements of 
digital blood flow and transcutaneous oxygen tension were attached to the fingers of the 
right hand. Studies were performed after acclimatization for at least one hour in a 20-21 °·C 
room. The patients were lightly clothed and lay supine on bed. The right hand was held 
stable on a sand bag slightly above heart level. Upon achieving stable baseline values 20 
ml of saline solution (9 g/1) was infused as placebo followed about ten minutes later by 10 
mg ketanserin dissolved in a volume of 20 ml (study 1 ). A week later the same protocol 
was followed but now the injection ofketanserin was preceded by an infusion of 
phentolamine, 20 mg dissolved in a volume of20 ml (study 2). Six patients were then 
given prazosin, t.i.d. orally, for at least one week in increasing maximal tolerable doses and 
then restudied with ketanserin 2 to 3 hours after the last dose of prazosin, which always 
was 4 mg (study 3). 
MEASUREMENTS 
Temperature. 
Digital skin temperature was measured at the volar side of the distal phalanx of digits I, 
II and V by three copperconstantan thermocouples (Telethermometers, Yellow Spring 
Instruments, Cleveland, USA). Seven measurements per finger per minute were taken and 
averaged. 
Venous occlusion plethysmography (VOP). 
Total finger flow was measured by a venous occlusion plethysmograph (Periflow) 
developed by Janssen Scientific Instruments (Beerse, Belgium). The venous occlusion cuff 
was placed just distal of the metacarpophalangeal joint of digit III and intermittently 
triggered by an electrocardiographic signal to inflate to a venous occlusion pressure of 60-
80 mmHg (2 heart beats occlusion, 1 beat release). 
A mercury - in - silas tic strain gauge was placed just distal to the proximal interphalangeal 
joint. Flow readings were estimated from 10 successive pulses. 
Transcutaneous oxygen tension (TcPOz). 
Oxygen diffusing through the skin of the volar surface of digit IV was measured by a 
polarographic technique using a transcutaneous POz sensor (Clark-type electrode) with a 
temperature- regulated heating element (Radiometer TCM-i, monitor, Radiometer, 
Copenhagen, Denmark). The probe was calibrated according to the manual. The skin at the 
measurement site was prepared by rubbing with alcohol and stripping off the stratum 
corneum with adhesive tape. The probe was mounted on the skin via a double-sided 
adhesive ring and a drop of contact gel(Radiometer). The skin below the electrode was 
heated to 44 °C and heat consumption of the probe was measured. At least 30 min was 
allowed to permit TcP02 to stabilize. 
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Laser-Doppler blood flow (LDF) . 
LDF was measured with a Periflux PF lc laser-Doppler flow meter (Perimed KB, 
Stockholm, Sweden). Briefly, the method involves conducting a coherent 2-mW light from 
a Re-Ne laser via a fiber optic light guide to the tissue surface. Reflected light is gathered 
by another set of light guides and processed This procession involves analog computation 
of the power spectral density of shifted light which, in theory, is a linear function of the 
average velocity of moving cells within the tissue. The LDF probe was positioned over the 
distal volar surface of the index finger and held by a black plastic disk supplied by the 
manufacturer. The disk, in turn, was affixed to the skin by an adhesive ring. Special care 
was taken to support the fiber optic cable and to keep the arm stationary. The same gain 
(xS), electronic zero (0 mV, by shining the laser probe on a stationary surface), upper 
frequency cutoff (4kHz), and time constant (3 s) were used throughout the study. Data 
were expressed as arbitrary LDF units (AU), which represent percent values of full-scale 
deflection on the instruments meter. 
STATISTICAL ANALYSIS 
Data are given as means ± SEM. Evaluation of results was done with the t-test for paired 
data (study 1) or the Wilcoxon signed-rank test Statistical significance was set at the level 
of 0.05, with two tailed values for p. 
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RESULTS 
Study 1 Effects ofketanserin (n=ll). 
Moderate body cooling, i.e. one hour at an ambient temperature of 20-21 °C, induced 
severe digital vasoconstriction in our patients. Skin temperature of the digits was low, 
22.8 ± 0.5°C, and measurements of fmger blood flow by venous occlusion plethysmo-
graphy and laser-Doppler flowmetry showed that hardly any blood was entering the digits. 
Compromised skin perfusion was also reflected by low levels of transcutaneous oxygen 
tension (TcP02), 19 ± 3.4 mmHg (normal: 44 ± 5.2 mmHg, n=l4).Ketanserin infusion but 
not saline had a pronounced effect on digital circulation. An example of a typical 
registration is shown in Fig. 2. It illustrates the discrepancy between huge increases of 
temperature and flow in comparison with the modest rise of TcP02. 
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Figure 2. Responses of finger skin temperature,finger blood flow (plethysmography, 
laser-Doppler flux) and transcutaneous oxygen pressure after intravenous infusion of 10 
mg ketanserin are shown for one patient. Digital vasoconstriction was provoked by 
moderate body cooling (room 20°C). Note that transcutaneous oxygen pressure remained 
low despite a pronounced increase in digital perfusion. 
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Fig. 3 summarizes the effects of ketanserin on digital skin temperature of the eleven 
patients studied. Fingertip temperature recovered from 22 ± 0.5 to 31 ± 0.7°C (p< 0.001) 
and the color of the digits changed from white-blue to pink red 
, 
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Figure 3. Response of individual finger skin temperatures to a single intravenous dose of 
10 mg ketanserin in 11 patients with primary Raynaud's phenomenon. Each line 
represents the mean of 3 simultaneous readings (fingers I, II and V). 
Fig. 4 depicts group averages of changes in digital blood flow and TcPOz. Total fmger 
blood flow rose from 8 ± 0.9 to 31 ± 2.2 mVmin per 100 ml tissue (p< 0.001) and 
subpapillary blood flow (laser-Doppler) increased from 9±2 to 45 ± 4 AU. (p< 0.01). In 
contrast, changes of TcPOz were modest. Thirty minutes after ketanserin TcP02 was not 
significantly higher compared to baseline values (19 ± 3.2 versus 23 ± 5.1 mmHg). 
t 10 mo ketanser1n '" t 10 mo ketansenn '" Tune (m~nl 
Figure 4. The effects of intravenous ketanserin (10 mg) on finger skin temperature, skin 
blood flow, total digital blood flow and transcutaneous oxygen in 11 patients with primary 
Raynauds' phenomenon. Changes in temperature, laser-Doppler flux and 
plethysmographic flow were significant (p< 0.01) throughout the observation period. The 
slow rise in transcutaneous oxygen pressure did not reach statistical significance. 
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Pronounced differences in response between individual patients were noted (Fig. 5). 
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Figure 5. Individual values for changes in transcutaneous oxygen pressure and heat 
consumption of the Clark-type electrode after administration of ketanserin. Note the 
biphasic response of heat consumpt 
However a consistent fmding was that after ketanserin heat consumption of the oxygen 
probe first rose and then fell below baseline (Fig. 5). There was no correlation between 
TcPOz and the maximum responses of digital blood flow measured either by occlusion 
plethysmography or by temperature change. After ketanserin systemic blood pressure fell 
from 114 ±4 /71 ± 3 to 108 ±4 /66 ±2mmHg (p< 0.01) and heart rate rose from 69 ±2 
to 76 ± 2 bpm (p< 0.01). 
Study 2 Effects ofketanserin during phentolamine infusion (n=6). 
During the pre-drug period, i.e. during body cooling, digital skin temperature and total 
finger blood flow did not differ significantly from baseline values measured during study 1 
(Table 1). High doses of phentolamine caused significant digital temperature and blood 
flow changes (Table 1, Fig. 6). However these effects were modest as compared to the 
effects of ketanserin in study 1. After phentolamine ketanserin further increased finger 
temperature and flow to the level seen during study 1. However during phentolamine the 
effects of ketanserin on systemic blood pressure and heart rate were blunted. 
Study 3 Effects ofketanserin after pretreatment with prazosin (n=6). 
Pretreatment with high oral doses of prazosin did not prevent digital vasoconstriction 
produced by body cooling (Table 1). Ketanserin, 10 mg i.v., under these circumstances 
increased digital skin temperature and flow to the levels seen during studies 1 and 2 (Fig. 6). 
In the presence of prazosin ketanserin had no effect on systemic blood pressure or heart rate. 
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Table 1. Comparison of measurements made in the six patients who participated in all 
three studies. 
digital skin digital blood blood pressure heart rate 
temp. flow systolic 
(OC) (rnl!min per lOOml) (mmHg) 
study 1 
placebo 25 ± 1.2 8±4 115 ± 3.9 
ketanserin 32±0.5* 33±6* 110±4.4* 
study2 
placebo 24± 1.4 9±4 111 ±4.2 
phentolamine 27±0.8# 18±5# 105±4.7# 
ketanserin 30± 0.9*t:l 31 ±6*t:l 105±6.0* 
study 3 
prazosin 25±0.8 9±4 113±5.4 
ketanserin 31 ± 0.9+ 34±7+ 113 ±6.0 
* p <0.05 ketanserin vs placebo 
# p <0.05 phentolamine vs placebo 
c p <0.05 ketanserin vs phentolamine 
+ p <0.05 ketanserin vs prazosin 
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Figure 6. Effects of ketanserin infusion on digital skin temperature in the presence or 
absence of selective and nonselective alpha-adrenoceptor blockade (n=6). For statistical 
evaluation see Table 1. 
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DISCUSSION 
Ketanserin: serotonergic or alpha-adrenoceptor blockade? 
In agreement with earlier data obtained by us (30) and by others, (25,31-33) the present 
study shows that ketanserin given intravenously has marked effects on digital blood flow in 
patients with Raynaud's phenomenon. In previous work, however, the relative 
contributions of the 5HTz-serotonergic and alphar- adrenergic antagonistic properties to the 
vasodilatory effect ofketanserin have not been assessed. The present study explores this 
issue. We deliberately chose body cooling in the presence or absence of alpha-adrenoceptor 
blockade as the stimulus to decrease digital blood flow. It has been shown that body 
cooling leads to a strong reflex sympathetic vasoconstriction in this particular vascular 
bed.(l2) These effects of the sympathetic nervous system are mediated on specialized 
vascular structures in the digital skin, namely arteriovenous anastomoses (AVA). AVA's 
play an important role in temperature regulation of the body and fingers; in a warm 
environment, they may be the pathway of greater than 80% of the digital blood flow while 
in a cool environment they are almost closed. An AVA and its associated related vessels 
and nerves constitutes a "glomus". Microscopically an AVA can be easily differentiated 
from other vessels by its thick wall surrounding a barely perceptible lumen.(8) By 
comparison a collecting venule is thin walled with a large lumen. The absence of elastic 
membranes in the AVA problably makes that an AVA can close completely. Adrenergic 
nerves are densely spread on the outer surface of the glomus cell layer and their 
innervation resembles a thread densely wound around a bobbin.(ll) 
Under conditions of reflex sympathetic vasoconstriction, however, the increase in digital 
blood flow seen with alphar- or alphar+z- adrenoceptor antagonists is sometimes not very 
large and seldom reaches the flow seen in warm, vasodilated subjects.(34) The present 
study confirms this. Administration of the non-selective alpha-adrenoceptor antagonist 
phentolamine in a dose considered to cause virtually complete alpha-blockade had a 
modest effect on digital blood flow as compared to ketanserin. In contrast, with ketanserin 
the low temperature of the fingers of our patients, during body cooling, returned to normal 
and the white-blue discoloration of the digits changed into pink-red. It is unlikely that these 
effects ofketanserin are due to the weak alphar-adrenoceptor antagonistic property of the 
drug. This conclusion is supported by the fact that ketanserin was able of 
causingvasodilatation also when alphar- adrenoceptors were blocked by high doses of 
prazosin. In addition, ketanserin caused a pronounced further increase in digital skin 
temperature in the presence of alphar+z-adrenoceptor blockade with phentolamine. 
Recently, the differential contribution of alphar-and alphaz-adrenoceptors to contractile 
responses to norepinephrine in human limb arteries was assessed.(35) Proximal (dorsalis 
pedis artery of the foot and superficial palmar arch of the hand) and distal (digital arteries 
of the hand and foot) arteries were obtained from patients undergoing amputation for 
reasons other than vascular disease. In proximal vessels, the alphar-adrenergic antagonist 
prazosin was more potent at inhibiting the responses evoked by high concentrations of 
norepinephrine compared to the alphaz-adrenergic antagonistrauwolscin. In distal blood 
vessels, the responses to norepinephrine were not affected by either prazosin or 
rauwolscine, but were depressed by the combination of the two antagonists. Moreover, it 
has been shown that local conditions can alter the relative importance of the subtypes of 
alpha- adrenoreceptors.(36) For example, cooling caused an instantaneous increase in the 
affinity of postjunctional adrenoceptors for the agonist. This involved however mainly 
alphaz-adrenoreceptors. Thus, from a physiological standpoint the postjunctional alphaz-
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adrenoreceptor may be more important in mediating vasoconstrictor responses during 
prolonged, intense, cold-induced, sympathetic nerve activity than the alpha.J.-
adrenoreceptor. 
Ketanserin is certainly not an alpha2-adrenoceptor antagonist It is a selective 5HT2-
receptor antagonist with some alpha1-blocking properties. Therefore our results indicate 
and confirm that SHT2-serotonergic receptors are present in the digital vasculature. Their 
blockade by ketanserin in "reflex" vasoconstricted patients leads to an important increase 
in digital blood flow. Digital alpha-adrenergic blockade seems not to be essential for this 
action of ketanserin. 
Along other lines of evidence Arneklo-Nobin and Owman (37) came to the same 
conclusion. They tested isolated hand arteries from healthy human subjects for their 
contractile response to noradrenaline and serotonin. Serotonin was as potent on hand 
arteries as noradrenaline, ED 50 being similar for the two substances. Ketanserin 
counteracted the contractions induced by serotonin in a dose-dependent manner but did not 
shift the dose-response curve of noradrenaline, indicating that, at the level of digital 
arteries, ketanserin does not possess affinity for alpha-adrenoceptors. 
In contrast to the effects of ketanserin on the digital vascular bed, pretreatment with 
prazosin or phentolamine abolished the modest blood pressure lowering effect of 
ketanserin in our normotensive Raynaud patients. This is in agreement with our previous 
findings in hypertensive patients.(38) In the systemic circulation a certain degree of alphal-
adrenoceptor blockade may contribute to the hyprtensive effect ofketanserin. However, 
ketanserin is also capable of lowering blood pressure independently of its effects on alpha-
adrenoceptors.In the finger, blockade of serotonergic receptors appears to be the 
mechanism for its vasodilating effect. 
Taken together, our findings indicate that serotonin probably plays an important role in 
cold-induced digital vasoconstriction. The source of serotonin causing this effect is not 
known. Serotonergic nerves like those present in cerebral blood vessels could be involved 
(39) but a more likely source of serotonin appears to be the aggregating blood platelet.(40) 
It has been shown that spiral strips of human digital arteries contract vigorously when 
exposed to a suspension of platelets aggregated by thrombin.( 41) Pretreatment of the 
arteries with ketanserin nearly abolished the contractile response to platelets but did not 
affect the contractile response to potassium chloride. In normal volunteers Cowley et al 
( 42) found a rather close correlation between the maximum reduction of forearm blood 
flow in response to cold and the concentration of sodium arachidonate that was required to 
induce platelets from each individual to aggregate and to liberate serotonin, indicating that 
cold exposure somehow had altered, at least temporarily, platelet behavior. In addition, 
cold-induced reduced blood flow and diminished serotonin degradation could contribute to 
high local serotonin concentrations. 
Ketanserin: AV shunt flow but not nutritional blood flow? 
In contrast to the large increments of digital skin temperature and digital blood flow after 
ketanserin, TcP02, which was very low in most patients, did not reach normal values. In 
some patients TcP02 even fell despite a huge increase in digital blood flow. How to explain 
this discrepancy and for what does it stand? It could mean that ketanserin did have a much 
more pronounced effect on arteriovenous shunt flow than on capillary blood flow. 
However before we accept this explanation, we should know what we actually were 
measuring with the Clark-type electrode. The most important determinants of the 
relationship between P02 and the transcutaneous P02 measured by the probe are 1) the 
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degree of arterialization of the capillary blood in the skin, i.e. the ratio between the mean 
capillary and arterial POz, 2) the diffusion gradient in the epidermal skin layer between the 
capillaries and the surface of the probe, and 3) the rate of Ozconsumption in this layer.(43) 
At a probe and skin temperature of 37°C the transcutaneous POz is much lower than the 
arterial value. However under normal operational conditions the skin below the probe is 
heated to about 44 °C to produce full local vasodilatation. Problably because of complete 
thermic arterialization of capillary blood, TcPOz approaches PaOz. However, when skin 
circulation is compromised as in our patients, PaOz and TcPOz remain dissociated despite 
high probe temperature and full local vasodilatation. 
By analysing the relation between TcPOz and perfusion pressure, Wyss et al (44) and 
Dowd (45) have shown that TcPOz falls in non-linear fashion with decreasing perfusion 
pressure; TcPOz is little affected by changes in the high perfusion range but much more so 
by changes in low perfusion pressures. In other words TcPOz is a sensitive indicator of low 
perfusion pressure.(46) It is this relationship between TcPOz and perfusion pressure we 
tried to explore in the assessment of ketanserin's mode of action. After ketanserin the heat 
consumption of the probe rose temporarily, indicating that heat under the probe was 
leaking away, problably as a consequence of an increase of skin blood flow. In addition, 
laser-Doppler flowmetry showed that blood flow in the subpapillary vascular bed of the 
skin did increase markedly after ketanserin. Despite these effects, the Clark-type electrode 
did not pick up more oxygen. A possible explanation could be that the huge increase in 
subpapillary blood flow after ketanserin somehow shunted the diffusion pathway of 
oxygen away from the electrode. Furthermore, the rise in skin temperature after ketanserin 
problably caused the epidermal oxygen consumption to increase. Unchanged values for 
TcPOz therefore do not indicate that no more oxygen was delivered but that rather the 
delicate balance between oxygen demand and supply was not altered by ketanserin. 
Unfortunately our knowledge about the multiple factors that affect the measurement of 
TcPOz under the experimental conditions of the study is far too limited to draw a firm 
conclusion. Vital microscopy of nailfold capillaries during ketanserin infusion may give a 
better insight in what really is going on in the microcirculation of the finger. It has been 
shown in a small series of patients with primary and secondary Raynaud's phenomenon 
(47) that oral treatment with ketanserin did increase capillary red blood cell velocity before 
and after cold provocation. However this increase in capillary perfusion was found only in 
a minority of patients. 
In conclusion, our findings are consistent with the hypothesis that in patients with 
primary Raynaud's phenomenon serotonin is involved in cold-induced digital 
vasoconstriction. The results of long-term placebo-controlled studies of the potential 
therapeutic usefulness of ketanserin in this condition are under way. 
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SUMMARY AND 
CONCLUSIONS 
Over the past decade, a great deal of clinical research of our group has been directed 
toward two major areas of the pathophysiology of hypertension: (1) the significance of the 
renin-angiotensin system; and (2) the role of serotonin. Serotonin was identified by Irvin 
Page as, in his words, a "nuisance factor" interfering with his attempt to isolate and identify 
angiotensin II,in which he fortunately succeeded. The first part of this thesis deals with 
clinical aspects of Page's second moiety, angiotensin II, and the enzymatic cascade 
involved in its formation. The second part of the thesis entertains the idea that the 
"nuisance factor" serotonin deserves more clinical attention than it had enjoyed in the past. 
PARTl 
ACE INHIBITION 
CHAPTER 1 
Chapter 1 of this thesis brings together studies which deal with the specificity of 
captopril's mode of action. We have tried to clarify whether or not pretreatment plasma 
renin is an important predictor of the blood pressure response to ACE inhibition. Renin has 
since long been suspected to play a role in the pathophysiology of hypertension, especially 
in patients with high levels of circulating renin and severe hypertension associated with 
renal and/or renovascular disease. Indeed captopril proved to be highly effective in this 
category of patients (Atkinson 1980). Unexpectedly, captopril was also effective in patients 
with milder forms of hypertension including patients with low levels of circulating renin 
(DeBruyn 1981, Vidt 1982, Veterans Administration Cooperative Study Group 
1983).These findings have aroused many questions. 
On theoretical grounds it seems more logical to use the plasma level of angiotensin II 
rather than renin as a measure of the activity of the renin-angiotensin system in vivo. 
Unfortunately, the plasma levels of angiotensin II are very low, a few picograms per ml, 
and the antibodies that are used in the radioimmunoassay crossreact with degradation 
products of angiotensin II. Angiotensin II measurements are therefore difficult to perform, 
and, until recently, unreliable in the low range. 
In clinical practice plasma renin activity (PRA) is generally accepted as a measure of the 
formation of angiotensin II in vivo. In the PRA assay, plasma of the patient is incubated at 
37°C. During this incubation in vitro, renin is catalysing the generation of angiotensin I 
from renin substrate. Plasma however has angiotensinase activity, by which angiotensin I is 
hydrolysed. This degradation of angiotensin I can be prevented by the addition of 
angiotensinase inhibitors. These substances, however, also inhibit angiotensin converting 
enzyme. The reaction stops therefore at the generation of angiotensin I. Angiotensin I is 
measured by radioimmunoassay. Under normal circumstances the plasma concentration of 
renin substrate (angiotensinogen) equals the Km value, which means that the generation of 
angiotensin I not only depends on the concentration of renin but also on the concentration 
of renin substrate. 
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The interpretation of PRA measurements is difficult in circumstances where the 
concentration of substrate is not normal (nephrectomized subjects, patients with heart 
and/or liver failure). Techniques were therefore developed, in which the reaction velocity 
in vitro is independent of the substrate concentration. In these assays endogenous substrate 
is selectively destroyed and an excess of purified substrate is added. The generation of 
angiotensin I then only depends on the concentration of renin. 
The quantities of angiotensin I generated in this type of assay of plasma renin 
concentration (PRC) appeared to be much greater than with the PRA method. In the PRC 
method the plasma is acidified (pH 3) in order to destroy the endogenous substrate. The 
increase in renin activity with acidification appeared to depend on the activation of an 
enzymatically inactive form of renin. It has been suggested that this socalled inactive renin 
is a proenzyme (prorenin) and that the activation is caused by pH dependent limited 
proteolysis. It appeared that about 90 percent of renin in plasma is in the inactive form, 
which is now known to be the biosynthetic precursor of renin, prorenin. These observations 
have important consequences for both the technical procedure and interpretation of plasma 
renin determinations. In our studies we report on active renin (or renin) and total renin 
(renin plus prorenin) concentration. 
We found that plasma converting enzyme activity is inhibited by more than 90 percent 
from 60 minutes up to four hours after a single oral dose of 50 mg of captopril. Active 
renin rose within 60 minutes after the first dose,and it remained high with chronic 
treatment. In contrast, prorenin fell initially and rose after four hours. Blood pressure 
reduction was maximal60-90 minutes after captopril both in patients with essential 
hypertension and in renovascular hypertension. A similar time course of blood pressure 
response was observed in patients with chronic heart failure (very high plasma levels of 
active renin). Blood pressure came also down in fluid-depleted nephrectomized subjects 
(active renin approximately zero,inactive renin approximately normal), although the 
response rate was more sluggish. 
The percent changes in blood pressure after ACE inhibition were not much different in 
these groups of patients despite large differences in the level of plasma active renin. Weak 
correlations of acute changes in bloodpressure with pretreatment plasma renin were found 
but they were absent with chronic treatment. The relation between renin and changes in 
resistance was sligthly better but clinically of no importance. 
Most of the circulating angiotensin II originates from angiotensin I-II conversion by 
ACE that is located at the luminal surface of endothelial cells lining the capillaries, 
particularly those in the lung. Conversion also occurs in circulating plasma. From our 
clinical observations we conclude that inhibition of ACE at these two sites is not the only 
mechanism by which captopril and ramipril exert their antihypertensive action. Originally 
ACE inhibitors were thought to act mainly through blockade of the circulating renin-
angiotensin system. Our observations, however, indicate that other mechanisms must play 
a role. 
A likely alternative explanation for the antihypertensive effect of ACE inhibitors is 
inhibition of ACE at the tissue level, resulting in diminished local formation of angiotensin 
II. Such inhibition has been demonstrated in animals to occur in blood vessels, kidneys, 
adrenals and the brain. Recently, the complete renin-angiotensin system has been 
demonstrated in several cell cultures, including neuroblastoma, juxtaglomerular cells, 
adrenal cells, endothelial cells and vascular smooth muscle. Our studies contribute to the 
growing evidence that local angiotensin II formation within some critical tissues is 
involved in blood pressure regulation. However, effects of ACE inhibitors on other systems 
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than the renin-angiotensin system, e.g. the prostaglandin- and the .kallikrein-kinin systems, 
cannot be excluded. 
CHAPTER2 
According to Page good research often originates from shrewd clinical observation. We 
would like to agree with him. Looking at relationships between pretreatment plasma active 
renin and the haemodynamic response to ACE inhibition, we were struck by the beneficial 
haemodynamic effect of a single gift of captopril in hypertensive patients who appeared to 
be in some state of heart failure (Swan-Ganz catheter positioned for other reason, i.e. 
measurement of cardiac output). This prompted us to go to heart failure. The results of an 
open study with captopril in patients with severe acute and treatment resistant chronic heart 
failure are presented in this chapter. We showed the sustained effectiveness of captopril in 
these patients. Cardiac output was raised and heart rate, arterial, pulmonary-wedge and 
pulmonary arterial pressure were reduced. Clinical improvement was often impressive. 
Nowadys ACE inhibition is considered to be a major advance in the treatment of heart 
failure. 
CHAPTER3 
In the first paper of this chapter we presented evidence that prorenin is a biosynthetic 
precursor of active renin and that, at least under certain circumstances, a major proportion 
of circulating prorenin originates from the kidney. In addition we found that changes in 
release ofprorenin and active renin after ACE inhibition did not run in parallel. The 
findings indicate that prorenin and renin are secreted via different pathways. The renin 
pathway is rapidly responsive to the stimulation of ACE inhibition (interruption of the 
negative feedback by angiotensin II), whereas the prorenin pathway is slowly responsive to 
this stimulus. This is compatible with the view that an acute stimulus only causes the 
release of intrarenally stored renin, whereas chronic stimulation causes in addition 
increased intrarenal synthesis and activation of renin. While the relative amounts of active 
and inactive renin released were variable, and conversion of inactive to active renin was 
also variable, our findings indicate that the classical "PRA" as such, which does not take 
into account concentrations of substrate or prorenin, has lost much of its meaning. 
In the last two papers of chapter 3 we present evidence that angiotensin II, either 
circulating or locally formed within the kidney, has an important function in maintaining a 
normal glomerular filtration, at least in patients with renovascular hypertension. After 
blocking the formation of angiotensin II by ACE inhibition, glomerular filtration rate of the 
stenotic kidney fell in all patients. In some of them the affected kidney even stopped 
filtering. Fortunately, function of the affected kidney returned on discontinuing treatment. 
Thus, we are left with a rather unexpected if not totally new perspective. ACE inhibitor 
therapy has originally been advocated for those forms of hypertension where circulating 
renin is high, i.e. renovascular hypertension. However, it appears that in these 
circumstances ACE inhibitor therapy can have major deleterious effects on renal function. 
Fortunately this is an infrequent and reversible complication. On the other hand we now 
know, in part because of our own studies, that ACE inhibitors are very effective in essential 
hypertension, despite that the levels of circulating renin and angiotensin II are normal or 
even low. 
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CHAPTER4 
Evidence concerning the clinical utility of a single dose captopril in the diagnosis of 
renovascular hypertension was evaluated in the first paper of this chapter. Our study 
included 179 consecutive hypertensive patients who were less than 40 years old with a 
diastolic blood pressure of greater than 120 mmHg or who had hypertension that was 
uncontrolled (greater than 100 mmHg) on at least three drugs. Sodium intake was 
controlled and antihypertensive medication was discontinued for at least two weeks. 
Patients received 50 mg of captopril after one hour in a recumbent position and had renin 
samples taken at -30, 0, 60, 120, and 240 minutes. All patients had an arteriogram after the 
captopril study. Defmition of a positive captopril test was determined retrospectively by 
finding the best balance between sensitivity and specificity of the various criteria from an 
ROC curve. 
Using this method an abnormal test was defined as a plasma active renin concentration 
of greater than 200 J.LU/ml one hour after captopril. The sensitivity and specificity of this 
defmition were calculated as 0,93 and 0,84, respectively. We concluded that a one hour 
post 50 mg captopril renin is a useful criterion for selecting patients for angiography, at 
least in a hypertension referral clinic where a population of patients is seen with a 
relatively high prevalence of renal artery stenosis and also with the proviso that the same 
inclusion criteria for testing are used as in our study. 
The second paper of this chapter deals with the diagnostic value of renal vein renin 
sampling. We used a new immunoradiometric assay to measure renin and we stimulated 
the secretion of renin prior to sampling by giving an ACE inhibitor. Our study included 116 
patients with unilateral renal artery stenosis and 160 patients with normal renal arteries. 
The renal vein-to-artery renin ratios obtained with the new direct assay proved to be as 
reliable as those provided by the more laborious indirect assay. In our group of patients 
with renal artery stenosis more than 90% had a renal vein-to-artery renin ratio on the 
affected side of 1,5 or more. In patients with normal renal arteries the ratio was always< 
1.5. Thus renal vein renin measurements appeared to have little additive diagnostic power 
over angiography, at least in patients with unilateral renal artery disease. 
CHAPTERS 
The purpose of this study was to assess and to compare in the same patient, a twice-daily 
dosing regimen of captopril with a once-daily dosing regimen of enalapril. The principal 
measure of treatment efficacy was its effect on 24-hour blood pressure profiles using an 
ambulatory non- invasive blood pressure measuring device. The mean of casual office 
blood pressures and heart rates during captopril and enalapril treatment were not 
significantly different. Unexpectedly, 24-hour blood pressure profiles demonstrated that 
enalapril caused a more sustained and consistent blood pressure reduction than captopril, 
particularly during late afternoon and evening. The dose of captopril used and the twice-
daily administration were, however, sufficient to reduce blood pressure at night and during 
the early morning. We related this temporary lack of blood pressure control in the late 
afternoon and evening with captopril to an effect of food intake on the amount and/or rate 
of drug absorption. We concluded that with captopril vigilance regarding the minimal 
effective dose and the dosage interval is inorder. The postulate that cumulative inhibition of 
tissue ACE allows dosing regimens independent of inhibition of serum ACE needs further 
clarification. 
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PART2 
SEROTONIN ANTAGONISM 
CHAPTER6 
The first paper of chapter 6 did set the stage for our own "serotonin story". In a rather 
provocative study we reported that the selective S-HT2 receptor antagonist ketanserin, 
given intravenously, caused a distinct fall in supine systemic arterial, right atrial, 
pulmonary artery, and pulmonary capillary "wedge" pressures. Cardiac output, renal blood 
flow, and glomerular filtration rate showed no persistent changes. Thus the fall in elevated 
blood pressure after ketanserin was due to a fall in total peripheral resistance. We 
concluded, rather preliminary, that ketanserin may unmask a role for serotonin in 
maintaining high blood pressure. 
The second paper examined long-term effects of ketanserin. We found that ketanserin 
lowered systolic and diastolic pressure during the day and at night, but did not modify the 
circadian blood pressure pattern. Ketanserin had no effect on heart rate. Although the fixed 
dose of 40 mg b.i.d. may not have been optimal in all patients, the continuous blood 
pressure measurements showed an effect that lasted for the full 24-hour period.If patients 
in whom diastolic pressure fell by more than 10% were considered to be responders, then 
about half of our patients were responders. 
CHAPTER 7 
The mechanism of action of ketanserin is the subject of the two papers of this chapter. 
We found that ketanserin, in a dose (10 mg intravenously) that lowered blood pressure, did 
not alter the pressor effects of bolus injections of the alphru -adrenoceptor agonist 
phenylephrine. Thus in man we could not confrrm important alphar-adrenoceptor blockade 
by ketanserin. Furthermore, ketanserin had a distinct hypotensive effect in 4 normotensive 
patients with autonomic insufficiency due to an efferent sympathetic lesion, who were 
unresponsive to alpha-adrenoceptor blockade. 
On the other hand, it appeared that the antihypertensive effect of ketanserin was blunted 
by pretreatment with high doses of prazosin but not by frusemide. Therefore, we proposed 
that a certain degree of alphar-adrenergic tone seems to be required for ketanserin to exert 
its full antihypertensive action. This may be related to the alleged amplifying effect of 
serotonin on alphru-adrenoceptor mediated vasoconstriction. 
CHAPTERS 
Rather by serendipity we found that ketanserin appeared to improve digital blood flow in 
a few patients with hypertension and concomitant Raynaud's phenomenon. We confirmed 
this beneficial effect in a later study including 11 patients with primary Raynaud's disease. 
We found that ketanserin given intravenously in a dose of 10 mg normalized digital skin 
temperature and digital blood flow as estimated by venous occlusion plethysmography and 
laser-Doppler flowmetry. Effects however on transcutaneously measured oxygen tension 
were modest. This could imply a preferential effect ofketanserin on arterio-venous shunt 
flow rather than on nutritional blood flow. 
149 
Pretreatment with high doses of selective and non- selective alpha-adrenoceptor 
antagonists did not abolish the effects ofketanserin on digital perfusion. We concluded that 
serotonergic type 2 receptors are present in the digital vasculature. In patients with 
Raynaud's disease, their activation plays an important role in cold- induced digital 
vasoconstriction. 
CONCLUSION 
The aim of this thesis was to answer the question of how angiotensin converting enzyme 
inhibitors and the serotonin antagonist ketanserin contribute to blood pressure 
normalisation. However it must be apparent from our clinical pharmacological data that the 
role of angiotensin and serotonin in the cardiovascular system is far more complex than 
ever imagined. Our clinical experiments do not allow us to draw sweeping, 
straightforward, conclusions as to the exact roles of these alleged bloodbome agents in the 
pathogenesis of hypertension. 
The fact is that our pharmacological probes were no razorblade-like knifes for dissecting 
the numerous physiological mechanisms involved. In spite of this difficulty, our results 
have contributed to a better insight in these mechanisms. Particularly, these studies have 
shown that the levels of the circulating components of the renin-angiotensin are not the 
only determinants of the hypertensive action of this system. In addition the studies have 
demonstrated the effectiveness of angiotensin converting enzyme inhibitors in 
hypertension and heart failure. Our studies were also useful in highlighting some 
unexpected effects of ACE inhibitors on the kidney, effects that can be made use of in the 
diagnostic work-up of renovascular hypertension. 
Our experience with the serotonin antagonist ketanserin suggests a role for serotonin in 
essential hypertension. It is problably the combined antagonistic action ofketanserin on 
S-HT2- and a1-receptors that is responsible for its blood pressure lowering effect. 
Furthermore, our results indicate that ketanserin is a promising drug for treating Raynaud's 
phenomenon. 
We should remember that in the past we could not find out how diuretics and 
be tab locking agents reduce blood pressure. Today, we have to admit that the exact mode of 
action of ACE-inhibitors and serotonin antagonists also rests on the knees of the gods. 
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SAMENVATTING EN 
CONCLUSIES 
INLEIDING 
Al bijna honderd jaar is bekend dat in ons bloed stoffen circuleren die 
bloeddrukverhogend werken. Tigerstedt en Bergman (1898) maakten waterige extracten 
van nieren van konijnen en spoten het verkregen extract in bij nierloos gemaakte andere 
konijnen. De mode van hun tijd volgend, waren zij op zoek naar een soort 
verjongingselixer maar vonden dat hun niersap bloeddrukverhogend werkte. Zij noemden 
hun extract renine. 
Wij weten nu dat dit uit de nier afkomstige, in het bloed circulerende, renine als zodanig 
geen effect heeft op de bloeddruk maar een onderdeel is van een ingewikkeld enzym 
systeem dat uiteindelijk verantwoordelijk is voor de vorming van het sterk 
bloeddrukverhogende eiwit angiotensine II. Deze uitvinding werd tegelijkertijd, maar 
onafhankelijk van elkaar, gedaan door de Amerikaanse dokter Irvin Page en de Argentijnse 
fysioloog Braun-Menendez. 
Bij zijn speurtocht naar angiotensine had Page veellast van de storende invloed die 
gestold bloed, serum, had op zijn experimenten. Gebruik van ontstold bloed, plasma, gaf 
geen problemen. Daarom isoleerde hij eerst de storende, bij stalling vrijkomende, faktor en 
noemde de gevonden stof serotonine. Kort daarop ontdekte hij het eindprodukt van de 
renine cascade, angiotensine. De afgelopen 40 jaar nam onze kennis over het renine-
angiotensine systeem exponentieel toe. Met serotonine konden de onderzoekers na een 
ogenschijnlijk flitsende start niet goed uit de voeten. 
VRAAGSTELLING 
De in dit proefschrift gebundelde en reeds elders gepubliceerde artikelen ("publish or 
perish") gaan over de twee bloeddruk verhogende "tonines" van Irvin Page, angiotensine 
en serotonine. Onze klinische interesse in deze stoffen werd namelijk gewekt door het in de 
zeventiger en tachtiger jaren ter beschikking komen van geneesmiddelen die het mogelijk 
maakten om zowel in het renine- angiotensine als in het serotonine systeem in te grijpen. 
Aan de introduktie van remmers van de aktiviteit van het renine ahgiotensine systeem 
ging grensverleggend industrieel-farmacologisch onderzoek, o.a. door Squibb Laboratories 
in de Verenigde Staten, vooraf. Het bleek mogelijk met listig "geconstrueerde" 
geneesmiddelen, waarvan de angiotensine converting enzyme (ACE) remmer captopril het 
prototype is, de vorming van angiotensine II in de renine-enzyme cascade te voorkomen. 
Meer bij toeval, maar toch niet zonder verdienste, werd door Janssen Pharmaceutica een 
stof ontdekt, ketanserin genaamd, die ervoor bleek te kunnen zorgen dat het uit 
bloedplaatjes afkomstige serotonine een deel van zijn werk, vemauwen van bloedvaten, 
niet kan doen. Ketanserin werd farmacologisch gekarakteriseerd als een zgn. competatieve, 
selectieve, serotonine type 2 receptor antagonist. 
Na uitvoerig over leg met de Ethische Commissie van ons ziekenhuis kregen wij 
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toestemming deze prototypes van nieuwe generaties van geneesmiddelen toe te dienen aan 
patienten met uiteenlopende vasculaire pathologie. Het spreekt voor zich dat de betrokken 
patienten tevoren duidelijk werden ingelicht 
Deel 1 van het proefschrift gaat over de ervaring die wij opdeden met verschillende ACE 
remmers. Wij trachten met deze geneesmiddelen als het ware te "sonderen" (geneesmiddel 
als onderzoeksinstrument) hoe aktief het renine-angiotensine systeem is bij patienten met 
verschillende vormen van verhoogde bloeddruk en bij patienten met insufficiente 
hartswerking. 
In het tweede deel van de thesis komt blokkade van de vasculaire serotonine receptor aan 
de orde. Met ketanserin probeerden wij de rol van serotonine in het cardiovasculaire 
systeem te ontmaskeren. 
DEELl 
ANGIOTENSIN£ CONVERTING ENZYME (ACE) 
REMMING 
HOOFDSTUKl 
ACERE~GENPLASMARENThffi 
Roofdstuk 1 gaat over hoe de ACE remmer captopril de bloeddruk verlaagt We gingen 
na of de activiteit van het renine-angiotensine systeem, zoals dat in een reageerbuis wordt 
gemeten, voorspellende waarde heeft voor de mate van bloeddrukdaling na inname van 
captopril. Wij bestudeerden patienten met sterk uiteenlopende plasmaspiegels van renine: 
(1) haemodialysepatienten zonder nieren, bij wie het plasma vrijwel geen enzymatisch 
actief renine bevat, (2) patienten met essentiele hypertensie met lage tot normale plasma 
renine spiegels, (3) patienten met hoge bloeddruk veroorzaakt door een vernauwing van de 
nierslagader met normale tot hoge renine spiegels en tenslotte, (3) patienten met een 
ernstige storing van de hartfunktie bij wie plasma renine spiegels extreem verhoogd 
bleken. 
Op theoretische gronden lag het meer voor de hand om niet de plasmaspiegel van renine 
maar die van angiotensine II te hanteren als maat voor de activiteit van het renine-
angiotensine systeem in vivo. Immers, het is niet renine maar angiotensine II dat krachtige 
bloeddrukeffecten heeft. Praktisch stuitte dit echter op grote problemen omdat de 
concentratie van angiotensine II in plasma zeer laag is, enkele picogrammen per ml, en de 
bij de radio-immunoassay gebruikte antilichamen behalve met angiotensine II ook met de 
in het plasma aanwezige niet actieve afbraakproducten van dit peptide reageren. 
Voor klinisch gebruik is de bepaling van de zogenaamde plasma renine activiteit (PRA) 
nog steeds de meest gebruikte maat voor de vorming van angiotensine II in vivo. Bij 
bepalingen van PRA wordt het plasma van een patient gedurende een bepaalde tijd 
geincubeerd bij 37°C. Tijdens deze incubatie in vitro wordt door de enzymatische werking 
van renine op renine substraat (angiotensinogeen) het biologisch niet actieve peptide 
angiotensine I gevormd. Plasma echter heeft angiotensinase activiteit, waardoor 
angiotensine I wordt afgebroken. Dit wordt voorkomen door remmers van angiotensinase 
aan het plasma toe te voegen. Deze stoffen remmen echter ook de omzetting van 
angiotensine I in angiotensine II, zodat de reactie stopt bij de vorming van angiotensine I. 
Ret gevormde angiotensine I wordt bepaald met behulp van een radio-immunoassay. Ret 
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zal duidelijk zijn dat wij de activiteit van het renine-angiotensine systeem dus slechts heel 
indirect konden benaderen. 
Onder normale omstandigheden ligt de concentratie van renine substraat in plasma op 
het niveau van de Km waarde, hetgeen betekent dat de snelheid waarmee angiotensine I 
wordt gevormd niet alleen afhankelijk is van de concentratie van renine maar ook van die 
van renine substraat. Dit zou geen probleem zijn wanneer de substraat concentratie altijd 
constant en in overmaat aanwezig was. Helaas bleek dit niet het geval. Bij patienten zonder 
nieren is de substraatconcentratie sterk verhoogd, bij patienten met hart- en leverfalen vaak 
zeer laag. Dit bemoeilijkt de interpretatie van PRA bepalingen. 
Om de reaktiesnelheid van renine in vitro onafhankelijk van de substraatconcentratie te 
maken ontwikkelden wij, in navolging van anderen, bepalingsmethoden waarbij het 
endogene substraat wordt gedenatureerd. Hiema wordt een grote overmaat gezuiverd 
substraat toegevoegd, zodat het enzym renine verzadigd is met substraat. De concentratie 
van renine op deze wijze bepaald, PRC, leek een nauwkeuriger maat dan de PRA bepaling. 
Het bleek echter dat bij de PRC bepaling meer angiotensine I wordt gevormd dan bij de 
PRA bepaling. Dit verschil bleek te berusten op de aanwezigheid in plasma van een 
enzymatische inactieve vorm van renine dat tijdens de bepaling ten dele geactiveerd wordt. 
Gaandeweg werd duidelijk dat ongeveer 90% van het bij gezonde personen in plasma 
aanwezige renine zich in de enzymatisch inactieve vorm (prorenine) bevindt en dat het 
renine angiotensine systeem in dit opzicht veel meer lijkt op andere enzymsystemen zoals 
het stollingssysteem dan op hormonale systemen waarbij het pro-hormoon niet in plasma 
circuleert. Het zal duidelijk zijn dat deze biochemische waamemingen belangrijke 
consequenties hebben voor de klinicus practicus die op zoek is naar een relatie tussen de 
activiteit van het renine angiotensine systeem en het bloeddruk verlagend effect van een 
geneesmiddel dat de activiteit van dit systeem remt. In ons onderzoek werd zowel gekeken 
naar actief renine als naar prorenine. 
Captopril bleek een effectieve remmer van de activiteit van het angiotensine converting 
enzyme (ACE). Na de orale inname van 50 mg captopril bleek reeds na 30 minuten 
belangrijke blokkade aantoonbaar, die enkele uren aanhield. Door het wegvallen van de 
vorming van angiotensine II steeg de concentratie aan actief renine (wegvallen van 
negatieve terugkoppeling) en deze concentratie bleef hoog tijdens chronische toediening. 
De sti jging van actief renine ging aanvankelijk gepaard met een daling van prorenine, maar 
later steeg ook de concentratie van dit proenzyme. Merkwaardigerwijs verschilde de 
bloeddruk response op captopril niet veel tussen de verschillende groepen patienten 
ondanks sterk uiteenlopende biochemische activiteit van het circulerende renine 
angiotensine systeem. Ook correlaties tussen daling in vaatweerstand na toediening van 
captopril en actief renine waren gering. 
Wij trokken de conclusie dat het niet blokkade van het circulerend renine-angiotensine 
systeem is dat bepaald in hoeverre de bloeddruk daalt na ACE inhibitie, maar dat 
bijkomende mechanismen een rol moesten spelen. Mede geinitieerd door onze klinische 
bevindingen, maar ook door die van anderen, werd de afgelopen jaren intensief gezocht of 
componenten van het renine-angiotensine systeem ook buiten de bloedsomloop konden 
worden aangetoond. Dit bleek het geval. De hele renine cascade werd o.a. aangetroffen in 
de vaatwand, het hart, denier en in de hersenen. Het zou goed kunnen zijn dat ACE 
remmers de bloeddruk verlagen door blokkade van dit weefsel renine-angiotensine 
systeem. Vooral in die gevallen waarbij na ACE remming wel de bloeddruk daalt maar 
activiteit van het circulerend renine- angiotensine systeem nauwelijks aantoonbaar is 
(nierloze patienten, patienten met zgn. essentiele hypertensie). 
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HOOFDSTUK2 
ACE REMMING EN FALENDE HARTSWERKING 
Page heeft eens gezegd dat nauwkeurige klinische observaties vaak ten grondslag liggen 
aan belangrijk:e vooruitgangen in de geneesk:unde. Dat deze uitspraak k:oren op de molen is 
van deze medicus practicus promovendus hoeft geen betoog. Onze klinische researchgroep 
was even betrok:k:en bij zo'n plotselinge vooruitgang. Tijdens het onderzoek: met captopril 
bij patienten met verhoogde bloeddruk: maak:ten wij gebruik: van een catheter die werd 
gelegd in de longcirculatie. Dit om vullingsdruk:k:en van bet hart te meten en bet 
hartminuutvolume te bepalen teneinde te kunnen vaststellen wat het effect was van 
captopril op de to tale vaatweerstand in bet lichaam. Deze invasieve metingen maakten 
duidelijk: dat sommige patienten op de grens van hartfalen balanceerden zonder dat daar bij 
lichamelijk onderzoek: veel aanwijzingen voor waren. Na toediening van captopril werd bij 
deze patienten sterke verbetering van de hartswerk:ing waargenomen. 
Dit bracht ons ertoe captopril te geven aan patienten met een veel ernstiger 
pompfunktiestoornis van het hart, al hoewel hartfalen toen nog niet als een indicatie voor 
ACE remming werd gezien. De studie werd uitgevoerd in nauwe samenwerk:ing met de 
cardiologische staf van bet Thoraxcentrum. De resultaten van dit onderzoek zijn 
beschreven in dit hoofdstuk. Captopril had een verrassend gunstig effect op de falende 
hartswerk:ing van deze patienten. Ook: na langduriger toediening van captopril bleef deze 
verbetering bestaan. 
Wij waren niet de enigen die dit verrassend effect van ACE remming waarnamen. Een 
stroom van publicaties volgde. De onze was er een van. ACE remming wordt nu als een 
belangrijk:e aanwinst gezien bij de vaak: medicamenteus moeizame behandeling van 
hartfalen. 
HOOFDSTUK3 
ACE REMMING EN DENIER 
In het eerste artikel van dit hoofdstuk wordt aannemelijk gemaak:t dat inactief renine een 
biosynthetische voorloper is van actief renine, en dat, althans onder bepaalde 
omstandigheden, een belangrijk deel van het circulerend inactief renine (prorenine) 
afk:omstig is uit denier. Verder vonden wij dat tijdens blok:k:ade van ACE de secretie van 
inactief en actief renine door de nier niet parallel verliep. Tevens bleek dat de nier 
waarschijnlijk: in staat is om circulerend inactief renine om te zetten in de actieve vorm. 
Deze ingewikkelde, variabele, verhouding tussen actief en inactief renine maak:te duidelijk 
wat een geringe betekenis moet worden toegekend aan de "gewone" renine bepaling (PRA) 
die geen rek:ening houdt met inactief renine. 
In de laatste twee artik:elen van dit boofdstuk k:omen de effecten van ACE inbibitie bij 
patienten met een eenzijdige vernauwing van de nierslagader aan de orde. Na ACE 
inhibitie stelden wij een belangrijk nierfunktieverlies vast van de aangedane nier. Wij 
k:wamen dit nadelig effect op bet spoor door gescbeiden nierfunktieonderzoek: te 
verricbten. Deze waarnemingen onderstrepen welk een belangrijke, lokaal-renale, rol 
angiotensine II speelt bij bet instand bouden van de filterfunktie van een nier die te lijden 
heeft van een verminderde bloeddoorstroming. 
Deze gegevens openden een onverwacht paradoxaal perspectief. ACE remmers werden 
ontwikkeld voor die vormen van hoge bloeddruk:, zoals tengevolge van een vernauwing 
van een nierslagader, waarbij bet renine angiotensine zeer actief is. J uist in deze gevallen 
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stelden wij vast dat remming van ACE problemen met de nierfunktie kan geven. Daar staat 
tegenover dat ACE remmers zeer werkzaam bleken zonder dat van een uitgesproken 
activiteit van het circulerende renine angiotensine systeem sprake is. Er zal nog veel water 
door de Maas gaan voor deze paradox ten volle is begrepen. 
HOOFDSTUK4 
ACE REMMING ALS DIAGNOSTICUM 
Diagnostiek van renovasculaire hypertensie en de rol die ACE remming hierbij kan 
spelen is het onderwerp van de twee artikelen in dit hoofdstuk. Captopril bleek de renale 
renine secretie van patienten met een nierarteriestenose in belangrijke mate te kunnen 
stimuleren. De na ACE remming gemeten perifere plasma renine spiegels bleken beter te 
kunnen voorspellen dat een patient lijdende is aan een vemauwing van een nierslagader 
dan mogelijk was op grond van niet gestimuleerde renine waarden. De sensitiviteit, 
specificiteit en voorspellende waarde van de "captopril renine test" (onderzoek bij 179 
patienten) bleken van dien aard dat de test een plaats verdient bij de diagnostiek van 
renovasculaire hypertensie. 
Of het tevens noodzakelijk is voor diagnostiek bloed te bemonsteren voor een renine 
bepaling uit de niervenen van patienten met een nicrarteriestenose is het onderwerp van het 
tweede artikel. Bij dit onderzoek maakten wij gebruik van een nieuwe 
immunoradiometrische renine bepaling (monoclonaal antilichaam gericht tegen het actieve 
deel van het renine molecuul), die wij vergeleken met onze standaard bepaling. 
Wij stimuleerden de renale renine secretie met een gift captopril. De nieuwe, snellere, 
bepaling bleek betrouwbaar maar niervene renine bemonstering als zodanig bleek weinig 
bij te dragen aan de diagnostiek van renovasculaire hypertensie. 
HOOFDSTUKS 
ACE REMMING EN 24-UURS BLOEDDRUK EFFECT 
De ene ACE remmer is de andere nog niet. Dat is het onderwerp van dit hoofdstuk. Wij 
vergeleken 24-uurs bloeddruk effect van captopril met dat van enalapril. 
Pharmacokinetisch zijn er belangrijke verschillen tussen beide medicamenten. Op grond 
van een korte eliminatiehalfwaardetijd werd aanvankelijk geadviseerd captopril4 x daags 
te doseren, maar in de praktijk van aile dag leek het erop dat men met een aanmerkelijk 
Ianger doseringsinterval ook uitkwam. Deze modieuze trend (eenmaal daags m6et kunnen) 
is echter niet grondig onderbouwd. 
Wij registreerden nauwkeurig, en bij dezelfde patient, 24-uurs bloeddrukprofielen tijdens 
2 x daags 37,5 mg captopril en 1 x daags 20 mg enalapril. Wij gebruikten een automatische 
bloeddrukrecorder die de patient met zich meedroeg en hem in staat stelde zijn gewone 
bezigheden te verrichten. 
Tijdens gebruik van enalapril werd een wat gelijkmatiger 24-uurs bloeddrukcurve gezien 
dan tijdens gebruik van captopril. Vooral rond de avonddosering van captopril en enkele 
uren hiema bleek de bloeddruk onder captopril hoger dan tijdens gebruik van enalapril. 
Echter 's nachts en in de vroege ochtend konden wij geen verschil aantonen. 
Het is bekend, maar op de achtergrond geraakt, dat voedsel inname de opname van 
captopril in het lichaam vertraagt. Onze patienten namen de avonddosering captopril rond 
de (hoofd)maaltijd. Verminderde cq uitgestelde resorptie van captopril zou een verklaring 
kunnen vormen voor de tijdelijk gedaalde effectiviteit. Oppassen lijkt geboden wanneer 
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men laag en weinig frekwent doseert. Men heeft wel gesteld dat het bloeddrukverlagend 
effect van captopril onafhankelijk zou zijn van de bloedspiegel van dit medicament. Onze 
gegevens ondersteunen dit postulaat niet. 
DEEL 2 BLOKKADE VAN SEROTONIN£ RECEPTOREN 
HOOFDSTUK6 
SEROTONINE, KETANSERIN EN VERHOOGDE BLOEDDRUK 
In hoofdstuk 6 komt de vraag aan de orde of toediening van ketanserin aan patienten met 
verhoogde bloeddruk de bloeddruk verlaagt. Ret antwoord bleek recht toe recht aan: ja, dat 
doet het middel. Wij interpreteerden de bloeddrukdaling op ketanserin als indirect bewijs 
voor een mogelijke rol van serotonine bij verhoogde bloeddruk. De twee artikelen deden 
nogal wat stof opwaaien. Ret lijkt daarom nuttig om onze "ketanserin-serotonine-
hypertensie story" in een wat breder kader te plaatsen. 
Geschiedenis. 
Al40 jaar brengt serotonine (5-hydroxytryptamine; 5-HT) onderzoekers in vervoering 
maar vooral ook in verwarring. De verbinding begon haar loopbaan als een darmhormoon, 
enteramine. Dit enteramine bleek echter identiek aan de door Page ontdekte serum faktor, 
serotonine, dat vrijkomt als bloedplaatjes samenklonteren. Nadat de structuur was 
opgehelderd, werd serotonine ook in de hersenen aangetoond. Spannende tijden braken 
aan, maar teveel onduidelijke stukjes maakten de puzzel onlegbaar. In vergelijking met 
haar familieleden, de monoaminen noradrenaline, adrenaline en dopamine, leek voor 
serotonine geen glansrol weggelegd. Een echte Assepoester met een onduidelijke taak in 
darm en brein om van de bloedsomloop maar niet te spreken. Bloedspiegels van vrij 
circulerend serotonine bleken extreem laag en toegediend als synthetische stof gaf 
serotonine in het ene vaatgebied vasoconstrictie, in het andere vasodilatatie. Tot overmaat 
van ramp wisselden deze effecten ook nog van uur tot uur en kwamen er belangrijke 
species verschillen aan het licht. De naam serotonine, door Page gekozen in de 
veronderstelling met een hypertensieve faktor "par excellence" te maken te hebben, leek 
weinig gepast. Recent inzicht in de diversiteit aan serotonine receptoren bracht onze 
Assepoester weer in het centrum van de belangstelling. 
Receptoren.. 
Bindingsstudies en andere farmacologische experimenten maakten aannemelijk dat er op 
zijn minst drie hoofdgroepen serotonine receptoren bestaan: 5-HTI, 5-HTz en 5-HT3. De 5-
HTI receptor werd gevonden in het centraal zenuwstelsel maar ook op het endotheel van de 
vaatwand. Er bestaan waarschijnlijk meerdere 5-HTI-achtige receptoren. Hun funktie is 
nog omstreden. Sceptici veronderstelden dat het slechts gaat om onduidelijk receptoren op 
zoek naar een ziekte. Recent werd echter aangetoond dat een subgroep van deze 5-HTI 
receptoren waarschijnlijk een beslissende rol speelt bij het ontstaan van migraine. 
De 5-HTz receptor is wat beter gedefinieerd. Hij wordt gevonden op de gladde spiercel 
van darm en bloedvaten maar ook in de hersenen, het hart en op de wand van 
bloedplaatjes. Prikkeling door serotonine van de 5-HTz receptor in de vaatwand leidt tot 
vaatvernauwing. De 5-HT3 receptor is waarschijnlijk een echte zenuwreceptor. 
Kortom, een veelheid dus aan receptoren met uiteenlopende en soms tegengestelde 
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funkties. Dit verklaart waarom de rol van serotonine zo lang onduidelijk bleef en nog 
steeds wei is. 
Vasculaire effecten. 
Synthese van serotonine vindt uitsluitend plaats in de enterochromafienne cellen van de 
darrn en in het centraal zenuwstelsel. In de darrn geproduceerd serotonine bereikt via de 
vena porta de lever waar de verbinding direct wordt afgebroken. Serotonine dat aan de 
lever ontk:omt, wordt geneutraliseerd door het endotheel van de longvaten. Bloedplaatjes 
beschikken over een actief opname mechanisme voor serotonine waarbij zij de verbinding 
opslaan in zogenaarnde "dense bodies". Een en ander zorgt ervoor dater praktisch geen vrij 
serotonine in het bloed circuleert. Men neemt aan dat de vasculaire effecten van serotonine 
worden veroorzaakt door serotonine dat ter plekke vrijkomt uit samenklonterende, 
uiteenvallende bloedplaatjes. 
Op deze wijze vrijgemaakt serotonine heeft meerdere en uiteenlopende vasculaire 
effecten. Serotonine dat de 5-HTl endotheel receptor prikkelt, geeft vaatverwijding. Het 
gaat hierbij om een indirect effect, waarbij bet endotheel wordt aangezet tot de produktie 
van een "relaxant factor". Serotonine dat via het endotheel de 5-HT2 receptor op de gladde 
spiercel in de vaatwand bereik:t, brengt deze spiercel en daarrnee bet bloedvat tot 
contractie. De 5-HT2 receptor is ook betrokken bij bet versterkend effect dat serotonine 
heeft op de bloedvaatvernauwing dat door bet syrnpathisch zenuwstelsel wordt 
bewerkstelligd. Ook sarnenklonteren van bloedplaatjes, eenmaal in gang gezet, wordt door 
vrijgekomen serotonine verder versterkt via een 5-HT2 receptor op het bloedplaatje. 
Op zich is bet dus niet onaannemelijk dat geneesrniddelen die een interactie aangaan met 
deze receptoren (stirnulering van 5-HTl receptoren, blok:k:ade van 5-HT2 receptoren) van 
nut zouden kunnen zijn bij de behandeling van vasculaire pathologic. 
Zoals eerder genoemd, de concentratie van vrij serotonine in de circulatie is echter 
extreem laag. Het is dan ook moeilijk voorstelbaar dat dit gehalte aan vrij serotonine 
verantwoordelijk is voor de verhoogde vaatweerstand waarrnee essentiele hypertensie 
gepaard gaat. De situatie ligt anders voor het lokaal vrijgemaakt serotonine dat wei zeker 
de vaattonus be"invloedt. Maar deze concentraties zijn moeilijk meetbaar. Wei zijn er 
aanwijzingen dat de bloedplaatjes van patienten met hoge bloeddruk serotonine minder 
gemakkelijk opnemen en dat deze bloedplaatjes makkelijker tot sarnenklonteren overgaan. 
De laatste jaren wordt steeds duidelijker dat het vaatwand bekledend endotheel geen 
indolente laag, maar metabool zeer ak:tief. Zo zijn er receptoren en metaboliserende 
enzymen gevonden voor serotonine, bradyk:inine, histamine, ADP, angiotensine etc. en 
produceert het endotheel ook zelf vaatverwijdende en vaatvernauwende stoffen. Na 
beschadiging, bijvoorbeeld door sterk verhoogde bloeddruk, herstelt endotheel betrekkelijk 
snel. Toch is er iets bijzonders aan de hand met "genezen" endotheel. Het reageert anders 
op prikkels. Druppelen van serotonine op zulk:e bloedvaten bleek in plaats van 
vaatverwijding (5-HTl effect) onverwacht sterke vasoconstrictie (5-HT2 effect) te geven. 
Vastgesteld werd dat de gevoeligheid van de vaatverwijdende 5-HTl receptor op "genezen" 
endotheel sterk verminderd is. Onder deze omstandigheden komen de vaatvernauwende 
eigenschappen van serotonine dus bij uitstek tot expressie. Op theoretische gronden 
konden wij het bloeddruk:verlagend effect van de 5-HT2 receptor blokker ketanserin dus 
goed verklaren. 
Bij onze patienten met verhoogde bloeddruk was de bloeddrukdaling na langzarne 
intraveneuse infusie van 10 mg ketanserin een gevolg van een daling van de totale perifere 
vaatweerstand. Activatie van de baroreflex zorgde voor een, geringe, stijging van de 
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hartfrekwentie. De reflexmatige toename in de sympathische zenuwactiviteit, zoals 
weerspiegeld in de stijging van de plasma noradrenaline concentratie, was waarschijnlijk 
ook verantwoordelijk voor de toename van het hartminuutvolume. Ondanks aanhoudende 
sympathische stimulatie bleek de hartminuutvolume stijging slechts van korte duur. 
Mogelijk: als gevolg van dalende vullingsdrukken van beide hartkamers, daalde het 
hartminuutvolume later tot zelfs iets onder de uitgangswaarde. Deze gegevens pleitten 
ervoor dat ketanserin niet aileen een effect had op de weerstandvaten maar ook op die 
vaten die het aanbod van het hart reguleren, de zgn. capaciteitsvaten. Geringe toename van 
bloeddoorstroming bij uitgesproken vaatverwijding werd ook: in de niercirculatie 
aangetoond. De weerstandsdaling in dit vaatgebied zorgde ervoor dat ondanks de dalende 
bloeddruk (nierperfusiedruk) de glomerulusfiltratie behouden bleef. 
Zijn al deze effecten van ketanserin nu toe te schrijven aan blok:kade van 5-IITz 
receptoren? Of is ketanserin toch niet zo selectief voor 5-IITz receptoren als werd gedacht 
en blokkeert de verbinding ook receptoren van het sympathisch zenuwstelsel? 
Dierexperimenten, door anderen verricht, gaven hier op een duidelijk antwoord.Ketanserin, 
zij het in hoge concentratie, blokkeert naast 5-IITz receptoren ook w-adrenoreceptoren. 
Maar geldt dit ook voor doseringen die bij de mens bloeddrukverlagend werkten? Deze 
vraag leek: ons zo belangrijk dat wij hier een apart onderzoek naar deden. 
HOOFDSTUK7 
HOE WERKT KETANSERIN? 
De twee artikelen in dit hoofdstuk gaan over het werkingsmechanisme van ketanserin. 
Aan patienten met licht verhoogde bloeddruk: gaven wij opklimmende doseringen van de 
a.1-adrenoreceptor agonist fenylefrine. Dit voor en na toediening van k:etanserin. De bloed-
drukstijging en de polsvertraging na fenylefrine werden door ketanserin nauwelijks 
beYnvloed. Toediening van de w-adrenoceptor antagonist prazosin gaf wel een duidelijk:e 
verschuiving van de fenylefrine dosiswerkingcurve. Dit laatste viel te verwachten daar 
prazosin bekend staat als een competatieve at-receptor blokker. Blokkade van Ul-
receptoren door ketanserin, althans bij de mens en in de gebruikte bloeddrukverlagende 
dosering, was dus niet erg evident. 
Wij dienden ketanserin ook toe aan een zeldzaam groepje patienten bij wie door ziek:te 
het sympatisch zenuwstelsel onwerkzaam was geworden. Een a.-adrenoceptor blokker had 
bij deze patienten geen effect op de bloeddruk, ketanserin had dit duidelijk wel. 
Het effect van ketanserin op de bloeddruk is dus uitsluitend toe te schrijven aan blokkade 
van 5-IITz receptoren? Wij deden een waameming die hier ogenschijnlijk: mee in strijd 
leek.Toen wij patienten "voorbehandelden" met hoge doseringen van de U1-adrenoceptor 
blokker prazosin en vervolgens ketanserin aan hen gaven, toen bleek het bloeddrukver-
lagend effect van ketanserin verdwenen. Dit in tegenstelling tot een controlegroep 
patienten die met furosemide werden voorbehandeld; bij hen bleef het bloeddrukverlagend 
effect van ketanserin behouden. Hoe dit te verk:laren? Hier gaf literatuur studie enige 
k:laarheid. Naast eigen vasoconstrictoire effecten versterk:t serotonine de werking van 
andere vasoactieve mediatoren zoals die van noradrenaline. Blokkeert men met prazosin de 
effecten van dit noradrenaline, dan valt er voor serotonine niets meer te "amplificeren". 
Serotonine blokkade onder deze condities heeft dan geen uitwerking meer. Het zou wel 
eens k:unnen zijn dat de door k:etanserin "ontmaskerde" amplificerende rol van serotonine 
belangrijk:er is dan de vasoconstrictoire effecten van het monoamine zelf. Ook k:omen er 
steeds meer aanwijzingen dat het ketanserin molecuul uniek is in die zin dat het in staat is 
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om een ingewikkelde onbegrepen interactie aan te gaan met zowel5-HTz- als met 0.1-
adreno receptoren. 
HOOFDSTUK8 
SEROTONINE, KETANSERIN EN HET FENOMEEN VAN RAYNAUD 
Min of meer bij toeval namen wij bij een patiente met hoge bloeddruk en een 
doorbloedingsstoornis van de handen waar dat er een opvallende verbetering van de 
vingercirculatie optrad na intraveneuse toediening van ketanserin. De kleur van haar 
vingers veranderde in enkele minuten van wit-blauw in rose-rood. De patiente was lijdende 
aan het zgn. primaire fenomeen van Raynaud. Deze onbegrepen, door koude en emotie 
geluxeerde, voorbijgaande vaatkramp in handen en voeten wordt wel toegeschreven aan 
een overactief sympathisch zenuwstelsel maar geneesmiddelen, die de sympathische 
zenuwactiviteit blokkeren, bleken weinig effectief. 
Serotonine zou een rol kunnen spelen. Althans de condities zijn gunstig. Pathologisch 
endotheel, zeer trage bloeddoorstroming, "low-grade" bloedplaatjesaggregatie. En de 
receptoren voor serotonine zijn er. Wanneer men serotonine druppelt op geisoleerde 
digitale arterieen dan trekken deze bloedvaatjes zich krachtig samen. Serotonine, 
rechtstreeks toegediend in een armslagader, geeft een belangrijke vermindering van de 
doorbloeding van de vingers. De kleurveranderingen, die dan aan de vingers zichtbaar 
worden, lijken sprekend op die van patienten met het fenomeen van Raynaud. 
Wij bestudeerden de effecten van ketanserin bij een serie Raynaud patienten. Aan hun 
vingers maten wij temperatuur en bloeddoorstroming (veneuse occlusie plethysmographie, 
laser-Doppler flux). Ook probeerden wi j een indruk te kri jgenr over het zuurstof transport 
door de huid van de vingers. Na intraveneuse ketanserin toediening nam de bloedsomloop 
door de vingers sterk toe en normaliseerde de huidtemperatuur zich. Effecten op zuurstof 
transport echter waren gering. Deze gegevens zouden er op kunnen wijzen dat ketanserin in 
de vinger de rijkelijk aanwezige arterioveneuse shunts opent, maar weinig doet aan 
verbetering van de capillaire doorstroming. Een opvallende bevinding was tevens dat de 
effecten van ketanserin in dit vaatgebied niet geblokkeerd konden worden door 
voorbehandeling met hoge doses van selectieve en niet-selectieve a.-adrenoceptor 
antagonisten. Wij trokken de conclusie dat serotonine type 2 receptoren aanwezig zijn in 
vinger circulatie en dat hun activatie mogelijk een rol speelt bij het optreden van het 
Raynaud fenomeen. 
CONCLUSIE 
Dit proefschrift verkent de mogelijkheden die prototypes van nieuwe generaties 
geneesmiddelen ons bieden bij de bestudering van bloeddruk regulatie mechanism en. Met 
behulp van angiotensine converting enzyme remmers probeerden wij de functie van het 
renine angiotensine systeem nader te karakteriseren. De rol van serotonine in het 
cardiovasculaire systeem sondeerden wij met de specifieke en selectieve serotonine 
antagonist ketanserin. 
Onze klinisch-farmacologische onderzoekingen maakten duidelijk dat de rol van 
angiotensine en serotonine in de pathogenese van verhoogde bloeddruk aanmerkelijk 
complexer is dan ooit voor mogelijk werd gehouden. Tevens bleken de gebruikte 
geneesmiddelen geen vlijmscherpe onderzoeksinstrumenten te zijn. Haarfijne dissectie van 
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fysiologische mechanismen bleek met dit "gereedschap" niet mogelijk. 
Toch hebben onze onderzoekingen ons inzicht verruimd. Analyse van het 
bloeddrukverlagend effect van angiotensine converting enzyme remmers bracht naar voren 
dat het niet aileen de circulerende componenten van het renine angiotensine systeem zijn 
die de hoogte van de bloeddruk bepalen. Ook bij geringe activiteit van het circulerende 
renine angiotensine systeem bleken ACE remmers effectief. Mede dankzij deze gegevens 
richt fundamenteel onderzoek zich nu op karakterisering van het renine angiotensine 
systeem zoals dat in de weefsels wordt gevonden. ACE remming bij onvoldoende 
hartswerking bleek onverwacht zo effectief dat bijna niemand zich de aarzelende start 
herinnert. Oppassen met ACE remming bij nierarteriestenose blijft geboden, maar 
diagnostiek van deze onderschatte aandoening is mede dankzij ACE remmers eenvoudiger 
geworden. 
Onze ervaring met de serotonine antagonist ketanserin suggereert dat serotonine een rol 
speelt bij verhoogde bloeddruk en het Raynaud fenomeen. De gunstige effecten van 
ketanserin moeten vermoedelijk worden toegeschreven aan een ingewikkelde interactie die 
de verbinding aangaat met zowel serotonine als alpha-adrenoreceptoren. 
Tot besluit, veel van het bloeddrukverlagend effect van de bestudeerde, in theorie zo 
specifiek werkende, geneesmiddelen bleef onverklaard. Daarmee is er niets nieuws onder 
de zon. Ook na vele jaren ervaring met diuretica en betablokkers weten wij nog niet exact 
hoe zij werken. Harvey (1628), de ontdekker van de bloedsomloop, formuleerde het 
zo: ... "it is to be understood by God alone". 
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DANKWOORD 
Het latijnse werkwoord "promoveo" staat voor "bevorderen" maar ook 
voor "opdrijven". Het moet toegegeven worden, deze doctorandus liet zich 
wel opdrijven maar niet in de richting van een dissertatie. Een klein 
geboortedefect, paralyse van de linker nervus abducens, stelde hem in staat 
steeds een andere kant uit te kijken als het onderwerp ter sprake kwam. 
Toen echter de reukzin van omstanders in het geding kwam - langdurig 
werkzaam zijn in een universiteitsziekenhuis als publicerend maar niet 
gepromoveerd academicus schijnt een soort lijklucht te verspreiden - moest 
het er maar van komen. Hooggeschatte promotor, beste Maarten, je wordt 
bedankt voor je acceptatie en uiteindelijk snelle correctie van mijn 
opthalmologische deviatie. Ik: voel mij bevoorrecht dat ik vanaf onze 
gemeenschappelijke start in Dijkzigt, nu al weer 15 jaar geleden, voor jou 
heb mogen werken. Je bent een dokter, onderzoeker, geleerde "pur sang". 
Dat bloed en met bloed het renine angiotensine systeem blijft kruipen waar 
het verstand niet bij kan, ligt niet aanjouw ijver en grijze stof. Sunt certe 
fines ... 
Zeer velen zijn betrokken geweest bij de publicaties waarop dit 
proefschrift is gebaseerd. Patienten, verplegenden, doktersassistenten, 
analytisch en administratief personeel, chemici, artsen, een schier 
onafzienbare rij min of meer cooperatieve mensen die tezamen het no-
nonsense "milieu interieur" van het Rotterdamse Dijkzigt vormen. In deze 
omgeving is het goed toeven. Ik: blijf erbij dat het onmatig is om de 
"output" van dit niet vervuilde milieu voor de eigen glorie aan te wenden, 
maar ala, het is nu gebeurd en de betrokkenen worden bedankt. Voor mijn 
homeostase in de Dijkzigt gemeenschap was symbiose met Arie Man in 't 
Veld en Frans Derkx, companen van het eerste uur, van grote betekenis. 
Hun namen sieren terecht menig bladzij van dit werkje. In publicaties niet 
genoemd maar onmisbaar bleek de hoofdzuster van 3N, Zr. A.M: 
Gantevoort. De stabiliserende bijdrage die zij op de achtergrond gedurende 
vele jaren heeft geleverd verdient alle lof. 
Tot slot, lang wachten met promoveren heeft ook zijn voordelen, het 
thuisfront evolueert. Onder het kritisch oog van mijn mooie vrouw Wil, 
typte de in Dijkzigt geboren jongste zoon Paul dit dankwoord met acht 
meer vingers dan ik dat kan in de computer. Dat Sandra en Michael zich 
daar nog even mee bemoeiden spreekt voor zich. 
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